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 The inherited form of primary open angle glaucoma, a disorder characterized by 
increased intraocular pressure and retina degeneration, is linked to mutations in the 
olfactomedin (OLF) domain of the myocilin gene. Disease-causing myocilin variants 
accumulate within trabecular meshwork cells instead of being secreted to the trabecular 
extracellular matrix thought to regulate aqueous humor flow and control intraocular 
pressure. Like other diseases of protein misfolding, we hypothesize myocilin toxicity 
originates from defects in protein biophysical properties. In this thesis, the first 
preparative recombinant high-yield expression and purification system for the C-terminal 
OLF domain of myocilin (myoc-OLF) is described. To determine the relative stability of 
wild-type (WT) and mutant OLF domains, a fluorescence thermal stability assay was 
adapted to provide the first direct evidence that mutated OLF is folded but less thermally 
stable than WT. In addition, mutant myocilin can be stabilized by chemical chaperones. 
Together, this work provides the first quantitative demonstration of compromised 
stability among identified OLF variants and placing myocilin glaucoma in the context of 
other complex diseases of protein misfolding. 
 Subsequent investigations into the biophysical properties of WT myoc-OLF 
provide insight into its structure and function. In particular, myoc-OLF is stable in the 
presence of glycosaminoglycans (GAGs), as well as over a wide pH range in buffers with 
functional groups reminiscent of such GAGs. Myoc-OLF contains significant β-sheet and 
β-turn secondary structure as revealed by circular dichroism analysis. At neutral pH, 
thermal melts indicate a highly cooperative transition with a melting temperature of 




and consists of approximately residues 238-461, which retains the single disulfide bond 
and is as stable as the full myoc-OLF construct. This construct also is capable of 
generating 3D crystals for structure determination. This data, presented in Chapter 3, 
inform new testable hypotheses for interactions with specific trabecular extracellular 
matrix components. 
 To gain further insight into the biological function of myoc-OLF, a facile 
fluorescence chemical stability assay was designed to identify possible ligands and drug 
candidates. In the assay described in Chapter 4, the target protein is initially destabilized 
with a chemical denaturant and is tested for re-stabilization upon the addition of small 
molecules. The assay requires no prior knowledge of the structure and/or function of the 
target protein, and it is amendable to high-throughput screening. Application of the assay 
using a library of 1,280 compounds revealed 14 possible ligands and drug candidates for 
myoc-OLF that may also generate insights into myoc-OLF function. 
  Due to the high β-sheet content of monomeric myoc-OLF and presence of an 
aggregated species upon myoc-OLF purification, the ability of myoc-OLF to form 
amyloid fibrils was suspected and verified. The fibril forming region was confirmed to 
reside in the OLF domain of myocilin. Kinetic analyses of fibril formation reveal a self-
propagating process common to amyloid.  The presence of an aggregated species was 
confirmed in cells transfected with WT myocilin, but to a greater extent in cells 
transfected with P370L mutant myocilin. Both cell lines stained positive for amyloid. 
Taken together, these results provide further insights into the structure of myocilin and 




 Finally, in a related study, small molecule drug candidates were investigated to 
treat acid β-glucosidase (GCase), the deficient lysosomal enzyme in Gaucher disease, 
another protein conformational disorder. Three new GCase active-site directed 3,4,5,6-
tetrahydroxylazepane inhibitors were synthesized that exhibit half inhibitory 
concentrations (IC50) in the low millimolar to low micromolar range.  Although the 
compounds thermally stabilize GCase at pH 7.4, only one of the synthesized analogs 
exhibits chaperoning activity under typical assay conditions.  This successful 
pharmacological chaperone is also one in which GCase is in its proposed active 
conformation as revealed by X-ray crystallography. Probing the plasticity of the active-
site of GCase offers additional insight into possible molecular determinants for an 












 Glaucoma is an irreversible, chronic, degenerative optic neuropathy affecting 70-
80 million people world-wide and is second only to cataracts as a cause of blindness [1]. 
A patient is considered to have glaucoma when at least one eye has both typical structural 
and functional defects, that is to say damage to the optic disc and subsequent visual field 
loss [2]. Damage to the optic disc is visualized by ophthalmologists as a topical 
deepening and widening of the cup due to loss of retinal ganglion cell (RGC) axons along 
with supporting glial and vasculature, and the deformation of connective tissues 
supporting the optic disk [3]. Injury to RGC axons occurs by a variety of factors, only 
some of which are understood. In its initial phase, glaucoma is asymptomatic and 
painless. Patients with glaucoma typically lose peripheral vision first and may lose all 
vision if not treated early. 
 Classification of glaucoma is based on three factors: (1) etiology, depending on if 
the symptoms present themselves on their own (primary) or if the symptoms are a result 
of disease or injury to the eye (secondary), (2) anatomy of the anterior chamber, open 
angle or closed angle, and (3) by the age of onset. Based on these classifications, 
glaucoma may be broken down into three categories: primary open angle glaucoma 
(POAG), primary acute closed angle glaucoma, and primary congenital glaucoma. Of 
these, POAG is the most common [4].  
 Glaucoma is a heterogeneous disorder and is frequently associated with elevated 
intraocular pressure (>21 mm Hg, IOP). However, increased IOP is neither necessary nor 
sufficient for onset or progression of the disease [5], and it is not clear how elevated IOP 




occurs. Since the lens and cornea lack a blood supply, the anterior chamber has its own 
circulatory system and is filled with aqueous humor. This clear fluid is produced in the 
ciliary body and circulates throughout the anterior chamber (Fig. 1.1).  
 Aqueous humor outflow is regulated by the trabecular meshwork (TM) in the 
iridocorneal angle (angle formed by the iris and cornea) and drainage occurs through the 
Schlemm‟s canal [7]. The TM is a filter-like structure composed of trabecular beams of 
extracellular matrix (ECM) and endothelial cells (TM cells). TM cells help regulate eye 
pressure by controlling the drainage of the fluid from the eye as new fluid is produced 
[8], and structural abnormalities in the TM are believed to obstruct aqueous humor 
outflow and lead to elevated IOP. Therefore, increased IOP does not result from an 
increased production of aqueous humor, but rather from a reduced outflow.  Since the 
optic nerve damage cannot be treated directly, focus in the field has been directed to treat 
the only known risk factor that can be modified, elevated IOP. Clinical trials have shown 
that reducing IOP slows the onset and progression of glaucoma [9-10] and current 
research focuses on identifying the site of resistance within the TM and the mechanism 
that changes the overall resistance.   
1.1.1 Myocilin Linked with POAG  
 Myocilin was first discovered as a result of research directed towards 
understanding steroid-induced glaucoma. Corticosteroids are widely used as anti-
inflammatory agents for the treatment of ocular inflammatory conditions. However, a 
link between the exogenous administration of corticosteroids and elevated IOP has been 
known since the 1950‟s, and can lead to secondary glaucoma [11-13]. Treatment of TM 
cells in vitro with corticosteroids, in particular dexamethasone (Dex), induced the 
expression of a 55 and 66 kDa protein in a time and dose-dependent manner similar to the 






Figure 1.1 Circulation of the aqueous humor. This anterior segment of the eye shows 
the circulation of the aqueous humor from the ciliary body through the pupil into the 
anterior chamber. The aqueous humor then passes through the trabecular meshwork into 
Schlemm‟s canal and travels from there into the episcleral venous system. A smaller 
amount of aqueous humor leaves the eye through the face of the ciliary body, just below 






arise from the same gene which was named Trabecular Meshwork Glucocorticoid 
Responsive (TIGR) gene [18-19] and is now known as myocilin (see below).  
 Attempts to identify promoter elements in the TIGR gene to explain the 
hypersensitivity of individuals to the corticosteroids and the up-regulation of TIGR were 
unsuccessful [20], and the finding of a delayed response (8-16 hrs) to induction by Dex 
suggested that TIGR‟s transcriptional regulation by glucocorticoids is a secondary 
response and not a direct stimulation [21]. However, genetic linkage studies conducted in 
a single large Caucasian family in USA with an autosomal dominant pedigree for early-
onset POAG (juvenile OAG, JOAG) localized a genetic defect in GLC1A, mapped to 
chromosome 1q21-1q31 [22]. This gene was confirmed by subsequent studies with other 
families diagnosed with JOAG. The TIGR gene was soon identified within chromosome 
1q [23], and its location was confirmed in an unrelated study [24]. The gene product was 
permanently renamed myocilin based on its homology to the N-terminal domain with 
non-muscle myosin, as well as the identification of the gene product in the connecting 
cilium of photoreceptor cells [24].  
 To date, at least 20 genetic loci associated with POAG have been reported [25], 
but only three genes have been confirmed to be linked to POAG so far: myocilin (MYOC) 
[23], optineurin (OPTN) [26], and WD repeat domain 36 (WDR36) [27]. Only myocilin is 
established as directly glaucoma causative, while the roles of optineurin and WD36 
remain unclear due to conflicting evidence. Mutations in the myocilin gene are attributed 
to 4% of adult-onset POAG cases and 10-33% of juvenile-onset cases [28-30].  
1.2 Myocilin 
 Myocilin (gi accession: 4557779, geneID 4653) is a 504 amino acid glycoprotein 
(~55 kDa) [18, 24] consisting of three structural domains: a 32 residue N-terminal signal 
sequence for secretion [18], a myosin-like coiled-coil region (residues 111-184), and a C-




myocilin possesses a uniquely bipartite secondary structure, α-helical N-terminus and β-
sheet in the C-terminal domain, and is believed to have evolved from two separate 
proteins [32]. The coiled-coil domain contains two leucine zippers, which are found in a 
wide variety of proteins and have the ability to form homo- or heteromeric complexes. It 
is this region that is responsible for multimerization [33-34] and interactions with certain 
extracellular matrix proteins [33, 35-36]. Current knowledge of the function of myocilin 
is primarily restricted to this region. Very little is known about the function of OLF 
domains, which are highly conserved across higher eukaryote species. More than 90% of 
glaucoma-associated mutations are found within the myocilin OLF domain.  
 1.2.1 Localization and Function 
 The normal function and localization of myocilin are topics of active and 
controversial research, as myocilin is expressed in almost every ocular tissue, and, 
depending on the tissue, it is observed extra- or intracellularly [37]. Within the eye, 
myocilin is expressed in the trabecular meshwork, cornea, lamina cribosa, ciliary body, 
iris, retina, post laminar optic nerve head, vitreous and aqueous humor [31, 33-34, 37-
39]. Of these tissues, the highest level of expression is within the TM, the region of the 
eye believed to regulate IOP [40-41]. Moreover, myocilin is found in a variety of tissues 
outside the eye and, of these, its highest levels were found in the skeletal muscle and 
heart [18, 29, 31].    
 Myocilin is a secreted protein (Fig. 1.3A), confirmed by the isolation of 
recombinant myocilin from conditioned medium of cultured TM cells [19, 42]. Given 
that secreted proteins are generally synthesized, folded, and processed through the 
endoplasmic reticulum (ER) and golgi apparatus, it is not surprising that myocilin has 
also been found within organelles associated with the secretory pathway [43-46]. 











Figure 1.2. Scheme of myocilin protein domains. Myocilin contains an N-terminal 
signal sequence (red), coiled-coil domain (blue), and a C-terminal olfactomedin domain 
(green). Numbers 203 and 243 correspond to the amino acid sequence of the linker 






Figure 1.3. Proposed pathways for normal secretion of myocilin into the aqueous 
humor and for secretion reduced by a MYOC mutation. In Panel A, wild-type 
myocilin protein (green symbols) is produced in the endothelial cells of the trabecular 
meshwork and passes through the secretory pathway to reach the extracellular space. In 
the first step in this process, messenger RNA (mRNA) is transcribed from the gene 
encoding myocilin (MYOC) and is delivered to ribosomes at the endoplasmic reticulum, 
where the mRNA directs the synthesis of myocilin. Next, transport vesicles convey 
myocilin to the cell membrane through the Golgi apparatus. These vesicles fuse with the 
cell membrane and release myocilin into the extracellular space and aqueous humor. 
Along the secretory pathway, molecules of myocilin may associate with each other and 
form multimers (dimers and tetramers are depicted). In Panel B, heterozygous mutations 




wild-type copy of MYOC encodes normal myocilin protein (green symbols), and the 
mutant MYOC copy encodes mutant myocilin protein (red symbols). Myocilin protein 
forms multimers that may be composed of both wild-type and mutant subunits. Secretion 
of mutant myocilin protein and multimers containing mutant subunits is greatly reduced, 
leading to the retention of the mutant protein in the endoplasmic reticulum and 
intracellular vesicles of trabecular-meshwork cells. This figure was reprinted with 





kDa N-terminal fragment and a C-terminal 35 kDa olfactomedin containing fragment 
[47]. Both the 35 kDa fragment and full-length myocilin have been reported to be 
secreted to the ECM and are present in aqueous humor and select monolayer cells 
engineered to over express myocilin, and thus hypothesized to maintain a normal ECM 
structure [34, 48-49].  
 Despite the evidence supporting myocilin as a secreted protein that would 
normally function in the ECM, myocilin is also believed to play an intracellular role [24, 
37]. Sakai et al. and others have shown that myocilin associates with mitochondria 
membranes [50-52]. However, these interactions appear to be cell-type specific as they 
are only observed in trabecular meshwork and astrocyte cells, but not in corneal 
fibroblasts [52-53]. Finally, myocilin has been shown to interact with microtubules [54]. 
Karali et al. argue that while the observed intracellular staining patterns suggest some 
intracellular localization, it is not clear whether some of the staining represented extra- or 
intracellular staining and whether some of the intracellular staining represents cells 
synthesizing large amounts of myocilin for secretion to the extracellular space [37].  
 During the subsequent 14 years since the linkage of myocilin to early and late-
onset POAG, considerable effort has been invested to determine its function in normal 
eyes, and how changes in myocilin expression or mutations may lead to glaucoma. It is 
critical to determine the function of myocilin to see if it is important in the regulation of 
IOP and normal trabecular meshwork function. Myocilin is likely a multifunctional 
protein, as it has been identified both intra- and extracellularly. Inside the cell, myocilin 
may influence mitochondrial function as over-expression in TM cells reduced 
mitochondria respiration, which sensitizes cells and triggers apoptotic events [50]. This is 
consistent with the observed loss of TM cells in POAG [55]. Overall, in spite reports of 
potential intracellular functions, myocilin is believed to be largely an ECM protein. Full-
length myocilin associates with components of the ECM via interactions with the Heparin 




[36, 51, 56-58]. These interactions lead to a possible role in cell-matrix interactions and 
regulation of these interactions in the TM [36]. Myocilin is thought to modify cell 
signaling events mediated by the Hep II domain of fibronectin, which impaires cell 
attachment and migration of human skin fibroblasts [59]. Myocilin is also hypothesized 
to control the adhesive properties of the cell, as over-expression in TM cells results in a 
loss of cellular adhesion [60]. Myocilin is also presumed to play a role in stress response, 
which is consistent with the expression being inducible by environmental factors such as 
steroid treatment with Dex, heat-shock, mechanical stretch, and oxidative stress [19, 40, 
45, 61]. In support of this hypothesis, targeted deletion of the myocilin gene does not 
result in glaucoma [6], which suggests myocilin may not be critical for normal eye 
function and that a stress response may be needed to see a disease-causing phenotype.  
 Taken together, myocilin shares many features of ECM or “matricellular” 
proteins that display diverse functions including the ability to bind to the ECM, influence 
cell-matrix interactions, and serve as stress and injury response proteins. Matricellular 
proteins can function both intra- and extracellularly [62-63]. For example, similar to 
myocilin, tenascin-C has de-adhesive effects when presented as soluble proteins to cells 
in a strong adhesive state [64]. However, myocilin differs from tenascin-C because it 
does not block cell attachment to fibronectin [59]. Whether or not myocilin functions as a 
extracellular matricellular protein remains to be confirmed, as well as its roles in other 
regions of the eye and other organs.  
1.2.2 Myocilin-Associated POAG  
 The first hypothesis regarding association of myocilin to POAG was that elevated 
IOP may be caused by increased levels in myocilin, which in turn leads to a reduction of 
outflow facility either by physically obstructing the outflow path and/or affecting cell-
mediated processes that control outflow [36].  The basis of this notion is founded on 




production in a dose-dependent manner that correlated with the timing and increase of 
IOP [14, 45]. Immunohistochemical staining of POAG eyes showed an increase in 
myocilin levels [65]. More recently, the levels of myocilin have been found to be 
statistically elevated in human aqueous humor of POAG patients [66] further supporting 
the connection between increased myocilin levels and POAG. Nguyen et al. hypothesized 
that increased levels of myocilin may accumulate within the TM and interfere with 
normal flow patterns, thus resulting in increased IOP [18]. This hypothesis was 
corroborated by a study in which human eyes treated with recombinant myocilin showed 
an increase in IOP over 12 hours, increasing outflow resistance 94% [67]. Cultured 
anterior segments of porcine and human eyes perfused with recombinant OLF domain of 
myocilin did not result in changes of outflow facility, indicating the observed elevations 
in IOP may be the result of the N-terminal myosin-like domain interactions in the ECM 
[49].  
 A complicating factor in studies involving animal models is that only a couple 
species are genetic carriers for POAG, including rats [68] and some canine breeds [69-
70].  Rats that spontaneously develop increased IOP had a 3.2-fold increase in myocilin 
transcription [68]. Conversely, rats treated with Dex display elevated IOP, but the protein 
and mRNA levels of myocilin in the trabecular meshwork and around Schlemm's canal in 
the steroid-treated eyes were the same as the controls [71]. However, in canine models, 
aqueous humor levels of myocilin were elevated in dogs with either primary or secondary 
OAG [69] and beagles had increased levels of myocilin in the aqueous humor 
proportionate to the severity of the disease [70]. To further complicate the matter, 
transgenic mice heterozygous (+/-) and homozygous (-/-) for the null MYOC mutation 
were both viable and fertile and no ocular abnormalities were observed indicating 
myocilin is not required for normal development [6].  
 As highlighted by the animal model studies, the hypothesis that increased levels 




controversial. Human anterior segment cultures over-expressing the recombinant N-
terminal domain of myocilin resulted in a construct that was sequestered in the cell, but 
displayed an increase in outflow facility resulting in decreased IOP [72], which is 
contrary to previous reports that the N-terminal domain is responsible for elevated IOP as 
mentioned above [49]. Based on the conflicting data, it is unclear if the differences that 
were observed are due to species variations (i.e. mice do not naturally acquire POAG) or 
due to the mode of delivery of the over-expressed myocilin. In humans, hemizygous 
deletion of myocilin [73] or the presumed homozygous null mutation (R46Stop) [74] 
does not result in POAG, which suggests that elevated myocilin levels may be a 
secondary effect of elevated IOP and not the primary cause. Therefore, increased levels 
of myocilin would not cause the elevated IOP, but may be the result of it. Taken together, 
evidence supports involvement of high myocilin levels in POAG, but the mechanism is 
unclear. 
1.3 Mutant Myocilin and POAG 
 The most common inherited form of POAG is linked to point mutations in the 
myocilin gene, accounting for 4% of adult-onset cases and ~10% of juvenile forms of the 
disease [23, 75-76]. The vast majority (>90%) of mutations are missense mutations in the 
C-terminal OLF domain, highlighting the functional importance of this domain in POAG 
pathogenesis (Fig. 1.2) [77] . Mutations in the first exon containing the coiled-coil 
domain account for the remaining glaucoma-inducing mutations, and no mutations are 
located in the second exon, which encodes a linker region between the two domains (Fig. 
1.2) [77]. According to the myocilin allele specific phenotype database 
(www.myocilin.com), there are currently 79 known disease-causing mutations located in 
the OLF domain alone [78]. These mutations are generally associated with a juvenile or 
early-onset form of POAG [79], but patients with Q368Stop mutation typically have a 




surgical intervention to manage the glaucoma. It is interesting to note that although 
myocilin is such widely distributed in many tissues throughout the body as discussed 
above, it is only associated with POAG, an eye disease.  
 Mutations in myocilin reduce its secretion in vitro and in vivo, resulting in a 
reduction or absence of myocilin in the TM of patients with glaucoma-associated MYOC 
mutations [80]. Myocilin variants accumulate in the ER either as homo-oligomers or 
hetero-oligomers when coexpressed with WT myocilin (Fig. 1.3B) [72, 81-86], resulting 
in a significantly reduced level of functional myocilin in the ECM of the TM [80, 82-83, 
86]. However, the reduced myocilin levels in these tissues are not believed to cause the 
POAG phenotype, as both myocilin knock-out mice [6] and patients with the R46Stop 
mutation do not acquire POAG [74]. Instead, sequestration of myocilin mutants in the ER 
likely results in a toxic gain-of-function, unrelated to the normal function of myocilin [6]. 
These aggregates have been shown to be detergent insoluble [87].   
 Under normal homeostasis in the cell, molecular chaperones are present in the ER 
to carefully monitor and assist proteins to their native conformations and continue on 
their path to maturity and cellular trafficking. ER quality control mechanisms ensure that 
nascent proteins that fail to fold or assemble correctly are retained in the ER [88]. It is 
believed that the quality control machinery of the ER recognizes general biophysical 
properties shared by incompletely folded proteins, including exposed hydrophobic 
patches, mobile loops, and a lack of compactness [89]. If the protein continues to misfold 
after multiple attempts of refolding, it is generally targeted for degradation and 
transported to the cytosol where it is rapidly degraded by an ubiquitin-mediated 
proteolytic pathway [90].   
 In this ER associated degradation (ERAD) process, the aberrant protein must first 
be extracted from the ER lumen to be degraded by the proteasome, a barrel-shaped 
structure which requires the substrate to be unfolded to gain access into the active site 




degradation rates of a cell, accumulation of the protein will occur [92]. Mutations, as in 
the case of myocilin, that interfere with protein folding as well as environmental factors 
may exacerbate this problem and trigger ER stress responses. In particular, the unfolded 
protein response (UPR) induces the upregulation of genes encoding ER resident 
chaperones [93-94] such as GRP78 (also called BiP) [95] or protein disulfide isomerase 
(PDI) [96]. Ultimately, programmed cell death is initiated if ER stress is not alleviated.  
 In myocilin-associated POAG, disease-causing variants of myocilin apparently 
possess a folding defect and lead to aggregation in cells. For example, large myocilin 
juxtanuclear aggregates have been observed within the ER of HEK and differentiated 
primary human TM cells [97]. Sequestration of mutant myocilin triggers the UPR and the 
apoptotic pathway [83, 86, 98] characteristic of an ER storage disease. Both the 
molecular chaperone GRP78 and the folding enzyme PDI have been shown to be up-
regulated in HTM cells expressing mutant myocilin [43, 84]. Aggregation of mutant 
myocilins in cultured HTM cells leads to a deformed cellular morphology and diminished 
cell proliferation [84]. The subsequent breakdown of TM cell structure leads to 
obstruction of aqueous humor outflow pathway [99], ocular hypertension, and, 
ultimately, POAG [17].   
1.3.1 Potential Myocilin-POAG Therapy  
 Many diseases are the result of amino acid substitutions in a protein leading to 
either a lack of functional protein (the result of ERAD) and/or due to toxic effects of the 
misfolded protein or aggregates. This may directly or indirectly influence the ability of 
the cell to function properly and can lead to cell death through apoptosis. Disorders that 
fall into this general pattern are referred to as ER storage disorders (ERSDs) or, more 
broadly, protein conformational disorders (PCDs) [100]. Furthermore, both intra- and 




well, including Alzheimer‟s disease, Parkinson‟s disease, multiple sclerosis, and loss-of-
function disorders such as lysosomal storage disorders [101].   
 PCDs are primarily the result of missense mutation(s) in a gene that leads to 
altered protein behavior, aberrant cellular or extracellular activity, and detrimental 
downstream effects that ultimately manifest in disease. However, many of these disease-
causing mutations do not seriously compromise the global fold of a protein, but rather 
lead to local perturbations that are recognized by the ER quality control system, as is 
predicted to be the case for myocilin. We, and others [76, 97], have hypothesized that if 
myocilin aggregation in the ER can be alleviated, either by stabilization of mutant protein 
to facilitate folding and secretion or to promote a more efficient degradation mechanism, 
the dysfunction of TM cells due to cytotoxicity could be relieved and delay the onset of 
clinical symptoms. Support for this therapeutic approach comes from cell-based assays 
where growth at lower temperatures allowed secretion of certain mutant myocilins, 
suggesting that when protein production is slowed, toxicity is reduced [76, 97]. In 
conjunction, addition of nonspecific chemical chaperones such as glycerol, 4-
phenylbutyrate [102], and trimethylamine N-oxide (TMAO) [103] improves secretion of 
mutant myocilin.  
 Pharmacological chaperones (PCs) hold promise as drug candidates since they are 
developed as selective and potent binders to their target protein. They are effective at 
lower concentrations than chemical chaperones [104]. These small molecules are 
typically substrates, inhibitors, ligands, or variations thereof. They are designed to be 
cell-permeable and capable of binding to endogenous mutant protein to confer enhanced 
thermodynamic or kinetic stability, and allow increased trafficking from the ER, thus 
alleviating ER stress and restored protein function. PC therapy has been proposed and 
investigated as a potential treatment for many genetic disorders that result from misfolded 
and/or unstable proteins [105], and partial or complete restoration of thermal stability by 




transcription factors, ion channels, G protein-coupled receptors, and lysosomal enzymes 
[106]. A similar approach for myocilin may lead to a therapeutic compound, but is 
currently unachievable due to limited structural and functional studies of which to base 
PC design.  
1.4 Thesis Objectives 
1.4.1 Chemical Chaperone Rescue of Mutant Myocilin Stability 
 Although one of the major challenges to studying molecular properties of 
myocilin has been the difficulty in recombinant expression of a soluble, well-behaved 
species, we have overcome this limitation. We developed a new high-yield expression 
and purification system for the C-terminal region of myocilin (myoc-OLF) comprising 
the OLF domain fused to maltose binding protein (MBP) and representative glaucoma 
causing mutants. We also developed a facile fluorescence thermal stability assay without 
removal of MBP to gain insight into the biophysical characteristics of WT and mutant 
myocilins. This system was also employed to identify chemical chaperones that thermally 
stabilize the mutant proteins. Our results provide the first direct evidence that mutated 
OLF is folded but less thermally stable than WT. Taken together, our results set the stage 
for studies to further evaluate the nature of the aggregated myocilin species as well as to 
identify therapeutic compounds that both exert a specific stabilizing effect on myocilin 
and enhance mutant myocilin secretion in cells. 
1.4.2 Biophysical Characterization of the Olfactomedin Domain of Myocilin 
 The objective of this study is to probe the molecular properties of myoc-OLF to 
gain insight into its function and structure, and we report the first detailed solution 
biophysical characterization. This work places the OLF domain for the first time in the 




for interactions with specific trabecular extracellular matrix components, and may assist 
in design of therapeutic agents for myocilin glaucoma. 
1.4.3 Application of SYPRO® Orange, a Fluorescent Hydrophobic Dye, for a High-
Throughput Ligand Binding Assay for Proteins of Unknown Structure and/or 
Function, such as Myocilin 
 Due to the lack of specific knowledge of the function and structure of myocilin, 
we sought to develop and validate a high-throughput chemical stability assay to identify 
ligands and potential drug candidates based on the premise that ligand binding confers 
conformational stability to its target protein. Since this ligand-induced stability is a 
general property of proteins, our assay may be adapted essentially to any soluble protein, 
regardless of prior knowledge of structure and/or function. The chemical stability assay 
was verified using MBP as a model protein, and stabilization upon ligand binding 
occurred in a dose-dependent fashion. Myoc-OLF, the protein of therapeutic interest, was 
stabilized in a similar manner with the TMAO, a known osmolyte. Our assay not only has 
identified the first potential therapeutic compounds, but may also generate insights into 
myoc-OLF function. 
1.4.4 Characterization of Amyloid Fibrils Formed by Myocilin 
 Although emerging clues to the pathogenesis of myocilin-induced inherited forms 
of glaucoma have come to light in the past decade, little progress has been made towards 
understanding the molecular mechanisms that lead to sporadic glaucoma, which may be 
due in part to the heterogeneity of the disorder. In this work, we initially sought to 
characterize the aggregated form of myoc-OLF and found that both WT and mutant 
forms of the protein form amyloid fibrils, similar to proteins in other PCDs described 
above. These fibrils may be created under a variety of conditions in vitro and 




mutant myocilin expressed in mammalian cells forms intracellular aggregates containing 
amyloid fibrils. Taken together, this work provides new insights into myocilin and 
suggests a novel molecular based hypothesis for pathogenesis.  
1.4.5 The Acid -Glucosidase Active Site Exhibits Plasticity in Binding 3,4,5,6-
Tetrahydroxyazepane-based Inhibitors 
 In a related study, small molecule drug candidates were investigated to treat acid 
β-glucosidase (GCase), the deficient lysosomal enzyme in Gaucher disease, another 
protein conformational disorder. These small molecules, called pharmacological 
chaperones, have largely been active-site-directed inhibitors of acid -glucosidase 
(GCase), the deficient lysosomal enzyme, usually containing five- or six-membered 
rings, such as modified azasugars. Here we extend the scaffold to seven-membered 
nitrogen-containing heterocycles (3,4,5,6-tetrahydroxyazepanes) with or without alkyl 
ether substructures. Comparison of crystal structures reveals that the core azepane 
stabilizes GCase in its proposed active conformation, whereas binding of an analog with 
a hydroxyethyl tail creates a conformation of GCase in which the active site is covered. 
Although all compounds thermally stabilize GCase at pH 7.4, reflective of the pH in the 
ER, only the core azepane is a micromolar competitive inhibitor and exhibits increased 
activity for the neuronopathic G202R- and the non-neuronopathic N370S- mutant GCase 
enzymes in an intact cell assay. Thus, the core azepane scaffold is a candidate for 
pharmacological chaperone development. The plasticity of the active site of GCase 
observed in binding azepanes offers a structure-based route to the design of second-
generation azepanes and more generally, insight into the possible molecular determinants 







CHEMICAL CHAPERONE RESCUE OF MUTANT MYOCILIN 
STABILITY 
2.1 Introduction 
 Open angle glaucoma (OAG) is a recent addition to the family of protein 
conformational disorders that includes cystic fibrosis, Alzheimer disease, p53-related 
cancers, and lipid metabolism disorders such as Gaucher and Fabry diseases, among 
others [107].  OAG, the most common form of glaucoma that affects ~70 million people 
worldwide, is a complex and heterogeneous disease characterized by irreversible vision 
loss often associated with elevations in intraocular pressure [108-109].  The molecular 
and physiological mechanisms that lead to intraocular pressure increase are poorly 
understood, but are thought to occur in the anterior region of the eye within the 
anatomical pathway for outflow of aqueous humor, which includes the trabecular 
meshwork [110-111].  In the last 10 years, significant progress has been made in 
identifying causative genes that account for inherited, autosomal-dominant glaucoma 
cases. Genes for three protein products, myocilin, optineurin, and WD36, have been 
linked to familial forms of OAG.  Of these, mutations in myocilin are by far the most 
common, accounting 10-33% of the juvenile (35 years of age and younger) and 3-4% of 
all adult-onset OAG cases [108].  
 Myocilin is a ~55 kDa glycoprotein expressed in ocular tissues, as well as 
throughout the human body [110].  Myocilin contains four main regions: (1) a secretion 
signal sequence, (2) a linker with a putative N-glycosylation site, (3) a coiled-coil/leucine 
zipper for multimerization [112] and interactions with certain extracellular matrix 
proteins [113-115], and (4) a ~30 kDa olfactomedin (OLF) domain in which the majority 




myocilin and the OLF domain in any human tissue have not been identified, but a major 
proposed function for myocilin in the eye is structural participation in the trabecular 
meshwork extracellular matrix believed to limit the migration of human trabecular 
meshwork (HTM) cells [116].  Accordingly, myocilin is expressed at relatively high 
levels in [117], and is secreted from [110], HTM cells.  More generally, emerging roles 
of OLF domains include involvement in adhesion as well as neuronal growth, as well as 
in development in the mammalian brain [118-119].  The prevalence and sequence 
conservation (~60-80% identity among mammals) [120] of OLF domains among higher 
eukaryotes underscores the need for additional structural and functional studies. 
 Recent evidence supports a toxic gain-of-function disease mechanism for mutant 
myocilin.  Mice heterozygous and homozygous for a myocilin knock-out allele [121] and 
human individuals with myocilin truncation mutations near the N-terminus [122] do not 
exhibit ocular abnormalities.  Instead of secretion to the extracellular matrix, mutant 
myocilins have been shown to accumulate in the endoplasmic reticulum (ER) of HTM 
cells with toxic consequences [123-124].  In cell-based assays, growth at lower 
temperatures enables secretion of mutant myocilins, suggesting that when protein 
production is slowed, toxicity is reduced [124-126].  In addition, the ability to rescue 
secretion of mutant myocilins at permissive temperatures indicates that these myocilin 
variants likely retain a native-like three-dimensional structure, but have compromised 
stability due to a local perturbation caused by the mutation. At lower temperatures, 
conformational variability is expected to decrease, as the protein is further away from its 
temperature of unfolding.   
 Proteins like mutant myocilins that are folded in the ER are prevented from 
continuing further along the path to protein maturation and cellular trafficking if they are 
not folded correctly. A collection of proteins defined as “ER quality control” recognize 
features/flaws in a newly folded protein, such as those in disulfide bonds, and a misfolded 




minor defects in structure remote from a functional site of the protein cannot escape the 
highly redundant, tightly regulated ER quality control system that can detect exposed 
hydrophobic patches in soluble proteins, mobile loops, and general reduced compactness, 
i.e. biophysical properties [128]. ER quality control does not test newly folded proteins 
for function, which may be preserved for a missense mutant that retains a native-like 
structure.  
 If mutant proteins are not cleared efficiently from the ER and instead are 
accumulated, cellular stress responses are provoked, which may predispose cells to 
additional pathological events. In particular, ineffective clearing of mutant myocilins 
leads to aggregation, cell stress and eventually death [123, 125, 129-131].  HTM cell 
dysfunction death is thought to lead to a compromised matrix unable to properly control 
eye pressure, and eventually, the retinal degeneration characteristic of glaucoma. Thus, 
the pathophysiology is not linked directly to abolished intrinsic function, but first to a 
defect in protein stability, then to a defect in cellular trafficking, ER stress, and finally to 
reduced function of the trabecular meshwork.  
 Mechanisms that stabilize a mutant protein in its native state or accelerate the rate 
of folding and enable it to meet ER quality control standards hold promise as therapy for 
protein misfolding diseases [132-133].  The ability to traffic mutant protein with residual 
function out of the ER is hypothesized to reduce toxicity and cell stress, allowing for 
partial restoration of function, which will ultimately delay the onset of clinical symptoms 
[134].  In the case of mutant proteins without a known ligand or molecular structure, such 
as myocilin, screening for tailored small molecules that accomplish these goals requires a 
top-down approach, i.e. without knowledge of specific surface binding patches.  
To lay the foundation for identification of small molecules capable of stabilizing mutant 
myocilin, we developed a high-yield expression and purification system for the C-
terminal region of myocilin (myoc-OLF) comprising the OLF domain and corresponding 




structural and biophysical properties of myocilin to date has been the difficulty in 
recombinant expression of a soluble, well-behaved species.  We also developed a facile 
fluorescence thermal stability assay and used this system to gain insight into the 
biophysical characteristics of wild-type and mutant myocilins and to identify chemical 
chaperones that thermally stabilize the mutant proteins. Taken together, our results set the 
stage for studies to further evaluate the nature of the aggregated myocilin species, as well 
as to identify therapeutic compounds that both exert a specific stabilizing effect on 
myocilin and enhance mutant myocilin secretion in cells. 
2.2 Results and Discussion 
2.2.1 Expression and Purification of Wild-Type Myoc-OLF 
 We have focused on the myocilin OLF domain primarily because this is the 
location of 90% of all known glaucoma-causing mutations 
(http://www.myocilin.com/variants.php).  Other benefits to studying the isolated, 
compact OLF domain include lack of oligomerization due to the presence of the coiled-
coil/leucine zipper region and complex disulfide patterns [112].  Myoc-OLF domain 
harbors no predicted glycosylation sites and has a single disulfide bond [112, 135], 
supporting the hypothesis that the domain expressed in a soluble recombinant form in E. 
coli will be structurally similar to that of the human protein produced in trabecular 
meshwork cells.   
 A major challenge to the study of myocilin is its known propensity to aggregate.  
Insoluble myocilin inclusions have been observed for both overexpressed wild type 
myocilin in Drosophila eyes [131] as well as mutant myocilin in mammalian cell culture 
[129], suggesting that myocilin aggregation may be relevant to both sporadic and 
inherited forms of glaucoma.  Poor yield and solubility is common among previous 




OLF domain in a soluble form using heterologous hosts such as P. pastoris [135], Sf9 
insect cells [136], 293 EBNA cells [113], or refolded from E. coli inclusion bodies [137-
138]. Thus, to date, experiments conducted on myocilin and/or OLF were limited to 
concentrations of 0.05-0.1 mg/ml, and aggregation was observed at higher concentrations 
[113].  
 We overcame the challenge of recombinant expression and generated a soluble 
OLF construct that can be produced at high yield (~2 mg purified protein /L culture), 
purified to homogeneity, and concentrated to at least 10 mg/mL (Fig. 2.1A) by fusion to 
MBP via an 8 amino acid linker. The linker was designed with a Factor Xa cleavage site, 
enabled by subcloning myoc-OLF from the pET-30 Xa-LIC vector (see Methods).  Thus, 
the linker length and position of the cleavage site are different from the commercial 
pMAL vector. The ability of MBP to facilitate proper folding and improve expression 
levels of difficult proteins in E. coli is well documented [139], and the short linker design 
can help prevent aggregation of a fused protein without affecting its three dimensional 
structure [140].  Indeed, our final MBP-OLF fusion protein proved superior to other 
longer-linker fusion constructs we tested, in which the purified protein was co-eluted 
with the E. coli folding chaperone GroEL (identified by Western blot and trypsin 
digest/mass spectrometry).  Expression levels of wild-type (and mutant MBP-OLF, see 
below) were increased, and GroEL was eliminated, with the use of the rare-codon 
correcting Rosetta-gami 2 E. coli strain, rich media, and growth after induction at 18°C.  
 Cytosolic MBP-OLF, purified initially by amylose affinity chromatography, is a 
mixture of aggregated, monomeric MBP-OLF, and MBP (identified by Western blot and 
trypsin digest/mass spectrometry) likely from cleavage by cellular proteases or 
incomplete translation. Fractionation by size-exclusion chromatography (Fig. 2.1B) 
reveals these three species.  An elution peak with a retention time corresponding to the ~ 








Figure 2.1. Protein purification. A) SDS-PAGE analysis of purified MBP-OLF (WT) 
and cleaved myoc-OLF. Left: lane 2, purified, concentrated (monomeric) MBP-OLF 
(WT) (72 kDa, ~10 mg/mL). Right: lane 2, cleaved myoc-OLF (~31 kDa, ~0.5 mg/mL). 
B) SEC of MBP-OLF WT) displaying aggregated MBP-OLF and monomeric MBP-OLF. 
C) SDS-PAGE analysis of purified MBP-OLF mutants.  Lane 1, MBP-OLF (D380A); 
lane 2, MBP-OLF (I477S); lane 3, MBP-OLF (I477N); and lane 4, MBP-OLF (K423E). 
Low levels of MBP (~40 kDa) do not impede thermal stability measurements (see text).  





(Table 2.1) composed of the only two cysteine residues, which are found in the OLF 
domain. 
 The second distinct peak is in the void volume, indicating an aggregated species is 
present.  The relative intensity of this cytosolic aggregate peak compared to monomer is 
not sensitive to time incubated at 4 °C, a freeze-thaw cycle, or concentration (not shown).  
In addition, neither the monomer nor aggregate re-equilibrates to the other species if each 
is reloaded separately onto the size exclusion column (Fig. 2.2). By SDS-PAGE under 
reducing conditions, the aggregates appear identical to monomeric MBP-OLF (Fig. 2.2, 
inset). The aggregated material comprises a broad spectrum of molecular mass as 
assessed by fractionation on a Sephacryl S-400 column designed to fractionate 
significantly larger macromolecules. The relationship of this high molecular weight 
aggregate species isolated from E. coli cytosol to inclusions observed in cellular 
glaucoma studies [131, 141] is not known at this time, but could be further evaluated in 
the context of improper disulfide bond formation as well as the observed high -sheet 
content for OLF [135], and its predicted amyloid propensity [142]. 
 Finally, as a consequence of the shorter link, accessibility of Factor Xa to the 
cleavage site is somewhat compromised.  Efficient cleavage for monomeric, wild-type 
MBP-OLF is observed after overnight incubation at 37°C, whereas almost no cleavage 
occurs at room temperature.  Cleaved wild-type OLF can be isolated from uncleaved 
MBP-OLF and MBP by amylose affinity chromatography, and appears as a purified 
monomer (~ 31 kDa) after gel filtration (Fig. 2.1A).  Cleaved wild-type OLF is well-
behaved.  No visible precipitation is observed for monomeric cleaved OLF concentrated 
to over 5 mg/mL, and no appreciable aggregation or degradation is observed by either 







Table 2.1. Characterization of disulfide bonds in OLF-containing proteins in this study. 
The thiol-modifying reagent ThioGlo® 1 only reacts with OLF-containing proteins when 




Sample Fluorescence Intensity (513 nm) 
Cleaved myoc-OLF 0.5 ± 0.3 
Cleaved myoc-OLF + TCEP 55.7 ± 2.6 
MBP-OLF 0.9 ± 0.1 
MBP-OLF + TCEP 46.6 ± 3.1 
MBP-OLF (D380A) 0.9 ± 0.2 
MBP-OLF (D380A) + TCEP 45.0 ± 2.0 
MBP-OLF (I477S) 0.7 ± 0.4 
MBP-OLF (I477S) + TCEP 60.9 ± 1.9 
MBP-OLF (I477N) 1.5 ± 0.3 
MBP-OLF (I477N) + TCEP 71.9 ± 1.5 
MBP-OLF (K423E) 0.6 ± 0.2 





Figure 2.2. Characterization of OLF and mutants by SEC. A) Aggregates purified as 
in Methods that are reloaded onto preparative Superdex 75 column do not disaggregate 
into monomers. Inset: Fractionation of aggregates on SDS-PAGE under reducing 
conditions yields monomer MBP-OLF (~ 72 kDa). Right: molecular mass markers (kDa). 
B) MBP-OLF monomers purified as in Methods that are reloaded onto analytical 
Superdex 75 column do not equilibrate to aggregates to any appreciable extent. C) MBP-
OLF(wt) and cleaved MYOC-OLF incubated at 4 °C for over a month do not aggregate 





2.2.2 Expression and Purification of Mutant Myoc-OLF 
 The four mutant myocilins selected for this study are well documented in the 
literature both in terms of prevalence among glaucoma patients as well as aggregating 
behavior in cells. The myocilin mutants selected represent mild (D380A) [143], moderate 
(I477S) [144], and severe phenotypes ((I477N[145], K423E [146]), as well as changes in 
size, polarity and charge.  The locations of these mutations within the three dimensional 
fold of OLF are not currently known, but they do not interfere with disulfide bond 
formation (Table 2.1).  In cellular studies [125-126], both D380A- and I477S- mutant 
myocilin secretion could be rescued by low temperature culture, whereas little or no 
secretion could be rescued with I477N- or K423E-mutant myocilin.  The latter two 
mutants are also observed as aggregates in the ER, and induce the unfolded protein 
response [123, 131] (Summarized in Table 2.2). 
 Given previous cellular studies on these mutant myocilins, it was not clear from 
the outset whether soluble, recombinant expression of any mutants would be achievable, 
but expression and purification of MBP-OLF mutants followed closely that of wild-type 
MBP-OLF (Fig. 2.1c), with similar yields (~1 mg purified mutant MBP-OLF/ L culture).  
All experiments with MBP-OLF mutants were conducted well within a week of 
purification. Like wild-type MBP-OLF, three species were isolated by gel filtration, but 
based on peak height, the amount of aggregate mutant MBP-OLF in the void volume 
relative to that isolated in a monomeric form, varied from ~ 1.8 ± 0.4 for wild type MBP-
OLF, 3.4 ± 0.2 for the D380A OLF domain mutant (MBP-OLF(D380A)), 12.1 ± 2.1 for 
the I477N (MBP-OLF(I477N) and 14.2 ± 2.0 for the I477S mutant (MBP-OLF(I477S), 
and 33.4 ± 3.6 for the K423E OLF domain mutant (MBP-OLF(K423E)).  Like wild-type 
MBP-OLF, these ratios were unaffected by protein handling or concentration loaded onto 
the Superdex 75 column. After purification, prolonged incubation at 4 °C leads to 
degradation of the OLF domain of the MBP-OLF mutants as observed by SDS-PAGE 




Table 2.2: Summary of solubilization and secretion behaviors reported for select mutant 











Secretion from 37 °C 
culture HEK293 
[125]/HTM [126] 
Secretion from 30 °C 





D380A Mild + +/- +/+ n.d. 
I477S Moderate - -/n.d. +/n.d. n.d. 
I477N Severe - -/- +/- + 




soluble aggregates and monomer (Fig. 2.2). Taken together, there appears to be 
considerable inherent aggregation propensities in spite of isolation from the E. coli 
cytosol.  After incubation with Factor Xa using conditions used for MBP-OLF, only the 
cleaved MBP could be isolated, suggesting mutant OLF had degraded at 37°C.  To date, 
Factor Xa cleavage could not be further optimized to isolate the mutant OLFs.  Circular 
dichroism spectra of the purified monomeric MBP-OLF mutants exhibit the expected 
mixture of the predominantly α-helical MBP (minima at 208, 222 nm) and predominantly 
β-sheet previously reported for OLF [135](minimum at 217), with some variation in 
overall intensity indicative of primarily local changes in structure (Fig. 2.3). 
2.2.3 Thermal Stability Assay 
 The ability to express and purify site-directed MBP-OLF mutants in E. coli 
similar to wild-type, combined with similar CD signatures, suggests that these mutants 
are folded and retain a native-like three dimensional structure at or below room 
temperature.  Thus, we developed a stability assay to compare wild-type OLF with that of 
mutants using a method that could be applied in a high-throughput fashion to test many 
mutants and stabilizing compounds.  For this reason, we also preferred an assay that 
minimized protein amount and concentration requirements.  The fluorescence thermal 
shift assay described originally for screening buffer conditions and stabilizing compounds 
[148] meets these criteria and was adapted to compare wild-type to mutant OLF.  
  The fluorescence thermal shift assay uses a real time (RT)-PCR instrument to 
conduct a slow melt while measuring fluorescence.  The excitation and emission settings 
of the RT-PCR instrument are compatible with Sypro Orange, a dye known to bind to 
hydrophobic regions of proteins, which become increasingly exposed as the temperature 
of the protein-dye solution is raised.  The Tm is determined as the midpoint of the 
transition given the upper and lower limits of the fluorescence signal, and assumes a two-





















Figure 2.3. Characterization of MBP-OLF and mutants by CD. Overall, the shapes of 
the mutants are similar to MBP-OLF(wt), exhibiting a mixture of α-helical and β-sheet 






explored protein stability as a function of buffer conditions or ligand [149-150], and a 
variant library of Rop, a well studied 14 kDa four-helix bundle [151-152], our study  
appears to be a novel application of the fluorescence stability assay to an explicitly 
aggregation-prone domain with disease relevance.  This was accomplished by adapting 
the fluorescence thermal stability assay to the MBP-OLF fusion protein.  
 The fluorescence stability assay provides a reproducible, precise (~ ± 1 °C; Table 
2.3), and convenient way to measure relative protein stability. The assay was used first to 
evaluate the melting temperature (Tm) of cleaved, wild-type OLF, which exhibits a 
reproducible transition at 52.7 ± 0.3 °C at neutral pH (Fig. 2.4A).  To expand the assay to 
include mutant MBP-OLF fusion proteins, which cannot be cleaved with Factor Xa, we 
examined next the thermal stability of MBP alone (Fig. 2.4B) and compared wild-type 
MBP-OLF and cleaved OLF each with and without maltose (Fig. 2.4A, C).  Apo MBP, 
which was isolated after Factor Xa cleavage of wild-type MBP-OLF, exhibits a transition 
at 56.1 °C, and the addition of excess maltose shifts the Tm to 67.1 °C.  These values are 
somewhat lower than those obtained for MBP from E. coli K-12 by differential scanning 
calorimetry (~ 64 °C without and ~ 72 °C with maltose at neutral pH) [153-154], but two 
amino acid sequence differences and the additional C-terminal linker may contribute to 
this discrepancy. Wild-type MBP-OLF without maltose exhibits a broad melting 
transition with a Tm of 51.8 °C.  With maltose, two discrete transitions are observed for 
wild-type MBP-OLF, one at 52.7 °C and the other at ~67 °C. The former transition 
overlaps well with cleaved OLF (Fig. 2.4A), and indicates that the first transition in the 
MBP-OLF fusion protein corresponds to the OLF domain.  Compared to results with 
MBP, the second transition in MBP-OLF with maltose present is likely MBP with bound 
maltose.  Notably, addition of maltose to the cleaved wild-type OLF sample does not 
alter the Tm (Fig. 2.4A).  Taken together, these experiments establish that in the presence 
of maltose at pH 7, the melting of MBP is independent of the OLF domain, and the Tm of 






Table 2.3. Effects of osmolytes on proteins investigated in this study.  
 Protein 
only 
+Betaine Tm +Glycerol Tm +4-PBA
a
 Tm +Proline Tm +Sarcosine Tm +Sucrose Tm +TMAO Tm 




6.9 56.0 ± 1.2 3.3 55.5 ± 0.5 2.8 57.2 ± 
0.3 
4.5 65.2 ± 
0.6 
12.5 64.3 ± 
0.1 









4.1 49.5 ± 0.2 2.8 47.2 ± 0.1 0.5 49.9 ± 
0.2 
3.2 58.3 ± 
0.6 
11.6 54.2 ± 
0.7 









6.1 45.1 ± 0.2 3.1 42.6 ± 0.1 0.7 45.3 ± 
0.3 
3.4 54.0 ± 
0.4 
12.0 50.7 ± 
0.2 









4.9 43.7 ± 0.4 3.5 41.4 ± 0.4 1.3 43.8 ± 
0.9 
3.7 52.5 ± 
0.3 
12.4 50.3 ± 
0.9 









5.4 42.6 ± 0.2 
 




2.1 48.6 ± 
0.6 
8.1 46.3 ± 
0.5 









4.2 68.2 ± 0.4 1.1 66.2 ± 0.1 -0.9 69.8 ± 
0.6 
2.7 75.1 ± 
1.0 
8.0 72.6 ± 
0.8 




5 mM 4-PBA. 
b








Figure 2.4.  Melting curves. A) Cleaved myoc-OLF with and without maltose. B) MBP 
melting with and without excess maltose. C) MBP-OLF with and without maltose. D) 





 In comparison to wild-type MBP-OLF, all four MBP-OLF mutants tested were 
destabilized, but retained a discrete melting transition expected for a folded protein (Fig. 
2.4D, Table 2.3). The transitions for MBP overlap well (not shown), reinforcing the 
independence of the two protein domains in the assay.  MBP-OLF(D380A), which is 
associated with a mild glaucoma phenotype, exhibited the highest melting temperature 
(46.1 °C) of those tested in this study.  This result is consistent with the observation that 
MBP-OLF(D380A) was expressed and purified in the highest yield among the mutants, 
and in cell studies is partially secreted at 37 °C [125] and largely secreted at 30 °C [125-
126].  MBP-OLF(I477S), associated with a moderate myocilin glaucoma phenotype, 
showed the next highest Tm of 41.9 °C, while the remaining two mutant proteins exhibit 
similar melting temperatures to each other, near 40 °C. Given that the temperature of the 
anterior eye is ~ 35 °C [155], a significant population of unfolded, aggregation prone 
mutant OLF domain is expected to be present. MBP-OLF(K423E) exhibits a weak pre-
transition prior to the major unfolding transition, which may have origins in extra 
instability conferred by charge inversion at this location in the OLF domain. The trend in 
Tm appears to follow generally the severity of aggregation and disease, although a strong 
correlation with disease phenotype will require the assessment of the stability of 
numerous other disease-causing myoc-OLF mutants, which is beyond the scope of this 
study.  
2.2.4 Stabilization of Wild-Type and Mutants of MBP-OLF with Osmolytes 
 A shift of the population to a more stable, native-like, folded state of myocilin 
could be an effective therapeutic intervention for myocilin glaucoma. One practical 
therapeutic avenue would be to stabilize mutant myocilin with small molecules delivered 
topically to the anterior region of the eye.  Compounds of therapeutic interest for 
myocilin could include those with general stabilizing ability called chemical chaperones, 




chaperones [156]. There are several ways that a chaperone may help trafficked proteins, 
both wild-type and mutant, meet the ER quality control requirements, which include both 
thermodynamic- and kinetic-based mechanisms.  For example, the chaperone could (1) 
accelerate folding, reducing the chance that it will be recognized as unfolded; (2) bind 
and stabilize a fully folded protein so that it is less likely to unfold or to be recognized as 
misfolded; (3) stabilize the protein for post-translational modification (e.g., 
glycosylation) or interaction with a binding partner required for proper trafficking; or (4) 
all or some combination of the above.   
 Numerous studies on potential pharmacological chaperones are focused on 
thermodynamic stabilization [157-160].  Even transthyretin, in which the chaperones 
ultimately decrease the rate of pathogenic amyloid fibril formation, the tetrameric state of 
protein is stabilized [161].  Thus, drawing upon these examples, we believe that an 
important feature of a therapeutic compound for myocilin glaucoma will be restoration of 
mutant myocilin stability to near wild-type levels.  We further suggest that therapeutic 
agents should not just enable mutant myocilin to pass ER quality control and be secreted 
from HTM cells, but should also prevent myocilin from aggregating in the ECM.  The 
latter effect could also include promoting proper protein-protein interactions that 
maintain ECM integrity.   
 As a starting point for this approach, and for proof-of-principle that mutant 
myocilins can be stabilized, we selected a subset of chemical chaperones called 
osmolytes, low molecular weight agents found in nature that improve protein homeostasis 
in eukaryotic cells in response to osmotic stress [162].  Osmolytes exert a stabilizing 
force on proteins not by direct ligand interaction but by destabilizing the unfolded state of 
the protein relative to that of the native, an effect thought to be due largely to unfavorable 
interactions of the protein backbone with the osmolyte-rich environment [163-166].  
Osmolytes are of particular interest for forced folding of biologically important proteins 




glycerol, proline, sarcosine, sucrose, trimethylamine N-oxide (TMAO), and 4-
phenylbutyrate (4-PBA) on myoc-OLF and MBP-OLF mutants (Fig. 2.5). TMAO in 
particular is known to counteract urea unfolding [168]. The last compound, 4-PBA, is not 
explicitly an osmolyte, but is a chemical chaperone originally identified for treatment of 
urea cycle disorders.  4-PBA has also been evaluated as a treatment for cystic fibrosis 
because it enables cellular trafficking of a mutant transporter caught in an intermediate 
folding state [133, 169]. Although these compounds do not necessarily bind to myoc-
OLF as ligands, any that are found to stabilize myocilin are in principle of therapeutic 
potential, and are therefore good test cases for evaluating the effects of small molecules 
on myocilin using the fluorescence stability assay. 
 First, we compared the effects of these stabilizing agents on MBP alone, wild-
type MBP-OLF, and myoc-OLF, at several concentrations of chemical chaperones. As 
expected, there is a concentration dependence of the chaperone on the extent of 
stabilization.  We chose to focus on assays in the presence of 3 M chaperone, except for 
4-PBA and TMAO where indicated, based on previous in vitro studies [167-168, 170-
171], ease of preparing solutions, and significant stability enhancement observed (Table 
2.3, Fig. 2.5).   Comparison of wild-type MBP-OLF and cleaved OLF (not shown) 
reveals only a small difference (~0.3°C) in melting temperature for all compounds tested; 
thus, we report in Table 2.3 only the results for MBP-OLF and corresponding mutants.   
In addition, compared to MBP-OLF, the extent of MBP stabilization is generally lower 
magnitude (Table 2.3).  In sum, the comparison of mutant MBP-OLF stability reflects the 
effect on the myoc-OLF domain alone.  
 The effects of the seven chemical chaperones on wild-type myoc-OLF rank as 
follows: sarcosine ~ TMAO ~ sucrose (8-10°C) >> proline ~ betaine ~ glycerol (2-4 °C) 
> 4-PBA (~ 0 °C) (Table 2.3, Fig. 2.5).  Given that osmolytes confer only limited 
stability to proteins via side chain effects [163], the degree of stabilization of the mutants 




Figure 2.5.  Effects of osmolytes on mutant myocilins.  Key: pink, sarcosine; purple, 
TMAO; blue, sucrose; green, betaine; yellow, proline; orange, glycerol.  (a) wild-type 
MBP-OLF, (b) MBP-OLF(D380A), (c) MBP-OLF(I477N), (d) MBP-OLF(I477S), (e) 
MBP-OLF(K423E). For (b)-(e), MBP-OLF mutant (no osmolyte) appears as the leftmost 
grey scale melting thermogram using the same scheme as in Fig 2D, and wild-type MBP-




zwitterionic, methylated analog of glycine that is highly stabilizing, is structurally similar 
to the less effective betaine and proline, illustrating the complexity of protein 
stabilization by osmolytes.  
 Sarcosine, TMAO, and to a lesser extent sucrose, were highly effective at 3 M in 
improving mutant MBP-OLF stability.  For MBP-OLF(D380A), stability to better than 
wild-type (Fig. 2.5B) was achieved for all three osmolytes, a result that may not be 
surprising given that the Tm between wild-type MBP-OLF and MBP-OLF(D380A) is 
smaller than the Tm of wild-type MBP-OLF with the same osmolytes (Table 2.3).  For 
both I477 variants (Fig. 2.5C, D), sarcosine gave the highest Tm. Consistent with the 
proposed stabilizing mechanism of osmolytes, the OLF domain is not sensitive to side 
chain at this position, as it is stabilized to the same degree when substituted with either 
the small serine or similar-sized asparagine side chains.  By contrast, MBP-OLF(K423E) 
(Fig. 2.5E) is relatively resistant to stabilization by chemical chaperones.  For each, the 
extent of stabilization of MBP-OLF(K423E) was less than for wild-type and the other 
three mutants.  Even in the presence of 5 M TMAO, the Tm could only be increased to a 
value between wild-type and MBP-OLF(D380A) without osmolytes (Table 2.3). 
Moreover, transitions observed for MBP-OLF(K423E) with TMAO and sarcosine, while 
shifted considerably, were correlated with more modest changes in Sypro Orange 
fluorescence signal in the assay.  The effects of the strongly stabilizing osmolytes on 
MBP-OLF variants observed here are consistent with emerging evidence for more 
compact protein structures in osmolyte solutions [172], which is expected to be most 
challenging to accomplish for the charge inversion in MBP-OLF(K423E). 
 Compared to the transitions observed for osmolyte-stabilized wild-type MBP-
OLF, all of which appear to have the same shape, those of the corresponding melting 
curves for mutants differ. In some cases, it was challenging to establish pre- and post-
denaturation baselines, which were either broad or very short.  This difficulty in 




shallow, broad pre-transition is observed for MBP-OLF(D380A) with proline and 
TMAO, whereas the remaining osmolytes follow closely the shape of the curve in the 
absence of osmolyte (Fig. 2.5B).  Pre-transitions are also apparent for MBP-OLF(I477N) 
in the presence of glycerol and sucrose, which are both polyols (Fig. 2.5D).  Conversely, 
sharper transitions are seen for MBP-OLF(I477S) in the presence of sarcosine compared 
to other osmolytes.  These comparisons do not directly inform an unfolding pathway, but 
suggest a deviation from assumed two-state behavior of a single domain unfolding.  For 
example, an unfolding intermediate may exist in which the mutated residue is 
accommodated by non-native interactions prior to full domain unfolding.  Alternatively, 
two sub-domains may exist within OLF, one of which is stabilized better by the osmolyte 
than the other.  In sum, the effects of osmolytes, which are generally believed to be an 
effect due to interactions with the protein backbone, may also be influenced by the side 
chains, either in terms of unfolding pathway or by unfavorable side chain environment 
such as charge inversion that limit the extent of stability achievable. 
 Our stabilization results differ from previous cellular trafficking studies using 
green fluorescence protein (GFP)-tagged mutant myocilin (C245Y, G364V, P370L, 
Y347H) [173] or peptide epitope (FLAG tag, used in D380N mutant myocilin) [174].  
These studies monitored secretion in the presence of a single concentration (mM) of 
glycerol [173], 4-PBA [173] or TMAO [173] by immunoprecipitation/ Western blot of 
myocilin in the media, in combination with immunofluorescence to detect myocilin 
retained in the ER.  Chaperones 4-PBA and TMAO showed a modest increase (~ 2x) in 
secretion.  In cell studies, however, chemical chaperones can have stabilizing effects on 
numerous proteins, such as those involved in stress or the unfolded protein response, so 
they do not establish a direct stabilizing effect on myocilin.  Whereas no effect on 
secretion was seen with glycerol in cell studies [173], this polyol results in a modest 
increase in mutant OLF stability, albeit at much higher concentrations that were not 




observed with 4-PBA, this compound had no direct stabilizing effect on wild-type myoc-
OLF in vitro at low mM concentrations, and was strongly destabilizing above 10 mM 
(not shown).  Only TMAO appears to both stabilize in our system and promote secretion 
from HTM cells, although the effects were observed with different mutants.   This limited 
comparison stresses the need for complementary studies to evaluate molecules that 
stabilize mutant myocilins directly and promote its secretion in cells, both of which are 
key to developing a new treatment for myocilin glaucoma. 
 In conclusion, we have produced in soluble form and purified in high yield wild-
type and four glaucoma-related mutant myoc-OLFs as MBP fusion proteins with a short 
intervening sequence.  This advance enabled the adaptation of a facile stability assay for 
OLF without removal of MBP to both compare stability among mutants and examine the 
relative effects of chemical chaperones.  All OLF mutants tested here are destabilized 
compared to wild-type myoc-OLF, includung D380A, which is associated with a mild 
OAG phenotype.  Wild-type and mutant OLFs are stabilized by osmolytes, with several 
compounds capable of restoring mutant myocilin stability to an extent near wild-type.  
Our results further suggest that screening a library of potentially stabilizing compounds 
first against wild-type myoc-OLF, either as the readily available MBP fusion or in the 
cleaved form, will identify compounds of potential therapeutic interest that can then be 
tested in a more focused way on mutant myocilins associated with inherited OAG.  These 
initial stability tests can then be followed by cellular studies to test for enhanced 
secretion.  Small molecules capable of stabilizing myocilin hold promise for delaying the 
associated autosomal-dominant inherited forms of glaucoma, for which no specific 






2.3.1 Molecular Biology 
 The OLF construct of the myocilin gene (myoc-OLF) was first amplified (5-
PRIME Master Mix, Fisher Scientific) from a plasmid reported previously [147] and 
annealed into the pET-30 Xa/LIC vector (Novagen). Attempts to express the pET-
30Xa/LIC OLF plasmid in E. coli did not yield sufficient soluble protein (not shown).  
OLF was then amplified from pET-30 Xa/LIC (retaining the N-terminal Factor Xa 
cleavage site) and ligated (Roche Quick Ligation Kit) into the pMAL-c4x vector using 
SacI and EcoRI (New England Biolabs) restriction sites, respectively. Primers used are 
listed in Table 2.4. The final pMAL-c4x construct incorporates an 8-amino acid linker 
between MBP and OLF (SSSEIGR), where the Factor Xa cleavage sequence is leftover 
from pET-30 Xa/LIC. After transformation into NovaBlue Gigasingles (Novagen) and 
overnight growth, the plasmid was isolated (Qiagen QIAPrep). Four mutant MYOC-
OLF, constructs were generated by site directed mutagenesis (Stratagene QuikChange) 
according to the manufacturer‟s instructions. Each mutant was amplified from the wild-
type OLF pMAL-c4x plasmid with complementary mutagenesis primers. After treatment 
with Dpn I to remove the parental strand, transformation into XL1-Blue cells and 
overnight growth, the mutant plasmid was isolated. Primers used in this study appear in 
Table 2.4.  All plasmids were verified by DNA sequencing (MWG/Operon). 
2.3.2 Protein Expression and Purification 
 Wild type and mutant plasmids were transformed into Rosetta-gami 2(DE3)pLysS 










 Primer Used 










  Reverse 5‟-GCCGAATTCAGGAGAGTTAGAGCCTTATCA 
   Mutagenesis 
D380A   5‟-GCTACACGGACATTGCCTTGGCTGTGGATG 
K423E   5‟-GGGAGACAAACATCCGTGAACAGTCAGTCGCCAATGCC 
I477N   5‟-GTACAGCAGCATGAATGACTACAACCCCCTGG 




Biological) to an optical density of 0.6 to 0.8 at 600 nm, cooled to 18 °C, and induced 
with 0.5 mM isopropyl -D-thiogalactopyranoside (IPTG). They were grown overnight 
for 12-16 hours, pelleted by centrifugation, flash frozen with liquid nitrogen and stored at 
-80 °C.  Cell pellets were lysed either by sonication or by French Press in the presence of 
50 mM HEPES pH 7.5, 200 mM NaCl, 1 mM EDTA (Buffer A), supplemented with 
Roche Complete Protease Inhibitor. Cell debris was removed by centrifugation (5000 x g 
for 15 min) and supernatant loaded onto a 20 mL High Flow Amylose Resin (New 
England Biolabs) column equilibrated with Buffer A. The MBP-OLF protein was eluted 
with lysis buffer supplemented with 10 mM maltose, concentrated using an Amicon Ultra 
YM-10 or -30 centrifugation device, and either frozen in liquid nitrogen and stored at -80 
°C, or further purified by gel filtration.  
 Gel filtration was carried out on a Superdex 75 Prep Grade resin equilibrated with 
10 mM Phosphate (Na/K), 200 mM NaCl, pH 7.2 (Buffer B).  Care was taken so that 
only those fractions corresponding to monomeric MBP-OLF were pooled and 
concentrated for further use.  Samples were stored either at 4 °C or at -80 °C.  
Cleavage was accomplished by overnight (~ 12 h) incubation with Factor Xa (New 
England Biolabs, 10g Factor Xa : 50 g purified MBP-OLF) in 50 mM Tris pH 8, 100 
mM NaCl, 5 mM CaCl2. After capture of Factor Xa (Xarrest, Novagen), cleaved OLF 
was fractionated from uncleaved material and MBP by Superdex 75 prepared as above. 
MBP used in these studies were isolated from this cleavage protocol. Purified protein was 
either flash frozen in liquid nitrogen or stored at 4 °C.  Samples were tested for melting 
properties within one week. 
2.3.3 Disulfide Characterization 
  The oxidation state of the two cysteines present in wild type OLF, as well as the 
OLF mutants, was determined by utilizing a maleimide fluorogenic SH reagent, 




DMSO to a final concentration of 10 mM. ThioGlo® 1 was further diluted to 20 μM in 
Buffer B, along with 1-2 μM OLF with and without 5 mM tris(2-carboxyethyl)phosphine 
HCl (TCEP; Thermo Scientific). Fluorescence emission spectra of cysteine– ThioGlo® 1 
protein adducts were recorded using excitation and emission wavelengths of 379 and 
513 nm respectively, using a Shimadzu RF-5301 PC spectrofluorophotometer. 
2.3.4 Circular Dichroism  
 Prior to CD scans, monomeric MBP-OLF samples were purified on an analytical 
Superdex 75 GL column and concentrated to 0.25-0.5 μM.  CD spectra were acquired at 
25 °C on a Jasco J-810 CD spectropolarimeter.  Twenty consecutive scans ranging from 
200 nm to 300 nm, using a bandwidth of 1 nm at a continuous scanning rate of 500 
nm/min, were averaged for each sample.   
2.3.5 In Vitro Thermal Stability Assay 
 The fluorescence stability assay was adapted from a thermal shift assay reported 
previously [148]. Sypro Orange dye (Invitrogen) was used to monitor the relative 
exposed hydrophobic protein regions. The dye, which is supplied as a 5,000X solution in 
DMSO, was diluted in the buffer solution (1:1000) and mixed well just prior to preparing 
samples for the assay. Total reaction volumes of 30 µL were prepared at room 
temperature and delivered to 96-well optical plates (Applied Biosystems) before sealing 
with optical film.  To the protein solution (maltose binding protein, wild-type OLF 
cleaved or uncleaved, and mutant MBP-OLF) at a final concentration of 0.5-1.5 M in 
Buffer B, 3 L of diluted Sypro Orange were added.  Except when indicated otherwise, 
maltose was added to a final concentration of 50 mM.  Compounds tested for stability 
enhancement include betaine (trimethylglycine), glycerol, sucrose, TMAO, sarcosine 
(methylglycine), and 4-PBA, which were obtained from commercial sources. TMAO and 




was tested in a concentration range of 1 mM to 0.5 M. All others were tested at 3 M by 
diluting 5 M stock solutions in Buffer B.  Test proteins citrate synthase and lysozyme 
were obtained in purified form from Sigma.  All plates included a baseline blank control 
containing diluted Sypro Orange with no protein.  The pH of the final solutions did not 
deviate significantly from 7. 
 Fluorescence data were acquired on an Applied Biosciences Step-One Plus RT-
PCR instrument, which is equipped with fixed excitation wavelength (480 nm) and 
optional ROX emission filter (610 nm) that can be used without a passive reference.  
Denaturation curves were conducted in the range of 25-95 °C at a rate of 1 °C per min, as 
no difference in Tm was observed when the rate of heating was decreased to 0.5 °C per 
min.  In addition, above a minimum threshold of protein concentration required to 
observe a discrete transition, no dependence of protein concentration on Tm was 
observed.  Data were processed using GraphPad Prism software.  After baseline 
subtraction, data were trimmed to include the boundaries and the melting transition of 
interest and normalized.  The reported melting temperature is the inflection point of the 






BIOPHYSICAL CHARACTERIZATION OF THE OLFACTOMEDIN 
DOMAIN OF MYOCILIN 
3.1 Introduction 
 Myocilin, the protein most closely associated with inherited forms of open angle 
glaucoma (OAG) through genetic linkage studies, is a ~57 kDa glycoprotein composed of 
a secretion signal sequence, coiled-coil region, and a ~30 kDa olfactomedin (OLF) 
domain (Figure 3.1), which harbors 90% of all reported pathogenic lesions [110].  The 
molecular mechanisms that lead to glaucoma are not well established but are of 
significant biomedical interest given that glaucoma is a leading cause of blindness 
worldwide, and early-onset myocilin glaucoma accounts for 4% of glaucoma cases, 
primarily afflicting children.  
 Wild-type (WT) myocilin is secreted from human trabecular meshwork (HTM) 
cells to the trabecular meshwork extracellular matrix (TEM) [114, 175-176], the 
anatomical region believed to regulate intraocular pressure [114, 116].  By contrast, 
mutant myocilins aggregate in the endoplasmic reticulum (ER), leading to cell death and 
a malfunctioning matrix. The net result is an increase in intraocular pressure and retina 
degeneration, a hallmark of glaucoma [108].  Defects in protein stability and trafficking 
that lead to this gain-of-toxic-function have been shown to underlie the pathophysiology 
of myocilin glaucoma [121-122]. Temperature-sensitive secretion of some myocilin 
variants [125-126] indicates that when protein production is slowed, some mutant 
proteins appear native-like and competent for trafficking out of the cell and to the TEM.  
In cell culture, the toxicity of mutant myocilins can be reduced by the addition of certain 
chemical chaperones [174, 177], and in vitro, the compromised stability of mutant myoc-








Figure 3.1. Multiple sequence alignment for myocilin and non-ocular ortholog 
amassin. Alignment includes myocilin from H. sapiens (gi 3065674), D. rerio (gi 
62632725), B. taurus (gi 74356501), S. scrofa (gi 47522798), M. musculus (gi 
15077142), R. norvegicus (gi 3845607), and amassin from S. purpuratus (gi 28453877). 
The region shaded in grey contains the N-terminal signal sequence and coiled-coil region, 
whereas the OLF domain remains unshaded. The consensus predicted secondary 
structures are shown in the last line (h, alpha-helix; e, beta-strand). Blue, similar residues; 
red, conserved residues; asterisk, reported disease-causing mutation in human myocilin 
[179]. The alignment and predicted secondary structure were generated using PROMALS 
[180]. Solid black boxes enclose peptides identified in both core-OLF and myoc-OLF by 







 In spite of the importance of myocilin in inherited glaucoma pathogenesis, little is 
known about its normal biological function in the TEM, especially the OLF (myoc-OLF) 
domain.  Full-length myocilin has been shown to bind to TEM proteins such as laminin 
and the Hep II domain of fibronectin [181-182], as well as the glycosaminoglycan (GAG) 
heparan sulfate, but these interactions are localized to the coiled-coil region of myocilin, 
and not myoc-OLF [113]. The normal biological roles of myocilin are further 
complicated by reports of myocilin localized to the mitochondria of HTM cells [175, 
183], calpain-II dependent cleavage prior to secretion [184], as well as its expression in 
other ocular tissues including sclera, ciliary body, iris, retina and optic nerve head [185]. 
Moreover, beyond the eye, OLF domains are found in numerous multicellular organisms, 
and more than half of reported OLF domains are found in neural tissues. OLF domains 
are proposed to play roles in neurogensis, neural crest formation, dorsal ventral 
patterning, cell-cell adhesion, cell-cycle regulation, cell-cell signaling, tumorigenesis, and 
have been implicated in psychiatric disorders [119]. The explicit roles of myocilin in any 
of these tissues and processes, however, are not clear due to a lack of functional assays. 
 The objective of this study is to probe the molecular properties of myoc-OLF to 
gain insight into its function and structure.  The study was enabled by our recent 
development of a preparative in vitro expression system in which myoc-OLF is closely 
fused to a cleavable maltose binding protein (MBP) [178].  Our current work places the 
OLF domain for the first time in the context of other known proteins.  The analysis of 
myoc-OLF described herein also provides a biophysical basis for the development of a 






3.2.1 pH Stability Profile of Myoc-OLF  
 We investigated the pH stability profile of myoc-OLF to elucidate any 
preferences of this domain as well as to gain insight into its resilience under different pH 
environments, such as low pH, that might be encountered under a known age-related 
TEM stressor, oxidative stress [186].  For the broad 96-well pH screen, we used the 
MBP-OLF fusion protein and adapted the differential scanning fluorimetry (DSF) 
technique used originally to assess thermal stability differences between WT and 
glaucoma-causing myoc-OLF variants [178].  The melting of MBP is deconvoluted from 
the melting of OLF by the addition of 50 mM maltose.  The melting curves of MBP and 
OLF are readily distinguished in the stability assay throughout the pH range tested. MBP 
is stable from pH 4-10.5 [154], OLF is not affected by the presence of maltose [178], and 
Sypro Orange is not pH sensitive in the range 4-10 (not shown).  
 To cross-validate the results obtained using the MBP-OLF fusion protein, we 
subsequently tested cleaved myoc-OLF in a subset of stabilizing and destabilizing buffers 
(Table 3.1). There was no difference in melting temperature (Tm) between the MBP-OLF 
and cleaved myoc-OLF among the pHs tested (Table 3.1), reinforcing the independence 
of the domains in the fusion protein.  Interestingly, myoc-OLF is stable in 100 mM 
buffers corresponding to a range in pH of 4.6 to 7.4, but specifically in sodium lactate, 
acetate, MES, phosphate and Hepes (Table 3.1-3.2). Bicine at pH 7.0 and glycine at pH 
8.2 were also stabilizing buffers, albeit within a more limited pH range (Table 3.1-3.2).  
By contrast, OLF was destabilized in pH 4.0-4.6, as well as the full pH range tested of 
Bis-Tris, Imidazole, Tris, and CHES buffers (Table 3.1-3.2).   
 The concentration dependence of buffer stabilization or destabilization was 
further investigated using acetate buffer pH 4.6 or Tris buffer pH 7.5 as examples, 




Table 3.1.  Melting temperature of myoc-OLF and MBP-OLF in buffer. 




Δ Tm (°C) 
(myoc-OLF - 
MBP-OLF) 
100 mM Sodium Lactate/HCl 4.0  39.4 ± 0.5  
100 mM Sodium Lactate/HCl 4.4  47.1 ± 0.3  
100 mM Sodium Lactate/HCl 4.8  52.2 ± 0.0  
100 mM Sodium Lactate/HCl 5.2  55.4 ± 0.1  
100 mM Sodium Acetate/Acetic Acid 4.2 47.7 ± 0.0 47.6 ± 0.5 0.1 
10 mM Sodium Acetate/Acetic Acid 4.6 49.8 ± 0.2   
100 mM Sodium Acetate/Acetic Acid 4.6 51.9 ± 0.3 50.8 ± 0.2 1.0 
100 mM Sodium Acetate/Acetic Acid 5.0 54.8 ± 0.3 54.0 ± 0.0 0.8 
100 mM Sodium Acetate/Acetic Acid 5.4 56.5 ± 0.4 55.8 ± 0.1 0.7 
100 mM Sodium Acetate/Acetic Acid 5.8 57.3 ± 0.1 56.2 ± 0.0 1.1 
100 mM Sodium Acetate/Acetic Acid 6.2 56.6 ± 0.0 55.7 ± 0.2 0.9 
100 mM MES/ NaOH 5.0 51.5 ± 0.2 51.3 ± 0.1 0.2 
100 mM MES/ NaOH 5.4 53.8 ± 0.1 53.3 ± 0.1 0.5 
100 mM MES/ NaOH 5.8 55.6 ± 0.1 54.7 ± 0.1 0.9 
100 mM MES/ NaOH 6.2 55.8 ± 0.3 54.6 ± 0.0 1.2 
100 mM MES/ NaOH 6.6 54.8 ± 0.2 53.9 ± 0.2 0.9 
100 mM MES/ NaOH 7.0 53.2 ± 0.2 53.0 ± 0.1 0.3 
100 mM MES/ NaOH 7.4 51.9 ± 0.0 52.1 ± 0.1 -0.1 
100 mM Bis-Tris/HCl 5.2  49.3 ± 0.1  
100 mM Bis-Tris/HCl 5.6  50.8 ± 0.4  
100 mM Bis-Tris/HCl 6.0  50.1 ± 0.1  
100 mM Bis-Tris/HCl 6.4  48.6 ± 0.0  
100 mM Bis-Tris/HCl 6.8  47.5 ± 0.2  
100 mM Bis-Tris/HCl 7.2  46.7 ± 0.3  
100 mM Bis-Tris/HCl 7.6  46.3 ± 0.1  
100 mM Bis-Tris/HCl 8.0  46.2 ± 0.2  
100 mM Imidazole/HCl 5.4  49.5 ± 0.4  
100 mM Imidazole/HCl 5.8  49.4 ± 0.5  
100 mM Imidazole/HCl 6.2  48.3 ± 0.5  
100 mM Imidazole/HCl 6.6  47.0 ± 0.8  
100 mM Imidazole/HCl 7.0  45.8 ± 0.2  
100 mM Imidazole/HCl 7.4  45.4 ± 0.5  
100 mM Imidazole/HCl 7.8  45.5 ± 0.6  
100 mM Imidazole/HCl 8.2  45.9 ± 1.1  
10 mM K2HPO4/NaH2PO4 5.8 56.9 ± 0.2   
100 mM K2HPO4/NaH2PO4 5.8 56.1 ± 0.3 54.8 ± 0.0 1.2 
100 mM K2HPO4/NaH2PO4 6.2 55.2 ± 0.2 54.1 ± 0.1 1.0 
100 mM K2HPO4/NaH2PO4 6.6 54.3 ± 0.4 53.4 ± 0.1 0.9 
100 mM K2HPO4/NaH2PO4 7.0 51.8 ± 0.6 52.1 ± 0.3 -0.3 
10 mM K2HPO4/NaH2PO4 7.2 55.3 ± 0.1   
100 mM K2HPO4/NaH2PO4 7.4 50.9 ± 0.9 51.0 ± 0.4 -0.1 
100 mM K2HPO4/NaH2PO4 7.8 49.3 ± 0.3 49.9 ± 0.0 -0.5 
100 mM K2HPO4/NaH2PO4 8.2 48.9 ± 0.0 49.4 ± 0.4 -0.4 
100 mM K2HPO4/NaH2PO4 8.6 48.3 ± 0.5 48.9 ± 0.2 -0.6 




100 mM Hepes/NaOH 6.4 53.5 ± 0.0 52.7 ± 0.1 0.8 
100 mM Hepes/NaOH 6.8 52.2 ± 0.1 52.3 ± 0.0 -0.1 
100 mM Hepes/NaOH 7.2 51.2 ± 0.3 51.1 ± 0.1 0.1 
100 mM Hepes/NaOH 7.6 49.9 ± 0.3 50.4 ± 0.1 -0.5 
100 mM Hepes/NaOH 8.0 49.7 ± 0.3 49.7 ± 0.1 0.0 
100 mM Hepes/NaOH 8.4 48.9 ± 0.2 49.2 ± 0.1 -0.3 
100 mM Tris/HCl 6.6  48.0 ± 0.0  
100 mM Tris/HCl 7.0  46.3 ± 0.5  
100 mM Tris/HCl 7.4  44.7 ± 0.3  
100 mM  Tris/HCl  7.5 44.5 ± 0.1   
10 mM Tris/HCl + 200 mM NaCl 7.5 52.4 ± 0.1   
100 mM Tris/Cl + 200 mM NaCl 7.5 50.9 ± 0.1   
100 mM Tris/HCl 7.8  45.1 ± 1.6  
100 mM Tris/HCl 8.2  43.5 ± 0.1  
100 mM Tris/HCl 8.6  43.8 ± 0.1  
100 mM Bicine/NaOH 7.0 51.9 ± 0.3 52.2 ± 0.0 -0.2 
100 mM Bicine/NaOH 7.4 50.0 ± 0.0 50.4 ± 0.6 -0.4 
100 mM Bicine/NaOH 7.8 48.5 ± 0.7 48.7 ± 0.1 -0.2 
100 mM Bicine/NaOH 8.2 47.5 ± 0.7 48.2 ± 0.2 -0.7 
100 mM Bicine/NaOH 8.6 47.2 ± 0.7 47.5 ± 0.3 -0.4 
50 mM CHES/NaOH 8.0  50.0 ± 0.7  
50 mM CHES/NaOH 8.4  48.3 ± 0.3  
50 mM CHES/NaOH 8.8  47.0 ± 0.3  
100 mM Glycine/NaOH 8.2 51.3 ± 0.0 52.3 ± 0.6 -1.0 





Table 3.2. Summary of stabilization of myoc-OLF by buffers of varying pH.  





Sodium Lactate/HCl 4.0-4.4 No 
Sodium Lactate/HCl 4.8-5.2 Yes 
Sodium Acetate/Acetic Acid 4.2 No 
Sodium Acetate/Acetic Acid 4.6-6.2 Yes 
MES/ NaOH 5.0-7.4 Yes 
Bis-Tris/HCl 5.2-8.0 No 
Imidazole/HCl 5.4-8.2 No 
K2HPO4/NaH2PO4 5.8-7.4 Yes 
K2HPO4/NaH2PO4 7.8-8.6 No 
Hepes/NaOH 6.0-7.2 Yes 
Hepes/NaOH 7.6-8.4 No 
Tris/HCl 6.6-8.6 No 
Bicine/NaOH 7.0 Yes 
Bicine/NaOH 7.2-8.6 No 
CHES/NaOH* 8.0-8.8 No 
Glycine/NaOH 8.2 Yes 
Glycine/NaOH 8.6 No 
a
No: Tm < 51.7 °C; Yes: Tm > 51.7 °C.  The lower limit cutoff is 1 °C less than the 
originally reported Tm of myoc-OLF in phosphate buffer, using DSF [178].  Full data are 





100 mM Tris pH 7.5.  For Tris buffer, increasing the ionic strength by the addition of 
NaCl partially restores stability, suggesting that counterions may play a role in this buffer 
system.  Conversely, for acetate buffer pH 4.6, a further increase of 2 °C in the Tm value 
for myoc-OLF is observed when 100 mM acetate buffer pH 4.6 is used compared to 10 
mM (Table 3.1), with no additional effects due to the presence of NaCl.  
 Finally, to evaluate any further possible effects of counterions, a variety of salts 
(50 mM) were added to MBP-OLF in stabilizing buffers, specifically acetate pH 5.8, 
MES pH 6.6, phosphate 5.8, or Hepes pH 6.4, and the melting temperatures were 
calculated and compared (Table 3.3). Overall, the addition of counterions produced 
negligible to minor stabilizing effects. Magnesium salts consistently stabilized MBP-OLF 
by 1-4 °C whereas potassium phosphate dibasic had a destabilizing effect in acetate and 
MES buffers. Zinc acetate in all buffers and ammonium chloride in acetate yielded poor 
spectrums. Only one melt transition was observed for calcium chloride in all buffers 
tested, indicating either a complete destabilization of OLF or a possible overlap between 
the OLF and MBP melt curves. Further analysis of cleaved myoc-OLF in either 100 mM 
Tris pH 7.5 or 100 mM Hepes pH 7.5, revealed a substantial increase in the melting 
temperature (+10 °C) with only 10 mM CaCl2 (Table 3.3).  
3.2.2 Stability Analysis in the Presence of GAGs 
 Interestingly, the preferred buffers for myoc-OLF contain sulfate and acetate 
functional groups that are reminiscent of GAGs, whereas those that are destabilizing in an 
overlapping pH range harbor aliphatic amines (Table 3.2).  Thus, we sought to evaluate 
the stability of myoc-OLF in the presence of individual GAGs found in the TEM [187] at 
physiologically relevant concentrations [188] (Table 3.4).  Indeed, a modest (ΔTm = 4.5 
°C) stabilizing effect was observed for myoc-OLF in the presence of a relatively low 
concentration (0.75 mg/mL) of heparan sulfate, whereas a similar increase in stability for 









 Sodium Acetate, 
pH 5.8 
MES, pH 6.6 K2HPO4/NaH2PO
4, pH 5.8 














Ammonium Acetate 56.6 0.9 55.4 0.2 57.1 0.9 55.3 2.2 
Magnesium Acetate 57.7 2.0 56.8 1.6 57.6 1.4 57.6 4.4 
Sodium Acetate 56.1 0.4 55.8 0.6 57.1 0.9 55.3 2.1 
Zinc Acetate Dihydrate N/A N/A N/A N/A N/A N/A 54.6 1.5 
Potassium Bromide 55.4 -0.3 55.2 0.0 56.1 -0.1 53.5 0.4 
Sodium Bromide 55.5 -0.2 55.2 0.0 55.9 -0.4 53.6 0.5 
Ammonium Chloride N/A N/A 54.5 -0.7 56.5 0.3 53.3 0.1 
Calcium Chloride
b
 N/A N/A N/A N/A N/A N/A N/A N/A 
Lithium Chloride 55.4 -0.3 55.0 -0.3 56.4 0.2 52.7 -0.4 
Magnesium Chloride 56.4 0.7 56.7 1.5 57.3 1.1 55.3 2.1 
Sodium Chloride 55.7 0.0 55.5 0.3 56.7 0.4 53.7 0.5 
Sodium Citrate 56.0 0.3 55.2 0.0 56.8 0.5 54.7 1.5 
Sodium Fluoride 56.2 0.5 55.5 0.3 57.0 0.8 54.6 1.5 
Magnesium Formate 56.9 1.2 57.2 2.0 57.4 1.1 56.8 3.6 
Potassium Iodide 55.0 -0.7 55.0 -0.2 56.4 0.2 53.7 0.5 
Potassium Phosphate 
Dibasic 
52.2 -3.5 53.0 -2.2 56.4 0.1 53.0 -0.1 
Sodium Dihydrogen 
Phosphate 
55.7 0.0 55.6 0.4 57.3 1.0 53.2 0.1 
Ammonium Sulfate 55.6 -0.1 56.5 1.3 56.9 0.6 53.2 0.1 
Lithium Sulfate 55.6 -0.1 54.0 -1.2 56.9 0.7 53.3 0.1 
Potassium Sodium 
Tartrate 
55.7 0.0 55.5 0.3 56.5 0.2 55.1 1.9 
Potassium Thiocyanate 54.2 -1.5 54.1 -1.1 55.4 -0.9 52.3 -0.8 
a
Buffer (100 mM) and salt (50 mM) concentrations were consistent throughout the 
stability assay. ΔTm represents the difference between Tm with and without salt in the 
specified buffer.  
b
Cleaved myoc-OLF melting temperatures were calculated in the presence of 10 mM 
CaCl2 to be 60.0 °C (ΔTm= 15.4 °C) in 100 mM Tris, pH 7.5 and 61.2 °C (ΔTm= 10.6 °C) 


















For these experiments, heparan sulfate concentration was 0.75 mg/mL, whereas all other 
GAGs were present at 10 mg/mL.   
  
 Tm (°C) ΔTm (°C) 
None 52.4 ± 0.1 0 
Chondroitin 
Sulfate 
57.7 ± 0.0 5.3 
Dermatan Sulfate 52.7 ± 0.0 0.3 
Heparan Sulfate
 a
 57.2 ± 0.0 4.8 




mg/mL, at the outer limit of the physiological range, suggesting a weaker effect.  The 
addition of dermatan sulfate did not change the Tm value of myoc-OLF in the full range 
tested.  
3.2.3 Conformational Analysis of Myoc-OLF at pH 4.6, 5.8, and 7.2 
 In order to detect structural changes across the stable pH regime, we next 
compared the secondary structure of myoc-OLF by conducting circular dichroism (CD) 
melts in stabilizing buffers of varying pH.  We measured the CD spectrum in 10 mM 
acetate buffer pH 4.6, below the calculated [189] pI = ~5 of myoc-OLF, at the lower end 
of the stable range, as well as in 10 mM phosphate buffer pH 5.8 where OLF was the 
most stable in our assay (Table 3.1-3.2), and at the physiological pH 7.2 expected in the 
TEM under normal conditions.  
 No major changes are observed among the three CD spectra at different pH 
values. The 200-210 nm range is more positive at pH 4.6 than the others, suggestive of 
non-native features of OLF in this buffer environment, but otherwise there are only slight 
differences in the intensity of the two major minima at ~217 and ~230 nm (Figure 3.2A).  
Component spectra, identified using singular value decomposition (SVD) analysis, reveal 
three significant spectral contributions. By far the most predominant component is one 
that contains both minima, followed by two minor contributions from spectra that 
resemble random coils (Figure 3.2B). Notably, there is no significant contribution from 
features at 208 nm and/or another at 222 nm; thus, there is no evidence of α-helices in 
myoc-OLF.  The broad ~217 nm minimum, which is characteristic of antiparallel β-
sheets, resembles the CD spectrum of a smaller OLF construct expressed in P. pastoris 
[135], but the prominent shoulder near 230 nm has not been seen previously. The lack of 
this latter feature in the P. pastoris OLF construct may have been a result of its N-
terminal truncation or the use of Tris pH 8.0 [135], a destabilizing buffer (Table 3.1-3.2).  




















Figure 3.2. CD signatures of myoc-OLF domain at varying pH. A) Prominent minima 
are observed at ~217 nm and ~230 nm for both experimental spectra (solid) and 
reconstructed spectral fit from SVD analysis (dashed). B) Top component spectra from 





 Consistent with the aggregation propensity observed in mutants that lead to 
myocilin glaucoma, the unfolding transitions of myoc-OLF are irreversible. Sample 
precipitation was seen under all experimental conditions tested, including all 
concentrations, pH and temperature ranges.  Nevertheless, there is substantial evidence 
[190] for a highly cooperative transition.  First, at all three pH values, a sharp transition 
and similar isodichroic point near 238 nm are observed for myoc-OLF (Figure 3.3).  
Second, the differences in Tm for the melting curves monitored at the two local minima 
are consistently within 1 °C of each other, and within error of the fit to the Tm obtained 
from the Boltzmann sigmoid equation, which assumes a two-state model (Table 3.5).  
Third, there is no obvious scan rate dependence of denaturation (not shown), suggesting 
that the melting transition is under thermodynamic, rather than kinetic control.  
Nevertheless, because we were not able to find experimental conditions of reversibility 
for myoc-OLF, the extent of the validity of thermodynamic parameters obtained using a 
two-state model cannot be assessed.  We note, however, that thermodynamic parameters 
we obtained using this assumption with excellent error statistics (Figure 3.4, Table 3.5) 
are similar to those of α-chymotrypsin [191], a protein that exhibits both similar mass and 
CD spectrum as myoc-OLF (see Discussion).  
 The transition to the denatured state for myoc-OLF at pH 4.6 occurs between 40-
50 °C (Figure 3.3A). Upon denaturation, the ellipticity is reduced by 50% and there is a 
shift in minimum at 216 nm in the folded state to 220 nm in the denatured state. SVD 
deconvolution (not shown) reveals a significant reduction in the β-sheet component and 
an increase in the random coil component, suggesting the precipitated sample is likely a 
molten globule with local secondary structure.  By comparison, for both unfolding 
experiments conducted at pH 5.8 (Figure 3.3B) and pH 7.2 (Figure 3.3C), the transition 
occurs between 50 and 60 °C with a fourfold reduction in signal intensity between folded 
and unfolded states of myoc-OLF. Less residual secondary structure remaining in these 



































Figure 3.3. Thermal unfolding of myoc-OLF monitored by CD spectropolarimetry. 
Melts were conducted at (A) pH 4.6 (B) pH 5.8 and (C) pH 7.2.  For each, 11 spectra are 
overlayed in the region of melting as well as two additional extrema. (D) Comparison of 
tryptophan fluorescence melt with CD melts from above. Each curve is normalized to the 







Table 3.5. Thermodynamic data for myoc-OLF unfolding assuming a two-state transition.  
pH Technique Boltzmann  Equation Van’t Hoff Equation 




 Tm (°C) 
 
G (37 °C, kcal mol
-1
)  Hm (kcal mol
-1







4.6 CD, 217 nm 46.1 ± 0.1 0.997 ± 0.001 46.5 ± 0.0 
 
3.5 ± 0.4 
 
118.4 ± 13.3 
 








 CD, 230 nm 46.9 ± 0.2 0.997 ± 0.003 
 
47.0 ± 0.7 
 
3.8 ± 0.6 
 
120.9 ± 23.9 
 








5.8 CD, 216 nm 55.3 ± 0.1 0.997 ± 0.000 55.5 ± 0.0 
 
9.0 ± 0.6 
 
158.1 ± 11.0 
 








 CD, 230 nm 56.1 ± 0.1 0.997 ± 0.001 56.5 ± 0.0 
 
9.7 ± 0.4 
 
156.0 ± 8.0 
 








7.2 CD, 214 nm 55.2 ± 0.2 0.998 ± 0.000 55.5 ± 0.0 8.85 ± 1.1 
 
159 ± 22.0 
 







 CD, 229 nm 55.8 ± 0.4 0.997 ± 0.004 56.0 ± 0.7 8.4 ± 0.2 
 
146.4 ± 9.5 
 










52.7 ± 0.8 0.998 ± 0.001 
 
N/A N/A N/A N/A N/A N/A 
 Tryptophan 
Fluorescence 
55.6 ± 0.1 0.998 ± 0.001 
 
55.0 ± 0.0 
 
10.4 ± 0.1 
 
180.5 ± 3.4 
 
















Figure 3.4. Melt data fit to a two-state transition. Melt curves and fitting residuals are 





conditions far from the pI of myoc-OLF, such as at pH 7.2, secondary structure would be 
expected to be disrupted due to the high net charge per residue.  By contrast, at pH 4.6, 
myoc-OLF is closest to its pI where it may experience less repulsion and therefore retain 
secondary structure in the denatured state [192].   
 The Tm of myoc-OLF at pH 4.6 is nearly 10 °C lower than the Tm at pH 5.8 or 
7.2, and ~3 °C lower than that measured by DSF using the same ionic strength buffer 
(Table 3.1). Using a two-state assumption (see caveats above), comparison of the free 
energy of unfolding, as well as both enthalpy and entropy components, also indicate a 
lower barrier to unfolding (Table 3.5).  Nevertheless, even the values at pH 4.6 are well 
within parameters obtained from numerous other folded proteins [191].  The 
thermodynamic values fit for myoc-OLF above its pI indicate a larger energy barrier and 
more stable protein, consistent with the measured increase in Tm. Finally, the unfolding 
transition at neutral pH was further corroborated by a thermal melt in which intrinsic 
tryptophan fluorescence was monitored at pH 7.2 (Figure 3.3D).  Indeed, the intrinsic Tm 
measured by both CD and Trp fluorescence melts is close to the Tm = 52.7 °C we 
previously reported using the more facile, if indirect, DSF technique [178]. The melting 
thermogram overlays particularly well with the curve obtained monitoring ~230 nm by 
CD, suggesting tryptophan residues contribute to this CD signal (see Discussion).  
3.2.4 Limits of the Myoc-OLF Core Domain 
 We subjected myoc-OLF to limited proteolysis to identify its three dimensional 
core structure(s). In most constructs of myoc-OLF studied in the laboratory, a disulfide 
bond is formed between the only two available cysteine residues (Cys 245 and Cys 433) 
[135, 178], which are 189 residues apart. Yet, protein domains are typically composed of 
~150 amino acids [193]. It is possible that the two cysteine residues, far apart in 
sequence, are nevertheless topologically close.  This could lead to either two or more 




 Overall, myoc-OLF is resistant to cleavage by proteases at room temperature, 
including trypsin, -chymotrypsin, pepsin, and V8 protease (not shown) suggesting that 
our construct consisting of residues 228-504 of myocilin, comprises a well folded, ~30 
kDa protein.  However, incubation with subtilisin A, a non-specific protease that cleaves 
after large uncharged residues, generated a smaller domain of ~25 kDa (Figure 3.5A).  
Similar results were obtained with the likewise promiscuous protease papain (not shown).  
The CD spectrum of core-OLF is similar to that of myoc-OLF with some minor 
exceptions, a 202 nm shoulder characteristic of a type I -turn [194],  and a more 
pronounced 230 nm shoulder (Figure 3.5B).  As seen previously with myoc-OLF [178], 
the disulfide bond remains intact in core-OLF.  Observed using the thiol-sensitive 
fluorogenic reagent, ThioGlo (see Materials and Methods), fluorescence increases only in 
samples in which the disulfide bond in core-OLF has been reduced with tris(2-
carboxyethyl)phosphine (TCEP) (Table 3.6). Finally, the Tm is unchanged, 53.4 ± 0.2 °C 
measured by DSF.   
 Peptide mass fingerprinting reveals that the N- and C-termini of core-OLF are 
truncated compared to myoc-OLF (Figure 3.1, Table 3.7).  For core-OLF, the most N-
terminal fragment observed in the spectrum encompasses residues 238-258, the extreme 
C-terminal peptide observed for core-OLF comprises residues 408-422 (Table 3.7), 
whereas the peptides TLTIPFK (residues 462-468, Figure 3.5C, Table 3.7) and 
YSSMIDYNPLEK (residues 473-484, Figure 3.5D, Table 3.7) are absent.  The truncated 
C-terminal 44 residues may form a motif not detected by SDS-PAGE due to its small 
size, or it may be largely unordered.  In sum, consistent with the ~25 kDa fragment size, 
and digest analysis, the main structural domain of myoc-OLF harbors a disulfide bond 




   
Figure 3.5.  Analysis of core OLF domain. A) SDS-PAGE analysis of myoc-OLF 
before and after limited proteolysis by subtilisin A.  Lane 1, myoc-OLF, Lane 2, core-
OLF.  Molecular mass markers denoted in kDa.  B) Overlay of core-OLF and myoc-OLF 
CD spectra at pH 7.2. C, D) Comparison of trypsin digest/MALDI TOF/TOF mass 








Table 3.6. Characterization of disulfide bond in core-OLF.  
 
Sample Fluorescence Intensity (513 nm) 
core-OLF (6 μM) 0.7 













ΔMass MS/MS Sequence 
Core-
OLF 
267-272 827.3868 827.3786 -0.0082  YGVWM
a
R 
 288-296 975.5105 975.5100 -0.0005 yes IDTVGTDVR 
 347-355 1096.5521 1096.5477 -0.0044 yes YELNTETVK 
 273-287 1882.8970 1882.8944 -0.0026  DPKPTYPYTQETTWR 
 406-422 2099.0403 2099.0400 -0.0003 yes LNPENLELEQTWETNIR 





462-468 819.4974 819.5486 0.0512  TLTIPFK 
 267-272 843.3817 843.3954 0.0137  YGVWM
c
R 
 288-296 975.5105 975.5311 0.0206  IDTVGTDVR 
 347-355 1096.5521 1096.5712 0.0191  YELNTETVK 
 473-484 1459.6672 1459.6852 0.0180  YSSMIDYNPLEK 
 273-287 1882.8970 1882.9452 0.0482  DPKPTYPYTQETTWR 
 406-422 2099.0403 2099.0972 0.0569  LNPENLELEQTWETNIR 
 297-314 2180.0369 2180.0801 0.0432  QVFEYDLISQFMQGYPSK 
a
A indicates oxidation of methionine, 
b
B designates carbamidomethyl cysteine, 
c
C 





 The first protein crystals for 3D structural determination were obtained with core-
OLF after limited proteolysis in situ. Initial crystals were grown in the Cryo I/II screen 
(Emerald BioSystems) and partially optimized (see Methods). A full data set was 
collected using a piece of a crystal (Fig. 3.6A-B) grown in 3% PEG 3000, 39% PEG 200, 
and 100 mM MES, pH 6.0 and diffracted to 2.0 Å resolution. The data set was 100 % 
complete to 2.3 Å resolution with an Rsym= 8.9% (Table 3.8), indicating the intensity 
measurements are accurately reproducible. Since no OLF structure exists, a predicted 
structural homolog (PDB code 3NOK) [195] was used to obtain phases by molecular 
replacement, but yielded unsuccessful results.  
 We are currently investigating both multiple isomorphous replacement (MIR) and 
anomalous scattering (MAD) methods using heavy atoms. In particular, YbNO3 and 
MnCl2 have been identified by DSF and shown to stabilize myoc-OLF, indicating 
potential binding. However, due to a lack of single 3D crystals, growth conditions will 
have to be optimized prior to soaking with heavy atoms. Co-crystallization conditions 
have been attempted, but will also require further optimization. Once a data set is 
obtained, these heavy atoms can be located using SOLVE [196] or other similar 
programs, followed by model building and refinement using Coot [197] and Refmac 
[198]. One final technique includes incorporating selenomethionine substitutions into 
myoc-OLF to obtain experimental phases by MAD. However, this has not been attempted 
as creating the selenomethionine derivatives requires growth in minimal media, a 
condition known to produce little soluble myoc-OLF and also a contaminant binding 
















Table 3.8. Data collection statistics. 
Data Statistics  
Space group C2 
Cell dimensions  
   a, b, c (Å) 111.5, 85.8, 68.5 
   α, β, γ (deg) 90.0, 127.7, 90.0 
Resolution (Å)
 a
 61.5-1.9 (1.98-1.93) 
Rsym
 a




 98.5 (58.3) 
a






3.3.1 Functional Significance 
 The human TEM, a microenvironment in the eye consisting of fibrillar and curly 
collagens, elastic fibrils, basement membrane and amorphous basement membrane-like 
materials, as well as other specific proteins, proteoglycans and GAGs, is the anatomical 
region that controls outflow of aqueous humor in the eye [187]. The structural and 
functional details of this interconnected matrix, its receptor-mediated interactions with 
HTM cells, and mechanisms leading to phenotypes observed in the diseased state, are 
poorly understood [110].  The proper functioning of this complex tissue involves 
adaptation to a host of cellular and environmental stressors over time, and cumulative 
long-term detrimental effects of oxidative stress have been implicated in decreased 
aqueous humor outflow.  Eventually, poor flow control leads to an impaired ability to 
regulate eye pressure, and subsequently, glaucoma [186].  Changes in GAG composition 
have also been observed in glaucoma-patient derived samples [199-200], but the 
mechanisms that bring about these changes are unknown. In addition, the roles played by 
myocilin in the TEM, either normal or pathogenic, are not clear.  In this study, we have 
unraveled some of the molecular characteristics of the myoc-OLF domain in the context 
of its TEM microenvironment, which will aid future functional characterization.    
 Several lines of evidence support the notion that GAGs provide a favorable 
environment for myoc-OLF to function, even though to date, no experiments have 
identified specific GAGs binders in the myoc-OLF region from any organism.  Four 
GAG attachment sites to the myoc-OLF domain are predicted by the ELM database [201] 
within residues 232-235, 237-240, 330-333 and 443-446, suggesting that direct linkages 
are possible.  The microenvironment of myoc-OLF in the TEM is also replete with GAGs 
at a total concentration of 1-2 mg/mL [202], with the approximate composition of 20-




karatan sulfate, and 15-20% heparan sulfate [187]. Our experiments reveal a modest 
increase in stability for myoc-OLF in the presence of heparan sulfate, chondroitin sulfate, 
and hyaluronic acid.  Although no change in Tm was observed in the presence of 
dermatan sulfate, no GAGs tested destabilized myoc-OLF. Interestingly, whereas direct 
binding of chondroitin sulfate to another OLF-containing protein, mouse photomedin, has 
been shown [203], the presence of chondroitin sulfate only weakly influences thermal 
properties of myoc-OLF.  This result suggests that chondroitin sulfate may have different 
functional significance for related OLF-containing proteins.  
 By contrast, a more notable effect on myoc-OLF stability was observed in 
physiologically relevant concentrations of heparan sulfate.  Even though direct binding to 
the OLF domain has been ruled out by a previous study demonstrating binding via the N-
terminal coiled-coil domain of myocilin [113], the knowledge that heparan sulfate binds 
to myocilin indicates that this GAG is in the local milieu of myoc-OLF.  The observation 
that heparan sulfate thermally stabilizes myoc-OLF should prompt experiments to further 
clarify the nature of this interaction.  
 In addition, although heparan sulfate appears to exert a modest stabilizing effect 
on myoc-OLF in the absence of other analytes, it seems plausible that cations might 
enhance the favorable specific interactions between the negatively charged GAGs and the 
negatively charged OLF domain under physiological conditions.  For example, detailed 
functional studies of amassin, a related, but non-ocular, OLF-containing protein (Figure 
1) from the invertebrate animal sea urchin, demonstrates the requirement of the amassin 
OLF domain for cell-cell adhesion in coelomocytes.  This process also requires the 
presence of Ca
2+
, and higher multimeric states of the amassin OLF domain [204].  To 
date, however, no canonical Ca
2+
-binding sites have been identified in myoc-OLF, and to 
the best of our knowledge, Ca
2+
 has not been included in any assays.  In our hands, myoc-
OLF is significantly thermally stabilized in the presence of Ca
2+









filtration [178]. Although it is possible that these two related proteins have unique modes 
of interactions and binding partners, based on our study we raise the possibility that 
certain key components, such as GAGs and/or metal ions, may be missing from 
functional assays of myocilin attempted to date. Further studies are required to elucidate 
the potential role of Ca
2+
 with myoc-OLF.    
 Lastly, the importance of elucidating the mechanism by which GAGs stabilize 
myoc-OLF is underscored by the finding that the concentrations of GAGs in 
glaucomatous eyes deviate from those of healthy eyes [199-200]. Specifically, 
concentrations of sulfated GAGs, such as chondroitin sulfate, are higher in samples 
derived from early-onset glaucoma patients than from controls [200], and the 
concentration of hyaluronan decreases in adult-onset OAG patient-derived specimens 
compared to controls [199]. Given the connection between myocilin and early-onset 
glaucoma [206], an understanding of the nuances of different GAG interactions with 
myoc-OLF may pave the way to a better comprehension of myocilin glaucoma 
pathogenesis. 
3.3.2 Structural Significance 
 Although predominantly -sheet-containing proteins, such as the 
immunoglobulins [207], exhibit a trough at ~217 nm that is characteristic of antiparallel 
-sheets [194], of particular interest is the prominent ~230 nm shoulder that had not been 
observed previously. One possibility is that a-turn [208] is present, a hypothesis 
supported by prediction of -turns in myoc-OLF by bioinformatics [209].  Alternatively, 
or in addition, the 230 nm feature may arise from aromatic residues, as observed in 
certain serine proteases.  For example, a notable 230 nm band in -chymotrypsin has 
been attributed to a tryptophan residue whose conformation is sensitive to changes in its 
environment upon activation of -chymotrypsinogen to -chymotrypsin [210].  In 




from 230 nm observed in CD (Figure 3D). Of the seven Trp residues in myoc-OLF, two, 
Trp 270 and Trp 286, are in and near, respectively, a proline-rich region.  Alternatively, 
Trp 373 is within a region with significant disorder probability as predicted by GlobPlot 
[211].  Future studies involving systematic mutagenesis of each Trp residue may shed 
more light on the properties of this unusual feature of the CD spectrum.   
 Intriguingly, the CD spectrum of core-OLF is similar to that of the -crystallin 
superfamily. Crystallins are cytoplasmic lens cell proteins associated with genetic forms 
of cataract, a condition in which the crystallins precipitate.  Regardless of their 
quaternary structure, which often exhibits functionally significant polydisperse, domain-
swapped oligomers [212], CD spectra of crystallins include the same features at ~202 
nm, ~217 nm, and ~230 nm as seen with core-OLF [213], albeit with different relative 
intensities.  Myoc-OLF exhibits no significant sequence homology with crystallins, is 
~10 kDa larger, is not known to oligomerize, nor observed to harbor two structural 
domains [214]. Nevertheless, OLF likely shares structural features such as similar length 
or twist of its -strands, and/or the unusually strained torsion angles in a -hairpin.  
Further characterization of the three-dimensional structure of an OLF domain will help 
elucidate the extent of similarity of features with the crystallins, including repeat 
structures in myoc-OLF that may be important for myocilin self assembly and/or function 
in the TEM, or plausible molecular mechanisms for the severe aggregation properties 
observed upon thermal unfolding.  
3.3.3 Implications for New Therapeutic Directions 
 The details of the unfolding mechanisms of WT and disease-causing myoc-OLF 
domains variants, particularly at physiological pH, are informative for a pharmacological 
chaperone therapeutic effort [215] for myocilin glaucoma.  In this approach, the binding 




after folding in the ER, mutant myocilins will meet quality control requirements and be 
competent for secretion to the TEM.  
 Both thermodynamics and kinetics may be important in chaperone therapy for 
myocilin glaucoma. The therapeutic small molecule might bind to a folded mutant 
protein to restore its stability to that of WT, and/or bind to a non-native conformation and 
accelerate folding to the native state.  From this study we know that the ~31 kDa WT 
myoc-OLF domain is a stable entity that appears to unfold under thermodynamic control 
in a highly cooperative transition.  We can now move forward to compare unfolding 
pathways of the numerous missense mutants of OLF.  If mutant OLFs unfold in similarly 
cooperative transitions, thermal stabilization of the fully folded protein may be sufficient 
for preventing aggregation and improving secretion, and screening for candidate 
chaperone molecules would be based on thermal stability alone.  However, a more likely 
scenario is that deviations from two-state unfolding exist for at least some of the reported 
mutants [179].  In this case, a pharmacological chaperone may need to be tailored in such 
a way that it alters the folding pathway back to a fully cooperative mechanism observed 
in WT myoc-OLF.  Future studies will examine to what extent such unfolding 
intermediates exist for specific glaucoma-causing myoc-OLF mutants. 
3.4 Methods 
3.4.1 Expression and Purification of Myoc-OLF  
 The myoc-OLF gene was introduced into the MBP fusion vector, pMAL-c4x as 
described previously (see Chapter 2) [178]. Expression and purification of MBP-OLF 
followed previously described procedures, as did generation of cleaved myoc-OLF by 
incubation with Factor Xa and further purification [178].  SDS-PAGE analysis was 





3.4.2 Thermal Stability Assay for Buffer and pH Analysis 
  Our fluorescence thermal stability assay [178] utilizing DSF (see Chapter 2) 
[148] was adapted to identify buffer and pH preferences for myoc-OLF. Reactions of 30 
μL were prepared at room temperature and delivered to 96-well optical plates (Applied 
Biosystems) before sealing with optical film (Applied Biosystems). The reaction mixture 
consisted of 1 μM myoc-OLF or MBP-OLF in 10 mM sodium phosphate dibasic/ 
potassium phosphate monobasic, 200 mM NaCl pH 7.2 (Buffer A) and 5X Sypro Orange 
(Invitrogen).  Buffers from pH 4 to pH 9 were obtained from the pHat™ Buffer screen 
(Emerald Biosciences) and added to each reaction at a final concentration of 100 mM, 
with the exception of N-Cyclohexyl-2-aminoethanesulfonic acid (CHES), which had a 
final concentration of 50 mM.  The salt screen was conducted in a similar format, but 
with 50 mM salt added to each reaction. Only for the initial screen was MBP-OLF used 
and 50 mM maltose added to the reaction mixture.  Selected DSF measurements were 
repeated with cleaved myoc-OLF in acetate, MES, phosphate, Tris, bicine, and glycine 
buffers. Fluorescence data were acquired on an Applied Biosciences Step-One Plus RT-
PCR instrument equipped with a fixed excitation wavelength (480 nm) and a ROX 
emission filter (610 nm). Melts were conducted from 25-95 °C with a 1 °C per min 
increase. Collected data were baseline subtracted, trimmed to include both the boundaries 
and the transition of interest, and subjected to Boltzmann sigmoid analysis (see below). 
3.4.3 Thermal Stability Assay in the Presence of GAGs 
 The thermal stability assay described above was employed to test for increased 
myoc-OLF stability in the presence of GAGs including chondroitin sulfate (shark 
cartilage, Sigma), dermatan sulfate (TCI America), heparan sulfate (bovine kidney, 
Sigma), and hyaluronic acid (rooster comb, Sigma) at concentrations ranging from 0 
mg/ml to 10 mg/mL.  Samples were prepared in 10 mM Tris, pH 7.5 and 200 mM NaCl, 




water, keeping protein and Sypro Orange concentration the same as above. Data analysis 
was performed as described above.   
3.4.4. Circular Dichroism (CD) Spectropolarimetry  
 CD was performed on a Jasco J-810 spectropolarimeter with purified myoc-OLF 
(8-10 μM) prepared in Buffer A, Buffer A adjusted to pH 5.8, as well as in 10 mM 
sodium acetate/acetic acid and 200 mM NaCl, pH 4.6. Melts were performed in triplicate 
on each of the samples by raising the temperature from 5 to 90 °C in 1 °C/min increments 
using a Neslab RTE-111 (Thermo Scientific) circulating water bath and monitoring the 
profiles between 200 and 300 nm in a 0.1 cm cuvette. Ten spectra, scanned from 300 to 
200 nm at rate of 500 nm•min
-1
, were then averaged at the designated temperature. Our 
attempts to acquire reliable data below 200 nm were not successful due to voltage limits 
of the instrument and available nitrogen flow rate. Temperature increase and spectra 
acquisition lasted about five minutes per degree Celsius, and no differences in melting 
transitions were observed when the scan rate was reduced to 0.5 °C/min (data not 
shown).  In all cases, samples precipitated after melting, including reversibility tests in 
which the temperature was raised just to the Tm and then cooled (not shown).  
 Each averaged spectrum was background-corrected and converted to mean 









where Mres = 112.9 is the mean residue mass calculated from the protein sequence; Θobs is 
the observed ellipticity (degrees) at wavelength λ; d is the pathlength (cm); and c is the 
protein concentration (g/mL).  CD melt data from 205 – 300 nm were deconvoluted into 
component spectra using the singular value decomposition procedure in Matlab (The 
Mathworks), and their statistical significance was calculated based on singular values.  




reconstitution for the final fit plotted in Figure 3.2.  Inspection of difference spectra 
confirmed that additional components consist of noise. 
3.4.5 Tryptophan Fluorescence Spectroscopy  
 Measurements were carried out in triplicate on a FluoroMax-3 spectrofluorimeter 
(Horiba Scientific). Intrinsic tryptophan fluorescence of myoc-OLF (2 μM) in Buffer A 
was excited at 280 nm (slit width 1 nm) and emission recorded in the range 300-400 nm 
(slit width 5 nm) with a maximum at 340 nm corresponding to tryptophan fluorescence 
emission. Each sample was heated from 20 to 70 °C or 45 to 65 °C, with a rate of three 
minutes per degree Celsius, using a Neslab RTE-7 Digital Plus (Thermo Scientific) 
circulating water bath.  
3.4.6 Boltzmann Sigmoid Analysis 
 The baseline-subtracted and trimmed melt curves acquired by the fluorescence 
thermal stability assay, CD, and intrinsic fluorescence were processed using GraphPad 
Prism. The reported Tm is the inflection point of the sigmoidal curve, and is calculated 




1 exp((Tm  X) Slope)  
where UL and LL are the values of minimum and maximum intensities, respectively 
[148].  
3.4.7 Limited Proteolysis 
 Myoc-OLF was pre-screened at room temperature against a variety of proteases 
including trypsin, -chymotrypsin, pepsin, papain, V8 protease and subtilisin A to 
identify a protease and concentration capable of producing a discrete smaller construct 
detectable by SDS-PAGE. The optimal reaction condition consisted of a 1:200 dilution of 




or 1:200 dilution of papain (Sigma, 1 mg/mL) in 0.2 mg/mL myoc-OLF in 10 mM MES 
pH 6.2. The reaction was incubated at room temperature for 30 mins followed by 
subsequent quenching by either the addition of Complete Protease Inhibitor Cocktail 
(Roche) or SDS-PAGE sample loading buffer for SDS-PAGE analysis and in-gel 
digestion for mass spectrometry analysis.  The core OLF product was fractionated from 
smaller digestion products on a Superdex 75 GL column (GE Healthcare) equilibrated 
with Buffer A. The core-OLF sample was further analyzed by CD as described above.  
Disulfide bond formation was confirmed with ThioGlo (EMD Biosciences) and the Tm 
measured as described [178]. 
3.4.8 In-gel Digestion and MALDI-TOF/TOF MS Analysis 
 In-gel digestion of myoc-OLF and core-OLF was carried out as described 
previously [217]. Digested and dried samples were subjected to peptide mass 
fingerprinting analysis using the Georgia Institute of Technology Bioanalytical Mass 
Spectrometry Facility. Spectra were acquired on an Applied Biosystems 4700 Proteomics 
Analyzer MALDI-TOF/TOF tandem mass spectrometer. Core-OLF was also analyzed by 
MS/MS. Peaks were analyzed by using MASCOT (GPS Explorer, Applied Biosystems). 
Only identified peptide fragments with a >3:1 signal-to-noise intensity were included in 
analysis. Samples were analyzed in duplicate. Due to the nonspecific nature of subtilisin 
cleavage, N-/C-terminal sequencing was not undertaken. 
3.4.9 Crystallization and Data Collection 
 Core-OLF was created repeating the limited proteolysis reaction in situ. In short, 
myoc-OLF (10 mg/mL) in 10 mM Hepes, pH 7.5 was mixed with a 1:200 dilution of 
fresh subtilisin A (Sigma Aldrich) immediately prior to crystal tray set up. Crystals of 
core-OLF were grown by vapor diffusion at 16 °C using a cocktail composed of 1-7% 




clustered crystals are grown with this condition, but one well provided a more 3D plate 
cluster. Pieces of this crystal cluster were removed and cryocooled in liquid N2. No 
cryoprotectant was needed as the crystallization cocktail served as one. Data were 
collected at the General Medical Sciences and National Cancer Institute Collaborative 
Access Team (GM/CA-CAT) Beamline 23-ID-B at the Advanced Photon Source at 
Argonne National Labs (Darien, IL). Data sets were indexed and scaled using the 






APPLICATION OF SYPRO® ORANGE, A FLUORESCENT 
HYDROPHOBIC DYE, FOR A HIGH-THROUGHPUT LIGAND 
BINDING ASSAY FOR PROTEINS OF UNKNOWN STRUCTURE 
AND/OR FUNCTION, SUCH AS MYOCILIN 
4.1 Introduction 
 Lead discovery, which is the intense search to find a drug-like small molecule or 
biological therapeutic that can progress into pre-clinical development, clinical 
development, and eventually to market, remains as the bottle neck to the drug 
development process [219]. In the late 1980‟s and 90‟s, the development of high-
throughput screening (HTS) consisting of screens of random compounds in libraries to 
find hits showing an activity against or affinity for a selected target [220] was thought to 
overcome this bottle neck. Sophisticated large-scale automation was anticipated to 
generate an unprecedented number of novel leads [221]. Unfortunately, the opposite was 
the case. Despite the significant advancements in large-scale automation, the FDA 
approved only 21 new drugs in 2010, with an average of ~23 new molecular entities per 
year in the past ten years [222]. 
 Of the 21,000 listed drug products in the US FDA‟s Orange Book and Center for 
Biologics Evaluation and Research website in 2006, only 1,357 are unique drugs and 
1,204 are small-molecule drugs [223]. Surprisingly, more than 50% of these drugs target 
only four key gene families: class 1 G-protein coupled receptors, nuclear receptors, 
ligand-gated ion channels, and voltage-gated ion channels [223-224]. One reason for this 
is that development of a novel drug is risky and expensive, costing on average $860 




formulations, combining already approved agents, and making subtle chemical changes 
[225].  Due to the availability of the sequenced human genome in 2002, there has been a 
surge in validated therapeutic protein targets. However, limited knowledge about the 
biology of these targets and therefore the types of compounds that they may interact with 
prevent knowledge-based drug design approaches, such as focused screening and 
structure-based design. HTS is therefore relied upon for compound identification [226] 
and may also provide an excellent starting point for understanding the interaction or role 
of a particular biochemical process in biology [227-228].  
 HTS starts with testing hundreds of thousands to millions of compounds against 
the target of interest by virtual screening, cell-based assay, or a biochemical assay 
approach [227]. In silico drug screening involves selecting compounds by predicting 
binding to a macromolecular target [221]. An estimate of the free-energy of binding is 
calculated and the compounds are ranked according to their scoring function [229], of 
which there are three types: force-field-based, empirical, or knowledge-based [230]. 
Force-field-based scoring involves quantifying the sum of the receptor-ligand interaction 
energy and internal ligand energy (i.e. steric strain induced by binding), and various 
scoring functions are based on different force field parameter sets. Empirical scoring 
functions are fit to reproduce experimental binding energies and/or conformations as a 
sum of several parameterized functions. Finally, knowledge-based scoring functions are 
designed to reproduce experimental structures rather than binding energies [230]. One of 
the main benefits to virtual screening is that the compounds tested may not actually exist 
and their testing does not consume material. However, knowledge of the target‟s 3D 
structure, either from X-ray crystallography, NMR, or homology modeling, is a 
prerequisite. Additional challenges associated with virtual screening include accounting 
for ligand flexibility, protein flexibility, protonation states, protein-ligand interactions, 
solvent effects, the role of individual water molecules and the decomposition of enthalpic 




amount and quality of the information available about the target [221], specifically, 
knowledge of the binding pocket of the target, but this ligand-based approach provides 
the least value to drug discovery for novel targets as there is already a small-molecule 
start point [231].  
 Cell-based assays measure cell proliferation, toxicity, production of markers, 
motility, activation of specific signaling pathways and changes in morphology [232]. The 
main benefit to this type of assay is that the compounds tested would be interacting in a 
biological milieu and therefore may decrease the chances for cytotoxicity at a later stage 
in the drug development process. Many of these assays rely on reporter gene technology, 
which is the discovery of compounds that modulate a pathway resulting in changes in 
gene expression [233]. This technique can be very sensitive and thus ideal for 
miniaturization. However, these assays tend to be based on signal transduction events that 
occur downstream or receptor activation and require gene expression. This causes a long 
response time, which may span from hours to days for analysis and also introduces the 
possibility of interference from other intracellular pathways [232]. Also, for all cell-based 
assays, potential hits of interest may be missed due to an inability to cross the cell 
membrane [226].  
 An ideal biochemical assay is usually one in which all the components of the 
assay are added at once. Advantages include being able to pipette, incubate, and measure 
directly from the microplate, which in turn saves time and cost. A homogenous assay also 
eliminates coating and washing of the plates that are usually required for a cell-based 
assay, which may introduce variability into the readout [228]. Usually the assay depends 
on a fluorescent readout which allows for high sensitivity and is amendable to a 
homogenous high-throughput format [226, 234]. However, other optical methods may be 
utilized including absorbance, luminescence, or scintillation.  
 Despite the advantages of a biochemical assay, many soluble target proteins 




multiple substrates and/or cofactors and proteins that display multifaceted biological 
functions [235]. Furthermore, there is a narrow range of enzyme targets for which 
fluorogenic substrates are available. Non-enzymatic proteins could potentially be of 
therapeutic interest, but the ability to assay for a specific readout based on function is 
highly problematic because biochemical assay techniques require prior knowledge of the 
function of the target in order to design an assay. Unfortunately, for many known targets 
linked to disease, such as myocilin in primary open-angle glaucoma (POAG), the 
function of the protein is unknown. Furthermore, approximately half of the proteins 
expressed by the human genome are functionally unclassified, even though some might 
prove to be „druggable‟ [236]. More importantly, compounds identified by HTS could 
provide valuable information into the function of these proteins. This underscores the 
necessity for an assay generally applicable to proteins of unknown structure and function 
and to help alleviate the bottle neck of the lead discovery process. 
 In this chapter, a high-throughput chemical stability assay was developed and 
validated. The assay is based on the premise that ligand binding confers conformational 
stability and overall compactness to its target protein, a known phenomenon for most 
proteins [237], and therefore the assay may be adapted essentially to any soluble protein, 
regardless of prior knowledge of structure and/or function. Here, we show substantial 
progress in assay development for both a model protein, maltose binding protein (MBP), 
and our protein of therapeutic interest, the olfactomedin domain of myocilin (myoc-
OLF). The homogenous assay requires no incubation steps, and is rapid, robust with low 
variability, cost-effective, and capable of generating a high signal-to-noise/background to 
minimize false negatives or positives. During the validation process, a total of 14 
potential drugs for myoc-OLF were identified that may provide not only a therapeutic 






4.2.1 Assay Principle  
 The principle of the assay is based on the well established property that soluble 
proteins are thermally stabilized upon ligand binding. In our assay, the soluble protein is 
slightly destabilized by the addition of guanidine hydrochloride (Gnd HCl), a denaturant, 
and may be re-stabilized upon ligand binding (Fig. 4.1A). Our assay employs Sypro 
Orange, an extrinsic fluorescent dye that monitors protein unfolding by fluorescing in the 
presence of exposed hydrophobic residues [238]. When the soluble protein is 
destabilized, a high fluorescent signal is observed due to the dye‟s colloquial interactions 
with exposed hydrophobic residues. When stabilization occurs after ligand binding, there 
is a decrease in fluorescence (Fig. 4.1B), creating the signal window. The primary benefit 
of this assay is that no prior knowledge of the protein‟s structure and/or function is 
required. However, the assay is limited to soluble proteins that may be expressed and 
purified and potential interference of compounds with Sypro Orange dye.  
4.2.2 Assay Optimization and Verification 
 The assay was first developed in a 96-well format with the well studied E. coli 
maltose binding protein (MBP). MBP was chosen because it binds to the disaccharide 
maltose as well as longer linear and some circular maltodextrins with Kd values in the 
low micromolar range [239], which is the high end of the typical hit potency range of 100 
nM to 5 μM for HTS [219]. The concentration of the denaturant Gnd HCl to be used in 
the assay was first determined by conducting a chemical melt with MBP (Fig. 4.2A), and 
0.6 M Gnd HCl was chosen as the concentration at the onset of unfolding (i.e. the most 
destabilized point without unfolding the protein). After conducting a serial dilution of the 
protein in 0.6 M Gnd HCl, a concentration of 2 μM MBP was determined to be the 






















Figure 4.1. Schematic of chemical stability assay. A) Native protein (left) is 
destabilized by the addition of relatively low concentrations of chemical denaturant 
(middle) and is re-stabilized by binding of the ligand (red, right). B) Example of a typical 
fluorescence spectrum upon the addition of increasing amount of ligand. High signal is 
observed for the destabilized protein in the presence of the reporter dye, Sypro Orange, 





























Figure 4.2. Concentration Optimization for MBP and myoc-OLF. Chemical melt of 
MBP (A) and myoc-OLF (C). Arrow denotes the Gnd HCl concentration at the onset of 
unfolding. Serial dilution of MBP (B) and myoc-OLF (D) to determine optimal 










 Fluorescence assays were then conducted to test for a dose-dependent 
stabilization of MBP upon binding three known ligands: maltose, maltotetraose, and 
maltitol (Fig. 4.3A). All three sugars stabilized MBP in a dose-dependent manner in the 
assay. Maltose stabilized to the greatest degree with a 50% drop in fluorescence intensity 
at 10 μM (Fig. 4.3A). Maltitol stabilized to the lowest degree (Fig. 4.3A), but this was 
expected since the Kd = 50 μM [240]. All three sugars stabilize reproducibly day-to-day 
and plate-to-plate with a signal-to-background (S/B) of 2.1 (Fig. 4.3A,B), which 
describes the separation of the signal window. Phenylmethanesulfonylfluoride (PMSF), a 
known protease inhibitor, was tested as a negative control and no stabilization of MBP 
was observed (Fig. 4.3C).  
 Compounds in a small molecule library are generally dissolved in DMSO, thus it 
was necessary to determine the tolerance of the assay to DMSO. The dose-dependent 
maltose stabilization assay with MBP was repeated, but with 1% DMSO added to the 
reactions. An almost identical stability curve was collected and it was determined that the 
solvent does not appreciably affect the assay (Fig 4.3D).  
 Once the initial controls were completed, statistics for the assay were calculated. 
Destabilized MBP was added to 48 wells of a 96-well microplate, and the same mixture 
without protein was added to the remaining 48 wells. The assay was assessed using the Z′ 
factor, which defines the difference between positive and the negative controls of the 
dynamic signal being measured and the variation of that signal [226]. The collected data 
exhibit a Z′ factor of 0.76 (Fig. 4.3D), indicating an excellent assay with a large 
separation between signal and background populations [241]. The CV value, a variability 
measurement, from this plate was 4.0%, which is an acceptable value for HTS (i.e. less 















Figure 4.3. Assay verification with MBP. A) Dose-dependent stabilization of MBP by 
addition of ligand. Error bars denote standard deviation. B) Signal window of optimized 
assay with MBP. High signal (circles) corresponds to MBP in the presence of Gnd HCl, 
whereas low signal (triangles) corresponds to the same sample but with the addition of 1 
mM maltose. C) Effect of the negative control, PMSF, when added to destabilized MBP. 
D) Stabilization of MBP by maltose in the presence of DMSO. E) Scatter plot of an 
equivalent amount of destabilized MBP (grey circles, n = 48) and background (black 
circles, n = 48) from a single 96-well plate. These data were used to calculate the Z′ value 









4.2.3 Assay Adaptation to Myoc-OLF 
 After verification of the chemical stability assay with MBP, the assay was adapted 
to the protein of therapeutic relevance, myoc-OLF, also in a 96-well format. After 
performing concentration optimization tests as with MBP, it was determined by chemical 
melt that 0.6 M Gnd HCl was the concentration at the onset of unfolding (Fig. 4.2C), and 
1 μM myoc-OLF from the serial dilution assay (Fig. 4.2D) provided the lowest amount of 
protein while still producing a measurable signal.  
 Since relatively little is known about structure or function of myocilin and no 
known ligands exist, trimethylamine N-oxide (TMAO) was chosen as a positive control 
to define the signal window. This was based on the results observed in Chapter 2 where 
myoc-OLF is thermally destabilized when a disease-causing mutation is introduced, and 
that these variants may be stabilized by the addition of non-specific small molecule 
chemical chaperones called osmolytes [243]. Both TMAO and sarcosine conferred a high 
degree of stabilization to WT and mutants increasing their melting temperatures [243]. 
Similar to MBP and maltose, TMAO stabilized myoc-OLF in a dose-dependent fashion 
(Fig. 4.4A), albeit at a 1,000-fold higher concentration range due to the nature of 
osmolytes. However, this stabilization effect provided an S/B = 7.7 (Fig. 4.4B), which is 
4-fold higher than that observed for MBP with maltose (Fig. 4.3B). 
 The tolerance of the assay to DMSO was again tested, and no appreciable effect 
was observed (Fig. 4.4C). The assay was verified for a dose-dependent stabilization 
effect over the course of one hour at room temperature. The same stability trend was 
observed after three days of incubation in the dark at room temperature, but the 
fluorescence intensity increased over time (Fig. 4.4D). Therefore, the assay may be 
conducted at room temperature as long as a positive control is included on each plate. 
The assay with myoc-OLF was statistically evaluated as described above for MBP. 
Again, a Z′ factor of 0.72 (Fig. 4.4E) was determined and a CV value of 3.3% was 














Figure 4.4. Assay verification with myoc-OLF. A) Dose-dependent stabilization of 
myoc-OLF in the presence of Gnd HCl by the addition of increasing amounts of the 
osmolyte, TMAO. B) Defined signal window for the myoc-OLF assay. High signal 
(circles) corresponds to destabilized myoc-OLF whereas low signal (triangles) 
corresponds to re-stabilized myoc-OLF by the addition of 1 M TMAO. C) Effect of 
DMSO on the stabilization curve of myoc-OLF. D) Effect of various incubation times on 
the assay output. E) Scatter plot of an equivalent amount of destabilized myoc-OLF (grey 
circles, n = 48) and background (black circles, n = 48) from a single 96-well plate. These 









4.2.4 Assay Validation 
 Before conducting the compound library pilot screen with the assay, the assay 
required validation for a 384-well format. The dose-dependent stabilization curve for 
MBP by the addition of maltose, as well as the stabilization curve for myoc-OLF by the 
addition of TMAO, were both repeated. However, in this miniaturized format, the S/B 
calculated for myoc-OLF was below a value of two, which is considered to be too low 
and may complicate the interpretation of the results. Optimization of the protein 
concentration was therefore conducted again in the 384-well plate, and it was found that 
4 μM myoc-OLF provided the greatest S/B= 8. An S/B plateau was observed at higher 
protein concentrations, indicating no appreciable gain in the signal window upon the 
addition of more protein (Table 4.1).    
 At Emory University Chemical Biology Discovery Center, the optimized 
chemical stability assay in 384-well format was automated and used to test the LOPAC 
compound library (Sigma Aldrich), which includes 1,280 compounds known to be 
pharmacologically active or are currently approved drugs. Each compound was added at 
a single concentration (1 mM final). Destabilized myoc-OLF and re-stabilized myoc-OLF 
by TMAO (positive control) reactions were added to each plate to define the signal 
window, and allowed for calculation of plate-to-plate statistics to detect any irregularities 
in the assay. The HTS protocol is outlined in Table 4.2 and a scatter plot of the HTS 
results for the entire pilot screen is shown in Fig. 4.5. The performance of the screening 
assay was assessed using the average Z′ value 0.78 (range of 0.76 to 0.83), consistent 
with a high-quality HTS assay. The S/B averaged between 4.2 and 5.5 and the CV value 
averaged between 4.3% and 6.1%, consistent with the values calculated in the 96-well 
format.  
 Molecules leading to a decrease in fluorescence intensity were considered as hits 
(Table 4.3). A total of 14 hits were identified during the pilot screen (Table 4.3, Fig. 4.6) 


















Table 4.2. Chemical stability assay HTS protocol.   
Myoc-OLF (μM) S/B Z′ Factor 
1.0 3.9 -0.40 
2.0 6.1 0.11 
3.0 4.9 0.46 
4.0 8.6 0.68 
5.0 8.4 0.67 
10.0 11.4 0.50 
Step Parameter Value Description 
1 Master Mix 20 μL 0.54 M Gnd HCl, 4.5X Sypro Orange, phosphate 
buffer, pH 7.2 
2 Library Compounds 0.5 μL 1 mM in DMSO 
3 Positive Control 4 μL 0.8 M TMAO 
4 Protein 4 μL 4 μM in phosphate buffer, pH 7.2 
5 Centrifugation 5 min 800 x g 
6 Assay Readout  485 nm excitation 
/572 nm emission  
























Figure 4.5. HTS results for the LOPAC compound library. The x axis represents the 
compounds screened (black circles). The solid red line represents the average signal for 
destabilized myoc-OLF without ligand and the dashed black line represents the average 
signal for re-stabilized myoc-OLF in the presence of TMAO. The Z′ stated is the average 






Table 4.3. Compounds identified in myoc-OLF pilot screen.  
  
Compound Compound Class Activity Effect 
Apigenin Cell Cycle Arrests cell cycle in G2/M phase + 
Aurintricarboxylic acid Apoptosis Topoisomerase inhibitor + 
GW5074 Phosphorylation Kinase inhibitor + 
Isoliquiritigenin Cyclic Nucleotides Aldose reductase inhibitor + 
Morin Cell Stress Oxyradical scavenger + 
Myricetin Phosphorylation Kinase inhibitor + 
Niclosamide Antibiotic Uncouples oxidative phosphorylation + 
Phloretin Ca
2+ 
Channel Blocks L-type Ca2+ channels + 
Piceatannol Phosphorylation Kinase inhibitor + 
Quercetin dihydrate Cyclic Nucleotides Mitochondrial ATPase and 
phosphodiesterase inhibitor 
+ 
Reactive Blue 2 P2 Receptor Antagonist for ATP-activated 
channels  
+ 
Rottlerin Phosphorylation Kinase inhibitor + 
(R,R)-cis-Diethyl tetrahydro-2,8-
chrysenediol 
Hormone Estrogen receptor beta antagonist + 
Tyrphostin AG 879 Phosphorylation Tyrosine kinase nerve growth factor 
receptor inhibitor 
+ 
    
4-Amino-1,8-naphthalimide Apoptosis Poly(ADP-ribose) polymerase 
inhibitor 
- 
Dequalinium analog, C-14 linker Phosphorylation Kinase inhibitor - 

















Figure 4.6. Compounds identified as hits from the LOPAC library screen that 

























Figure 4.7. Identified compounds from the LOPAC library screen that may 
destabilize myoc-OLF significantly, as indicated by a substantial increase in Sypro 





that the high fluorescence intensity for the dequalinium analog in particular could be the 
result of Sypro Orange interacting with the alkyl linker and not the result of myoc-OLF 
destabilization. Interestingly, the stabilizing potential drug candidates include a variety of 
were the most predominant compound class accounting for ~36% of the total hits. The 
well containing the kinase inhibitor GW5074 yielded the lowest fluorescence intensity, 
indicating a potential stabilization effect that was greater than the positive control, 
TMAO. In previous work, myoc-OLF was shown to be stabilized in buffers with 
functional groups mimicking glycosaminoglycans (GAGs) (Chapter 3) [244]. In our 
assay, two compounds, aurintricarboxylic acid and reactive blue 2, also possess 
carboxylate and sulfate functional groups similar to GAGs (Fig. 4.6). While it is tempting 
to speculate the potential therapeutic relevance and functional importance of these 
molecules with myoc-OLF, the binding of these compounds must be verified first by 
conducting a dose-dependent assay for each hit to eliminate false positives, followed by 
isothermal titration calorimetry.  
4.3 Discussion 
 HTS is the primary method used by pharmaceutical companies to generate leads 
in the drug discovery process, and starts by testing hundreds of thousands to millions of 
compounds against a target in an assay. However, this method requires tailored assays to 
the biological target of interest and many limitations arise, including most importantly, 
detailed knowledge of either the structure and/or function of the protein. This level of 
detail is not always available and may be costly and time-consuming to generate. 
Therefore, a generally applicable assay to detect ligand binding for essentially any 
soluble protein is needed.  
 The chemical stability assay was designed to be a „mix-and-measure‟ 
homogenous assay with a facile, one-step readout. The premise of the assay is that a 




dose-dependent fashion. The reporter dye, Sypro Orange, fluoresces only in the presence 
of a hydrophobic environment, i.e. in the presence of destabilized protein with exposed 
hydrophobic residues. Protein stabilization upon ligand binding is a general property of 
proteins and is not dependent on prior functional knowledge of the target of interest. Both 
enzymatic and non-enzymatic proteins may be equally screened in this assay, since 
activity and/or inhibition is not required to produce an optical signal for read out. In this 
work, the assay was first verified with the well characterized, non-enzymatic protein, 
MBP. Stabilization upon ligand binding was shown to occur in a dose-dependent fashion, 
and is not affected by the addition of DMSO. Since the compounds in this library are 
dissolved in this solvent, it is important to verify that the results obtained from the pilot 
screen were due to ligand-induced stabilization and not solvent effects.  
 The assay was next applied to myoc-OLF to identify potential ligands. Previously, 
we have shown that glaucoma-causing mutations in the myoc-OLF result in a 
destabilized protein, and that these variants retain similar secondary structure to wild-type 
[243, 245]. Instead of secretion to the human trabecular extracellular matrix (HTM), 
mutant myocilin has been shown to accumulate in the endoplasmic reticulum (ER) of 
HTM cells, triggering cell stress responses, and eventually leading to cell death [84-85, 
97-98]. It has been hypothesized in our lab and others [76, 97] that if mutant myocilin 
could be stabilized endogenously and pass the ER quality control for subsequent 
trafficking, toxicity due to protein accumulation would be reduced, thus alleviating cell 
stress and delaying the onset of glaucoma. Pharmacological chaperones (PCs) are of 
particular interest as they are small molecule compounds capable of stabilizing 
endogenous mutant enzyme and lead to cellular trafficking, but design of such a 
beneficial molecule is hampered due to lack of knowledge of the myoc-OLF structure 
and function. A top-down approach is therefore required for the identification of 




 A total of 14 potential drug candidates from the LOPAC library were identified, 
with a hit rate of 1.25%. The chemical stability assay was amendable to miniaturization, 
easy to automate, and displayed excellent statistics, indicating a robust and reproducible 
assay. Further work will be required to verify the hits as potential drug candidates and 
would include generation of concentration response curves to eliminate false positives. 
Confirmation of binding should also be tested by isothermal titration calorimetry (ITC) or 
equilibrium dialysis. False positives due to the possible interference of the compounds 
with Sypro Orange should also be tested. Finally, myoc-OLF drug screening may be 
advanced by further miniaturizing to 1536-well format and screening hundreds of 
thousands of compounds at the National Institute of Health‟s Molecular Libraries Probe 
Production Center. Potential drug candidates identified by this chemical stability assay, 
and verified for binding by alternative methods, may yield further insight into the 
function of myoc-OLF as well as provide the first therapeutic molecules targeted at 
alleviating cell stress induced by mutant myocilin intracellular sequestration and 
accumulation.  
4.4 Methods 
4.4.1 Protein Purification 
 MBP was expressed in E. coli Rosetta-gami™ 2(DE3)pLysS competent cells 
(Novagen) using the pMAL-c4x vector (New England Biolabs) and purified on a 20 mL 
high-flow amylose resin (New England Biolabs) column. The myoc-OLF gene was 
introduced into the MBP fusion vector, pMAL-c4x, as described previously [178]. 
Expression and purification of MBP-OLF followed previously described procedures, as 
did generation of cleaved myoc-OLF by incubation with Factor Xa and further 





4.4.2 Chemical Stability HTS Assay 
 The optimal denaturant concentration was first determined by performing a 
chemical melt with Gnd HCl. Increasing concentrations of Gnd HCl (0-2 M) were added 
to 10 μM MBP or myoc-OLF in phosphate buffer (10 mM sodium phosphate dibasic/ 
potassium phosphate monobasic, 200 mM NaCl pH 7.2), and 5X Sypro Orange 
(Invitrogen). The reactions were assembled at room temperature and delivered to 96-well 
microplates (Grenier). Fluorescence data were acquired on a Biotek Synergy 2 instrument 
with a 485/20 nm excitation filter and a 590/35 nm emission filter. Data for each sample 
were taken in triplicate and blank subtracted. Protein concentration was then tested for by 
serial dilutions of the protein (0.625-10 μM) in the phosphate buffer, Sypro Orange, and 
optimized Gnd HCl concentration reaction. Fluorescence data was acquired and analyzed 
as before. 
 After optimal denaturant and protein concentrations were established, known 
ligands (maltose, maltotetraose, and maltitol) of MBP were added in a dose-dependent 
fashion (0-1 mM) to MBP in phosphate buffer, Gnd HCl, and Sypro Orange. 
Phenylmethylsulfonyl fluoride (PMSF), a known protease inhibitor, was also tested in a 
dose-dependent fashion (0-1 mM) as a negative control for MBP. In the case of myoc-
OLF, TMAO (0-1 M) was added as a positive control and fluorescence data were 
acquired. In every case, the protein was added last and prior to fluorescence readings. All 
assays were conducted at room temperature in 100 μL reaction volumes.    
4.4.3 Screening of Small Molecule Library 
 In the primary screen, approximately 1,280 compounds (LOPAC
®, 1280
, Sigma 
Aldrich) were tested at the Emory University Chemical Biology Discovery Center. The 
assay volumes were adjusted to a 384-well format (25 μL reaction volume). Due to a low 
S/B value, myoc-OLF concentration (1-10 μM) was optimized for the 384-well format, 




(0.54 M Gnd HCl, 4.5X Sypro Orange, phosphate buffer, and water) was dispensed via a 
MultiDrop Combi (ThermoScientific) to a 384-well microtiter plate (Costar). The 
Sciclone ALH 3000 Workstation with 384-channel cannula array (Caliper LifeSciences) 
was used to transfer 0.5 μL of compound (1 mM final) to the dispensed master mix 
solution. Myoc-OLF was added last, again using the MultiDrop Combi. The plates were 
centrifuged for five minutes at 800 x g to remove air bubbles prior to fluorescence 
reading in a 2103 EnVision Multilabel Plate Reader (Perkin Elmer) (Exλ= 480 nm; Emλ= 
572 nm).  
4.4.4 Data Analysis 
 To validate the chemical stability assay, the Z′ factor (Eq. 1), the coefficient of 
variation (CV, Eq. 2), and signal-to-background ratio (S/B, Eq. 3) were calculated from a 
96-well plate containing the destabilized sample in GndHCl and the same solution 
without protein:  
 
                                                             (1) 
                        (2) 
                                             (3)  
 







CHARACTERIZATION OF AMYLOID FIBRILS FORMED BY THE 
OLFACTOMEDIN DOMAIN OF MYOCILIN  
5.1 Introduction 
 Amyloidoses are a subset of protein conformational disorders (PCDs) and a group 
of diverse diseases in which soluble polypeptides/proteins undergo a conformational 
change and accumulate to form stable, ordered filamentous protein aggregates, 
commonly referred to as amyloid fibrils [246]. These >20 diseases include such infamous 
disorders such as Huntington‟s disease, Alzheimer‟s disease, Parkinson‟s disease, and the 
prion diseases. Each disease involves predominantly the aggregation of a specific protein, 
but other additional proteins and carbohydrates, specifically glycosaminoglycans (GAGs) 
[247-248], have been identified in plaques and deposits in vivo [249-250]. Amyloid 
deposits may accumulate intracellularly leading to impaired organelle function and cell 
death [251-252], extracellularly resulting in disrupted tissue architecture and function 
[246, 253], or both [254].  
 Fibrils described for amyloidoses are structurally similar in spite of the fact 
constituent monomers exhibit diverse amino acid sequences and diverse tertiary structure. 
X-ray fiber diffraction reveals that the fibrils are composed of a cross-β-sheet structure in 
which the backbone hydrogen bonding is parallel to the fibril axis [255]. Fibrils are ~10 
nm in diameter, un-branched, and mature fibrils have a twisted, rope-like appearance, as 
identified by transmission electron microscopy (TEM) and atomic force microscopy 
[256]. Mature fibrils also exhibit a green birefringence under polarized light when stained 
with Congo Red [257] and are resistant to proteolysis [258]. Formation of the fibrils is 
generally believed to follow the nidus theory, in which amyloid fibril fragments serve as 




T (ThT), which only fluoresces when bound to mature fibrils [259]. The dye binds 
rapidly to amyloid fibrils and produces an increase in fluorescence at 485 nm when 
excited at 440 nm [260]. Finally, polymerization may occur with a natively folded protein 
or unstable intermediates (i.e. mutated protein or protein altered by its environment) 
[261].  
 Amyloidogenic proteins are generally small in size (3-30 kDa) [246] and may be 
natively unfolded and prone to aggregate under physiological conditions, as is the case 
for huntingtin with polyQ expansion in Huntington‟s disease and amyloid-β peptide (Aβ) 
in Alzheimer‟s [262]. For vulnerable globular proteins, aggregation may be transmissible 
(prion), familial, or sporadic. Hereditary forms of the amyloidoses generally occur due to 
a genetic mutation that produces a less stable and less cooperative variant, and will 
therefore tend to fold and aggregate more readily. Familial forms usually have an early 
age of onset and higher severity than sporadic cases [254]; age of onset is generally 
closely related to the extent of destabilization by the mutation [263].  
 A large percentage of amyloid diseases occur sporadically and are observed in 
aged individuals. Premature aggregation earlier in life is prevented largely in part to the 
adapted mechanisms of the cell that serve to assist proteins to their native conformations 
and maintain them in a stable and controlled environment [264]. Intracellularly, 
molecular chaperones play a key role in protecting an incompletely folded polypeptide 
chain from non-productive interactions, including aggregation [249]. In the extracellular 
environment, abundantly secreted glycoproteins, including clusterin, α2-macroglobulin, 
and haptoglobulin, act as extracellular molecular chaperones by protecting a range of 
proteins from stress-induced aggregation [261, 265]. It is likely that this control is lost in 
ageing in conjunction with environmental changes (such as oxidative damage) that may 
promote protein unfolding and aggregation.   
 Emerging evidence places myocilin-associated glaucoma in the context of a PCD. 




disease. In particular, mutations in the secreted protein myocilin have been linked to 
inherited forms of glaucoma. To date, more than 70 glaucoma inducing mutations have 
been documented, located primarily in the C-terminal olfactomedin domain (myoc-OLF) 
[77]. Interestingly, missense mutations do not seriously compromise the overall tertiary 
structure of myoc-OLF, as in vitro studies for ~25 variants have shown that thermal 
unfolding occurs in a cooperative manner and variants retain similar secondary structure 
to wild-type (WT) by circular dichroism [243, 245]. However, these variants are 
thermally less stable than WT [243, 245] and in cell studies, are found to be sequestered 
within trabecular meshwork cells [266-267]. At physiological temperatures, the less 
stable mutant myocilin would be partially unfolded and therefore prone to aggregate. 
Moreover, diminished secretion of WT myocilin is observed when WT and mutant 
myocilin are co-expressed [80, 86, 268], suggesting that mutant myocilin can recruit WT 
to produce a pathogenic response even in the heterozygotes. In both human embryonic 
kidney (HEK) and human trabecular meshwork (HTM) cells expressing mutant myocilin, 
large juxtanuclear aggregates were observed and found to be primarily located in the ER, 
co-localizing with known ER chaperones [86, 97]. Aggregates of mutant myocilin have 
even been observed in transgenic flies [98]. These aggregates have been shown to be 
toxic, inducing the ER stress response [84-85, 98], and eventually cause cell death [86, 
97-98, 269].  
 Although emerging clues to the pathogenesis of myocilin-induced inherited forms 
of glaucoma have come to light in the past decade, little progress has been made towards 
understanding the molecular mechanisms that lead to sporadic glaucoma, which may be 
due in part to the heterogeneity of the disorder. In this work, we initially sought to 
characterize the aggregated form of myoc-OLF and found that both WT and mutant 
variants of the protein form amyloid fibrils, similar to proteins in other PCDs described 




Table 5.1. Summary of experiments and results from this study. 
  
Goal Technique Result Summary 
Identification of Amyloid 
Fibrils 
SEC Void-volume peak corresponding to aggregated MBP-OLF 
 ThT Fluorescence WT and mutant olfactomedin domain fluoresce ThT 
 TEM Fibrils observed  
 Proteolysis Fibril core is resistant to PK 
   
Determination of 
Conditions that Increase 
the Fibrillization Rate 
Anionic Detergent SDS promotes fibrillation 
 Oxidizing Agent <1.5% H2O2 promotes fibrillization 
 Low pH Incubation in citrate buffer, pH 3 promotes fibrillization 
 Reducing Agent BME, DTT, and TCEP promote fibrillization 
   
Examination of Fibril 
Formation Kinetics 
Seeding Assay Fibril formation is self-propagating  and the rate of 
fibrillization increases when the concentration of seeds is 
increased 
 Multiple Round 
Seeding Assay 
Fibrils are matured after three rounds of seeding 




N-terminal Sequencing Failed due to multiple N-termini 
 Systematic Build-Up of 
Myoc-OLF 
One amyloidogenic stretch is present within the first N-
terminal 17 residues 
 N-terminal and C-
terminal truncations 
The presence of other amyloid fibril forming regions, 
beyond the N-terminal 17 residues, are verified  
   
Identification of Myocilin 
Amyloid in Cell Culture 
Triton X-100 
Extraction Followed by 
Gel-Boiling Analysis  
P370L TX insoluble myocilin formed aggregates unable to 
migrate through the SDS-PAGE stacking gel. The 
aggregates were able to enter the gel after incubation over a 
boiling water bath and a second electrophoresis step. 
 ThT Staining of CHO 
Cell Cultures 
Intracellular deposits in the P370L myocilin transfected 




occurs in a nucleation dependent, self-propagating manner (Table 5.1). Mutant myocilin 
expressed in mammalian cells forms intracellular aggregates containing amyloid 
fibrils.Taken together, this work provides new insights into myocilin and suggests a novel 
molecular based hypothesis for pathogenesis.  
5.2 Results  
5.2.1 Identification of Amyloid Fibrils 
5.2.1.1 Initial Identification of Aggregates by Size Exclusion Chromatography  
 During the original development of the myoc-OLF purification protocol, a void-
volume peak corresponding to a large cytosolic MBP-OLF species was isolated by size-
exclusion chromatography (SEC) from monomeric MBP-OLF (Fig. 2.1) after amylose 
affinity purification. Reducing SDS-PAGE revealed that the void-volume fractions are 
composed of MBP-OLF in an aggregated form (Table 5.1). The intensity of the void-
volume peak compared to that of the monomer is not sensitive to incubation at 4 °C, 
freeze-thaw, or concentration loaded on the column. Furthermore, the species do not 
interconvert (Fig. 2.2). Indeed, a species eluting in the void-volume of the SEC 
chromatograph is observed for all variants of myoc-OLF studied in our lab. Even when 
subjected to fractionation on a column designed to fractionate much larger species 
(HiPrep 16/60 Sephacryl S-400 HR column; Mr 20,000–8,000,000), a distribution of high 
molecular weight species is observed (Fig. 5.1).  
5.2.1.2 Identification of Amyloid Fibrils Formed from Olfactomedin Domain by ThT 
 Due to the observed unusual high molecular weight species observed for MBP-
OLF by SEC, the high β-sheet content for the myoc-OLF [243-244] and its predicted 
amyloid propensity [270], we sought to test the hypothesis that the void-volume SEC 

























alterations upon binding a variety of amyloid fibrils and not their precursor polypeptides, 
monomers, or amorphous aggregates of the protein [259, 271]. An increase of ThT 
fluorescence for MBP-OLF and full-length myocilin aggregates was observed but not in 
the presence of their respective monomers (Fig. 5.2A, Table 5.1). Similar to WT 
aggregates, all of the ~30 disease-causing MBP-OLF mutant aggregates studied in lab 
[243, 245] fluoresced with ThT (Fig. 5.2B, Table 5.1).    
 To rule out the possibility that MBP could be forming fibrils and contributing to 
the observed ThT signal, the MBP-OLF void-volume fraction was treated with Factor Xa 
and aggregates subjected to ThT fluorescence analysis. The cleaved aggregates were 
purified by an initial amylose affinity purification to remove any cleaved MBP or 
uncleaved MBP-OLF, followed by SEC to separate the fibrillar material from Factor Xa. 
Similarly, the small aggregate peak observed by SEC after the cleavage reaction for the 
monomeric fraction of MBP-OLF at 37 °C, was tested for ThT fluorescence. In both 
cases, a fluorescent signal for ThT was observed (Fig. 5.2C). No void-volume peak by 
SEC was observed when MBP was expressed and purified alone (data not shown). It was 
therefore concluded that the amyloidogenic region was contained to myoc-OLF and not 
MBP.  
5.2.1.3 Proteolysis 
 The cross-β-sheet core of amyloid fibrils is resistant to proteinase K (PK), a 
protease highly active against globular or disordered conformations but not against 
densely packed cross-β regions [258, 272-273]. Treatment of MBP-OLF aggregate with 
PK followed by purification by SEC revealed a ThT positive void-volume elution peak 








































Figure 5.2. ThT fluorescence spectra in the presence of amyloid fibrils. A) 
Fluorescence emission increase in the presence of aggregated MBP-OLF (black) and 
aggregated myocilin (red) compared with the monomeric versions (blue, green, 
respectively). B) Emission spectra for selected aggregated OLF variants. C) ThT 
emission spectra for myoc-OLF aggregates obtained after incubation at 37 °C (blue), PK 
treated aggregates (black), and Factor Xa treated aggregates (red). All spectra collected at 










Figure 5.3. Electron micrographs of myoc-OLF amyloid fibrils. A-B) Myoc-OLF 
fibrils obtained after incubation at 37 °C for 95 hrs. C) Micrograph of myoc-OLF fibrils 
(black arrows) and torus-shaped oligomers (white arrowhead) formed after incubation at 
37 °C in the presence of SDS. D) Myoc-OLF fibrils formed after incubation at 37 °C in 







5.2.1.4 Amyloid Fibrils Visualized by TEM 
 Transmission electron microscopy was next employed to visualize myoc-OLF 
fibrils, which were formed de novo by incubation at 37 °C for 95 hrs as opposed to the 
fibrils isolated from E. coli by SEC described above. TEM revealed typical amyloid 
morphology: unbranched fibrils with a diameter of about 10 nm (Fig. 5.3 A-B, Table 
5.1). Although amyloid fibril formation can be a generic property of the polypeptide 
backbone and that essentially any protein could form fibrils under the right destabilizing 
conditions, we believe this is not the case in our system as fibrils are observed after a 
long incubation of the OLF domain alone at physiological temperature. Taken together, 
although there is no definitive test for amyloid, the collection of evidence is strong for 
myoc-OLF.    
5.2.2 Conditions That Promote Spontaneous Fibrillization In Vitro 
 In vitro fibril formation of myoc-OLF takes multiple days (with agitation of 
sample; Fig. 5.4) to weeks (no agitation of sample; data not shown) to occur because 
amyloid fibril formation is a nucleation-dependent process [274-275], consisting of both 
a nucleation phase and an extension phase. The nucleation process requires the self-
assembly of monomers, and therefore is the rate-limiting step. However, as described 
below, the kinetics of myoc-OLF fibrillation can be accelerated by exposing the protein 
to slightly destabilizing conditions that allow the peptide backbone to be exposed and 
form the interchain hydrogen bonds associated with amyloid fibrils.   
5.2.2.1 SDS, an Anionic Detergent, Promotes Fibrillization 
 Negatively charged GAGs, such as heparin and heparin sulfate, and anionic 
detergents accelerate the kinetics of amyloid fibril formation by serving as a nucleating 
surface [247, 250, 276-278]. In particular, SDS induces the extension of both β2-




Figure 5.4. Myoc-OLF fibrillization monitored by ThT fluorescence. Myoc-OLF was 





Table 5.2. Conditions that promote fibrillization
a
.  
Additive ThT Intensity, 485 nm (afu) 
Myoc-OLF (4 °C) 2.1 
  
0 mM SDS 3.7 
0.2 mM SDS 139.6 
0.4 mM SDS 275.4 
0.5 mM SDS 259.4 
0.6 mM SDS 255.6 
0.8 mM SDS 216.3 
1.0 mM SDS 208.4 
5.0 mM SDS 26.1 
10.0 mM SDS 13.5 
  
0% H2O2 21.4 
0.03% H2O2 152.3 
0.3% H2O2 313.8 
1.5% H2O2 275.4 
2.9% H2O2 32.6 
  
50 mM Citrate, pH 3.0 57.6 
  
5 mM BME 57.6 
5 mM DTT 175.3 
5 mM TCEP 124.4 
a





concentrations to enhance myoc-OLF fibril formation were tested. SDS (0-10 mM) was 
incubated with 30 μM myoc-OLF without agitation for 95 hrs followed by measurement 
of ThT fluorescence. Consistent with previous results found with β2-microglobulin and α-
synuclein, SDS stimulates fibril formation at concentrations less than 0.8 mM (Fig. 5.2C, 
Table 5.1-5.2). This result is consistent with previous reports that concentrations of SDS 
at or below the critical micellar concentration (CMC) (0.67 mM) induce fibril growth as 
well as stabilize the fibrils [279]. At concentrations above 1.0 mM, fibrillization was 
vastly reduced (Table 5.2) most likely due to the formation of amorphous aggregates 
instead of fibrils. When monomeric myoc-OLF is incubated at 30 °C in the presence of 
0.5 mM SDS, no lag phase is observed and a plateau in ThT fluorescence is observed 
after 30 hrs (Fig. 5.5B, black curve).  
5.2.2.2 Oxidizing and Reducing Conditions Promote Fibrillization 
 We also attempted to mimic in vitro certain stresses myocilin is expected to 
encounter during the ageing process that may promote fibrillization, namely, oxidative 
stress and low pH. Accumulating evidence supports the role of oxidative stress in POAG 
[281-283] and it has already been shown to play a role in the development of cataracts, as 
reviewed by Sharma et. al. [284]. To test the effect of oxidative stress in vitro, various 
dilutions of hydrogen peroxide (up to ~3%) were added to monomeric myoc-OLF, 
followed by incubation at 37 °C for 95 hrs. Treated samples fluoresced with ThT (Table 
2) and showed fibrils by TEM (Fig. 5.2D), except for the ~3% sample, which had a ThT 
signal similar to untreated myoc-OLF (Table 5.1-5.2) and displayed only amorphous 
aggregates by TEM (data not shown). Myoc-OLF at an identical concentration was also 
subjected to incubation in citrate buffer (pH 3.0) at 37 °C for 95 hrs. This sample 
fluoresced with ThT, but to a lesser extent than described for the conditions listed above 
(Table 5.1-5.2). Conversely, the effect of reductants, expected to reduce the single 




































Figure 5.5. Extension of myoc-OLF fibrils in the presence of SDS. A) The formation 
of fibrils is accelerated by the addition of pre-formed fibrils (seeds). B) Self-seeding 







reduction is not unprecedented, as dithiothreitol (DTT) was shown to accelerate the fibril 
formation process for β2-microglobulin [285]. Myoc-OLF was incubated in the presence 
of β-mercaptoethanol (BME), DTT, and tris(2-carboxyethyl)phosphine (TCEP). All three 
treated samples fluoresced with ThT (Table 5.1-5.2). The ThT signal was the lowest for 
BME and identical to that of the citrate (pH 3.0) sample (Table 5.2).   
5.2.3 Myoc-OLF Forms Amyloid Fibrils by a Nucleation Dependent Mechanism 
 As mentioned above, in vitro amyloid fibril growth occurs with an initial lag 
phase, during which monomers assemble to form nuclei. Once the solution is nucleated, 
fibril extension occurs at a rapid rate by the addition of monomer to the fibril ends 
(elongation phase) until the solution is depleted of monomeric protein and a plateau is 
observed (Fig. 5.4) [286]. Fragmented amyloid fibrils may also serve as nuclei when 
added to globular protein and initiate rapid fibril growth in a process known as seeding.   
5.2.3.1 Kinetics of Fibril Formation 
 In the seeding assay, myoc-OLF fibrils, formed in vitro by incubation at 37 °C in 
a water bath in the presence of 0.5 mM SDS, were verified by ThT fluorescence and 
fragmented by sonication. The ‘seeds’ were added at a 1:1 molar ratio with purified 
monomeric myoc-OLF in the presence of 0.5 mM SDS and incubated at 30 °C. ThT 
fluorescence was monitored and a rapid growth rate was observed with a t1/2= ~3 hrs 
(Fig. 5.5A). Upon doubling the quantity of seeds, fibrillization occurred at a faster rate 
(t1/2= ~1.5 hrs) (Fig. 5.5A, Table 5.1). This reaction reached a plateau presumably after 
the pool of globular myoc-OLF was depleted, about 10 hrs sooner than when fewer seeds 
were used. Both seeding experiments were performed in duplicate and rates were 





5.2.3.2 Maturation of Fibrils by Multiple Seeding Rounds 
 The self-seeding propensity of myoc-OLF was analyzed by conducting multiple 
seeding rounds where the fibrillized material from a previous round was used to seed a 
subsequent round. To produce initial seeds, monomeric myoc-OLF was incubated alone 
in the presence of 0.5 mM SDS (Fig. 5.5B, black curve).The product was used to seed 
monomer in the second round (Fig. 5.5B, red curve), and the second round product was 
used to seed the third round (Fig. 5.5B, blue curve). An increase in the rate was observed 
each time (Fig. 5.5B). Subsequent seeding rounds did not yield an increase in rate of 
formation, indicating full maturation of the fibrils was achieved after three rounds (Table 
5.1).  
5.2.4 Identification of the Amyloidogenic Core 
 To identify the sequence(s) in myoc-OLF prone to forming amyloid fibrils, 
preformed fibrils were initially treated with PK, as described above, to digest any 
extraneous residues leaving only the core fibril, followed by N-terminal sequencing. 
Unfortunately, there was a heterogeneous mixture that did not allow for unambiguous 
determination of N-terminal sequence(s). As an alternative approach to identify the 
amyloidogenic core, we systematically assembled the myoc-OLF domain in ~20 residue 
segments by fusion to MBP (Fig. 5.6A). SEC was employed to identify which constructs 
contained the fibril forming sequence, as a void-volume peak would be present for those 
that did. Surprisingly, the construct containing the first 17 residues (MBP-OLF228-244) 
(Fig. 5.6A, blue), as well as all subsequent constructs tested, yielded an aggregate void-
volume peak (Fig. 5.6B, Table 1). All void-volume peaks fluoresced with ThT (Fig. 
5.6C).  
 The sequence for MBP-OLF228-244 was analyzed in silico for amyloid propensity 
by ZipperDB [287], and a predicted fibril forming region was located in the middle of 






















Figure 5.6. Systematic construction of the myoc-OLF domain. A) Schematic of 
constructs. B) SEC chromatograph of selected truncated constructs (dotted and dashed 
lines) including the construct containing the first 17 residues (solid blue) and full-length 
myoc-OLF (solid black). C) ThT fluorescence spectra for each selected construct‟s void-
volume fraction isolated by SEC. Spectra were not acquired at equal concentrations, but 































Figure 5.7. Identification of amyloidogenic regions in myoc-OLF. A) Myocilin 
sequence with various truncations tested in this study including the MBP-OLF construct 
containing the first 7 residues (red, MBO-OLF228-234), containing the first 17 residues 
(blue, MBP-OLF228-244), lacking the first 17 residues (green, MBP-OLF245-504), and 
lacking the first 17 N-terminal residues and last 48 residues from the C-terminus (orange, 
MBP-OLF245-455). The N-terminal region of myocilin eliminated in our myoc-OLF 
construct is grey. B) SEC chromatogram of the above listed constructs. C) ThT 
fluorescence spectra of the void-volume fractions isolated by SEC for each construct. D) 
ThT fluorescence spectra of monomeric MBP (black) and MBP-OLF228-243 (red) after 





codon was introduced at Y235 to create MBP-OLF228-234 (Fig. 5.7A, red). After 
expression and purification of MBP-OLF228-234, no void-volume peak was observed by 
SEC (Fig. 5.7B, red curve, Table 5.1). To test whether the lack of aggregated MBP-
OLF228-234 material was due to a disruption in the fibril forming region and not a 
byproduct of folding in close proximity to the C-terminus of MBP, monomeric MBP-
OLF228-234 was incubated for 95 hrs at 37 °C in the presence of 0.5 mM SDS. The ThT 
fluorescence for MBP-OLF228-234 was less than MBP treated in an identical manner (Fig. 
5.7D) indicating that neither fibrillated, as the overall intensity was significantly lower 
than for MBP-OLF228-244 and WT MBP-OLF (Fig. 5.7C).  
 The presence of additional fibril forming segments was tested in several ways, 
based on the knowledge of one fibril forming segment located in the first 17 residues 
(Table 5.1), and the identity of a core-OLF domain (OLF228-455) (Chapter 3) [243]. First, a 
truncated construct lacking the first 17 residues (MBP-OLF245-504) (Fig. 5.7A, green) was 
created. This construct displayed a void-volume peak isolated by SEC (Fig. 5.7B, green 
curve) that fluoresced strongly with the addition of ThT (Fig. 5.7C, green curve, Table 
5.1). Thus, other amyloidogenic regions beyond the N-terminal 17 residues of myoc-OLF 
axist and need further identification.  
 Second, a variation of the core-OLF (see Chapter 3) sequence (OLF228-455) was 
tested [244]. Previous attempts to generate core-OLF by de novo molecular biology 
yielded only a void-volume peak in the SEC chromatogram (Fig. 5.8). To test the 
presence of amyloidogenic sequences after the N-terminal 17 residues of myoc-OLF, but 
before the last ~50 C-terminal residues that are eliminated in the core-OLF domain, 
MBP-OLF245-455 was expressed (Fig. 5.7A, orange). Again, only a void-volume peak was 
present in the SEC chromatogram (Fig. 5.7B) that also fluoresced in the presence of ThT 
(Fig. 5.7C). These results indicate that one or more amyloidogenic sequences are present 

























Figure 5.8. SEC chromatogram of MBP-core-OLF (MBP- OLF228-455).  





5.1), and does not exclude the possibility that an amyloidogenic stretch is present in the 
removed C-terminal residues (456-504).  
5.2.5 Myocilin Amyloids in Cell Culture Model (Chinese Hamster Ovary Cells) 
 Previous work in the field has shown that disease-causing myocilin mutants are 
detergent insoluble [87], highly aggregation-prone, and accumulate in large aggregates in 
the ER of human embryonic kidney (HEK) cells and differentiated HTM cells [80, 84]. 
The possibility that aggregates found in cell models are amyloid fibrils was tested by 
expressing full-length myocilin in Chinese hamster ovary (CHO) cells for analysis by a 
gel-boiling assay and ThT staining of intact cells. CHO cells were transfected with either 
vector control, WT full-length myocilin, or a severe disease phenotype mutant myocilin, 
P370L, in the laboratory of Dr. Douglas Vollrath at Stanford University. All constructs 
possessed an N-terminal S-tag which was exploited for immunoblotting experiments. The 
cultured cells were harvested and myocilin was extracted by a previously reported Triton 
X-100 (TX) solubility assay, in which WT and non-glaucoma causing variants of 
myocilin are TX soluble, whereas disease causing variants are TX insoluble [87].  
5.2.5.1 Triton X-100 Extraction and SDS-PAGE Gel-Boiling Analysis 
 Equivalent amounts from the TX soluble and insoluble fractions were analyzed by 
SDS-PAGE and immunoblotting. The samples were loaded into the SDS-PAGE gel in a 
loading buffer with a reduced amount of SDS (1% final) as opposed to the typical 2%. 
Due to their aggregated nature, amyloid fibrils are reluctant to enter polyacrylamide gels. 
This was indeed the case for the P370L TX insoluble sample, as aggregated material was 
present and unable to migrate through the stacking gel and enter the resolving gel (Fig. 
5.9, left). This was also observed to a lesser extent in the P370L TX soluble and WT TX 
insoluble fractions (Fig. 9, left). As expected, neither vector control samples nor WT TX 





























Figure 5.9. Boiled gel analysis of myocilin aggregates in transfected CHO cells. Left) 
Immunoblot of TX soluble (S) and insoluble (I) fractions. Stacking gel is outlined with a 
black box. Right) Immunoblot of same samples, however, the polyacrylamide gel was 





have been observed for D380A, E323K, Y437H, G364V, and K423E glaucoma-causing 
myocilin variants [97]. Amyloid aggregates can be disrupted by boiling of the gel, 
allowing the constituent monomers to be released and enter the gel upon electrophoresis 
[288]. This was the case for our samples, as all aggregated samples entered the resolving 
gel after the gel was boiled for 10 minutes and a second electrophoresis step was 
performed (Fig. 5.9, right, Table 5.1).  
5.2.5.2 ThT Staining of CHO Cell Cultures 
 Finally, to explicitly observe amyloid in cell culture and determine if the 
identified aggregated species were indeed forming amyloid fibrils, we stained the 
transfected CHO cells were stained with ThT. There was minimal ThT fluorescence in 
the WT sample (Fig. 5.10, top panels) signifying low levels of amyloid fibrils, a result 
consistent with the gel-boiling assay described above. Conversely, ThT staining of CHO 
cells transfected with P370L myocilin fluoresced (Fig. 5.10, bottom panels), indicating 
the presence of mature fibrils in the cells as predominantly intracellular deposits (Table 
5.1). For this sample, there was no discernible extracellular staining.  
5.3 Discussion  
 Amyloidoses display considerable heterogeneity and are influenced by various 
factors including inherited mutations in proteins [289], interactions with pathological 
molecular factors/environments [290], as well as by intracellular and extracellular quality 
control systems against misfolded proteins [261, 265, 291-292]. These factors, whether 
acquired or inherited, contribute to ER stress which may trigger apoptotic pathways. In 
inherited amyloidoses, the efficiency of the ER machinery to target destabilized mutant 
proteins for degradation is central to disease etiology, as well as the enhanced tendency 
of these variants to aggregate [289]. 



















Figure 5.10. Comparison of ThT fluorescence in CHO cells transfected with WT or 
mutant (P370L) myocilin. Left) Differential interference contrast micrograph (DIC); 






 In these inherited conformational disorders, intracellular accumulation of 
amyloidogenic protein due to point mutations in the amino acid sequence is a common 
phenomenon. For example, familial amyloidotic polyneuropathy and familial 
amyloidoticcardiomyopathy are autosomal dominant inherited diseases caused by genetic 
mutations in the transthyretin gene, of which over 100 variants have been described 
[289]. Another example includes familial Alzheimer‟s disease (AD), in which autosomal 
dominant inheritance of mutant genes that encode for either amyloid precursor protein 
(APP), presenilin 1, or presenilin 2 cause early-onset AD [293]. Amyloid deposits 
localized to the ER and Golgi have been identified in Type-II diabetes mellitus which 
occurs when human islet amyloid polypeptide aggregates in these organelles leading to 
apoptosis and β-cell death [294-296].  
  In familial forms of POAG, aggregation has been shown to occur in the ER of 
HTM cells expressing myocilin variants, which eventually leads to apoptosis [84, 97]. 
Large juxtanuclear aggregates have been observed in the ER of both human embryonic 
kidney and HTM cells [97]. Destabilizing point mutations have been shown to increase 
the aggregation propensity of myoc-OLF, as identified by an increased ratio of aggregate 
to monomer when purified from E. coli by SEC (Chapter 2) [243, 245]. In this work, we 
have shown that intracellular deposits present in CHO cells expressing mutant (P370L) 
myocilin fluoresce in the presence of ThT. Promiscuous β-strand interactions due to a 
destabilized or misfolded protein are a general feature of the protein aggregates that make 
up amyloidoses [297], as highlighted by multiple amyloidogenic regions, both identified 
and proposed, in the OLF domain of myocilin. In vitro characterization of recombinant 
myoc-OLF revealed that the OLF domain of myocilin, for both WT and mutant, is prone 
to fibril oligomerization, identifying glaucoma as a possible new amyloidosis. Structural 
analysis of the OLF fibrils showed that the recombinant myoc-OLF assembles in vitro 
into unbranched ~10 nm thick fibrils. Importantly, the fibrils show tinctorial affinity for 




 In addition to familial POAG, a novel hypothesis for the origin of pathogenesis of 
late-onset glaucoma has emerged from this work. In vitro, WT myoc-OLF fibril 
formation displays a lag phase of several days to weeks when incubated alone at 
physiological temperature but can be accelerated by the addition of destabilizing agents, 
and some WT myoc-OLF aggregates are present in CHO cells. However, the ability of 
myocilin to form fibrils in the trabecular extracellular matrix would be low under normal 
conditions in the eye, as homeostasis is tightly regulated and molecular chaperones are 
present to modulate the earliest aberrant protein interactions that lead to amyloid fibril 
formation [291]. In the aged eye, these regulations may not be as strictly controlled due 
to gradual deterioration of stress response mechanisms. Myocilin fibrillization and 
deposition could occur, seed other monomeric myocilin, which in turn could create a 
denser trabecular extracellular matrix and alter aqueous humor outflow leading to 
increased intra-ocular pressure (IOP). In addition, accumulating evidence has linked 
oxidative stress with glaucoma. Antioxidant enzymes, such as superoxide dismutase, 
malondialdehyde, and glutathione peroxidase, have been reported in aqueous humor and 
levels have been shown to be significantly higher in the aqueous humor of POAG 
patients [283]. In our study, monomeric myoc-OLF samples incubated with low levels of 
H2O2 formed amyloid fibrils, suggesting that oxidative stress may play a role in initiating 
the myoc-OLF fibrillization process in late-onset glaucoma. It is plausible that other 
proteins in the trabecular extracellular matrix, many of which are not well-characterized, 
might be similarly prone to fibrillization upon exposure to oxidative stress.     
 It should be noted that glaucoma is a very heterogeneous disorder, and that 
myocilin-associated POAG may be one of many origins of pathogenesis. Another 
amyloidogenic peptide, Aβ, has been identified to both colocalize with and induce 
apoptosis in retinal ganglion cells in vivo, and a compound used to reduce Aβ deposits in 
Alzheimer‟s disease was equally effective in treating glaucomatous degeneration [298]. 




untested, that co-aggregation between myocilin and Aβ could occur. This “molecular 
cross-talk” is not unprecedented. Inoculation of an Alzheimer‟s transgenic mouse model 
with prions has been shown to lead to a dramatic acceleration and exacerbation of both 
pathologies, and in vitro protein misfolding could be enhanced by a cross-seeding 
mechanism [299]. Another example occurs in the case of familial amyloidosis of Finnish 
type (FAF), in which point mutations in plasma gelsolin cause aberrant cleavage that 
results in amyloidogenic fragments that fibrillize extracellularly [247]. However, mouse 
models for this disorder also experience a decline in cellular proteostasis, due to amyloid-
like intracellular inclusions containing Aβ, APP, and other amyloidogenic polypeptides 
[300].   
 Taken together, this work provides a new hypothesis as to the role of myocilin in 
the pathogenesis of both familial and sporadic forms of glaucoma. Despite strong 
evidence that myoc-OLF forms amyloid fibrils both in vitro and in transfected CHO cells, 
the relevance to glaucoma is highly dependent on future experiments focused on studying 
fibril formation in HTM cells. Once this key experiment is established, a connection 
between raised myocilin expression levels and amyloid formation could be explored, as 
increased myocilin expression leads to elevated IOP and aqueous humor outflow 
resistance [67]. Finally, the exact identification of amyloidogenic sequences in the OLF 
domain could be achieved by optimizing the PK cleavage protocol and subjecting the 
treated aggregates to mass spectrometry or NMR analysis.  
5.4 Methods 
5.4.1 Protein Expression and Purification 
 The plasmid for MBP-OLF was cloned as described before (see Chapter 2) [243-
244].  Myocilin mutants and truncated forms of myoc-OLF were generated by site-




plasmids were verified by DNA sequencing (MWG Operon) and transformed into 
Rosetta-Gami 2(DE3)pLysS cells (Novagen), cultured, induced, harvested, and purified 
as described before [243-244]. In summary, all constructs were subjected to an initial 
purification over an amylose affinity column. Cytosolic aggregates and monomeric 
protein were further fractionated by size-exclusion chromatography (SEC). In the case of 
the truncated constructs, SEC was carried out on a Superdex 75 GL column (GE 
Healthcare). Cleavage of myoc-OLF from MBP was accomplished by incubating with 
Factor Xa by following the previously described protocol [243-244].  
5.4.2. In Vitro Fibril Formation 
 Monomeric myoc-OLF (30 μM) was incubated in the presence of various 
destabilizing agents at 37 °C for 72-95 hrs. These agents included 50 mM citrate, pH 3.0, 
SDS (0-10 mM), H2O2 (0-2.9%), 5 mM β-mercaptoethanol (BME), 5 mM dithiothreitol 
(DTT), or 5 mM tris(2-carboxyethyl)phosphine (TCEP). The presence of amyloid fibrils 
was confirmed by monitoring the fluorescence intensity using a RF-5301 PC 
spectrofluorophotometer (Shimadzu) after 1 min incubation with 5 μM Thioflavin T 
(ThT, Ex λ: 440 nm; Em λ: 485 nm).  
5.4.3 Spontaneous and Seeded Aggregation Assays 
 In the spontaneous aggregation assay, myoc-OLF was incubated in 0.5 mM SDS, 
phosphate buffer (10 mM Na2H/KH2PO4, 200 mM NaCl, pH 7.2)  and 40 μM ThT at 30 
°C. Fibril formation of myoc-OLF without SDS was also monitored, in which 10 μM 
monomer was mixed with Buffer A and 5 μM ThT. In both cases, fibril formation was 
monitored by ThT fluorescence.   
 For seeding assays, preformed myoc-OLF fibrils (0.5 mM SDS, 37 °C incubation 
in a water bath for 72 hrs) were pelleted and washed in phosphate buffer to remove SDS. 




Sonifier 450 (VWR). Monomeric myoc-OLF (15 μM) was inoculated with 15-30 μM 
seeds in a 100 μL reaction volume in the presence of 0.5 mM SDS, phosphate buffer, and 
40 μM ThT. Fluorescence intensity was monitored while the sample incubated at 30 °C 
via a circulating water bath (VWR). In the case of the multiple round seeding assays, the 
fibrils of the previous round were used as seeds for the next round using a 1:1 ratio seeds 
to monomer (15 μM each). Fibril formation was followed by increase in ThT 
fluorescence.  
5.4.4 Proteinase K Digestion 
 Proteinase K (2 μL of 20 mg/mL solution; New England Biolabs) was added to 2 
mL of 8 μM MBP-OLF fibrils in 50 mM Tris HCl, pH 8.0 and 150 mM NaCl. The 
reaction was incubated for 1 hr at 37 °C. The reaction was then purified by amylose 
affinity resin, and the unbound flow through fractions were subjected to SEC on a Sup 75 
column. The elution fractions corresponding to the void volume were concentrated and 
analyzed by SDS-PAGE and ThT fluorescence.   
5.4.5 Transmission Electron Microscopy 
 Myoc-OLF fibrils were visualized by transmission electron microscopy.  Sample 
volumes of 2 ul were pipette onto carbon-coated 400-mesh copper grids and blotted after 
60s with Whatman #4 filter paper.  Immediately after blotting, a 2 uL aliquot of 1% 
uranyl acetate was pipetted onto the grid and again blotted after 30 s.  Images of 
negatively stained samples were collected with a JEOL JEM-1400 transmission electron 
microscope.  Samples were screened at low magnification (20,000x – 30,000x) with an 
Orius SC1000 CCD camera.  Once fibrils were identified, higher-magnification images 





5.4.6 Creation of Stable Cell Lines with Tetracycline Inducible Myocilin Expression 
 To place myocilin cDNAs under the control of a tetracycline-inducible promoter, 
DNA fragments encoding wild type or P370L mutant myocilin fused at the 3‟ end with a 
sequence encoding the 15 amino acid S-peptide from E. coli RNAse A [301] were 
inserted into the PmeI site of pcDNA4/TO (Invitrogen). DNA sequence analysis was 
performed to confirm that coding sequences were correct and in-frame with the S-peptide 
tag. To create stable cell lines with inducible myocilin expression, plasmids 
pcDNA4/TO-Myoc WT-S-tag and pcDNA4/TO-Myoc P370L-S-tag and the vector 
pcDNA4/TO control were individually transfected into T-REX-CHO cells (Invitrogen) 
using Lipofectamine plus. Two days after transfection, 50 g/ml zeocin was added to 
select transfectants. Single cell colonies were picked following selection with zeocin for 
about two weeks. The expression of recombinant myocilin protein was induced by adding 
1g/ml tetracycline and verified by immunoblot at 48hr post-induction. Cloned cell lines 
were designated T-REX-CHO (pcDNA4/TO-Myoc WT-S-tag), T-REX-CHO 
(pcDNA4/TO-Myoc P370L-S-tag) and T-REX-CHO (pcDNA4/TO vector). For 
experiments, stable inducible cells were grown in Ham‟s F12 medium supplemented with 
5% FBS, 1% penicillin-streptomycin, 2 mM glutamine, 10 g/ml blasticidin, and 50 
g/ml zeocin. 
5.4.7 Thioflavin T Staining for Amyloid Fibrils 
 6 X 10
4
 cells were grown on poly-D-lysine-coated cover slips overnight and the 
expression of myocilin was then induced by adding 1 g/ml tetracycline for 48 hr. Cells 
were processed for thioflavin T staining essentially as described [302]. Briefly, cells were 
fixed in 4% paraformaldehyde at room temperature for 15 min and washed in PBS three 
times. Cells were stained with Mayer‟s hematoxylin for 2 min, washed in water for 5 
min, then incubated in 1% (w/v) thioflavin T for 3 min, rinsed in water again for 5 min, 




washed thoroughly in water, cover slips were mounted with FluorSave Reagent 
(Calbiochem) for 2 hr. Fluorescence microscopy was used to identify and quantify 
thioflavin T positive cells, which appeared green.  
5.4.8 Triton X-100 Extraction and Boiled Gel Analysis 
 WT, P370L myocilin, and vector control cell pellets were thawed from -80 °C on 
ice, resuspended in 400 μL of extraction buffer (1X PBS, pH 7.4, 5 mM EDTA, 1% 
Triton X-100 (TX) with Complete protease inhibitor cocktail (Roche)), and incubated on 
ice for 30 minutes. The samples were centrifuged at 13,000 rpm for 15 minutes. After 
which, the supernatant was transferred to a new microcentrifuge tube and set aside as the 
TX soluble fraction. The pellet is the TX insoluble fraction and is solubilized in 100 μL 
of SDS buffer (1% SDS in PBS) for 10 minutes at room temperature. After addition of 
300 μL extraction buffer, the sample was sonicated for 20 s with the output at 5.  
 The boiled gel protocol was adapted from a previously reported protocol for 
purification of yeast prion polymers from cell lysates [288]. In summary, TX soluble and 
insoluble samples containing 1% SDS and 40 μg total protein were loaded onto an SDS-
PAGE gel and run for 45 minutes. The electrophoresis step was halted and the wells were 
sealed with a new portion of stacking gel. Once the newly added acrylamide was 
solidified, the gel was incubated over a boiling water bath for 10 minutes, cooled to room 
temperature, and then subjected to a second electrophoresis step. The proteins were 










THE ACID -GLUCOSIDASE ACTIVE SITE EXHIBITS 
PLASTICITY IN BINDING 3,4,5,6-TETRAHYDROXYAZEPANE-
BASED INHIBITORS: IMPLICATIONS FOR 
PHARMACOLOGICAL CHAPERONE DESIGN FOR GAUCHER 
DISEASE 
6.1 Introduction 
 Gaucher disease (GD), the most common lysosomal storage disorder, is caused by 
inherited point mutations in alleles of acid--glucosidase (GCase), a lysosomal enzyme 
that hydrolyzes glucosylceramide (GlcCer) (Fig. 6.1) and related substrates [303]. GD-
associated GCase variants exhibit endoplasmic reticulum (ER) folding and trafficking 
defects [304] and are either retained in the ER [305] and/or undergo ER-associated 
degradation (ERAD) [306-307]. As a result of decreased GCase function in the lysosome, 
GlcCer and other substrates accumulate, leading to GD-associated pathologies such as 
hepatomegaly, splenomegaly, anemia, a weakened skeleton, and in severe cases, central 
nervous system (CNS) complications [303, 308].  
 Although intravenous enzyme replacement therapy (ERT; imiglucerase, 
Cerezyme®, Genzyme; velaglucerase alfa, Vpriv®, Shire), the standard of care for 
Gaucher patients, significantly improves organ and blood parameters in non-
neuronopathic GD [309], ERT does not improve pre-existing bone and lung disease. ERT 
also does not arrest neurological complications [310], due, at least in part, to the 
recombinant enzyme‟s inability to cross the blood-brain barrier. In addition, the cost of 







Figure 6.1. Chemical structure of the natural GCase substrate, GlcCer, 
representative azasugars investigated as pharmacologic chaperones, IFG, NB- and 






developing countries; only ~10% of GD patients worldwide are treated [309]. Due to 
these limitations, efforts to develop new therapeutic strategies have turned towards 
orally-available small molecules. Substrate reduction therapy (SRT), in particular, the 
FDA-approved miglustat (N-butyldeoxynojirimycin, NB-DNJ, Zavesca®; Acetlion), 
aims to reduce accumulation of GlcCer by inhibiting its synthesis. However, miglustat 
exhibits significant side effects and has therefore only been approved as a second-line 
therapy for patients with non-neuronopathic GD [309]. A second generation inhibitor 
[312], eliglustat (an analog of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; 
Genzyme), which passed Phase 2 clinical trials, may overcome some of the adverse 
reactions of miglustat [313-314], but does not reach the brain. 
 A promising therapeutic approach under development for GD is referred to as the 
pharmacological chaperone (PC) strategy, wherein a small molecule is designed to bind 
to and stabilize the native state ensemble of the endogenous mutant GCase enzyme in the 
ER. This allows more folded mutant GCase to engage its trafficking receptor LIMP-2 
[315], increases its concentration in the lysosome which in turn increases overall cellular 
GCase activity [308]. The premise of the approach is based on the knowledge that 
missense mutations in GCase are not localized to its active site. Thus, while mutations 
diminish protein stability [158] and cellular trafficking, they do not completely abolish 
enzymatic activity [316-317]. As little as 1% GCase activity is thought to improve 
clinical symptoms of GD [318], but >10% of wild type GCase activity is generally 
required to prevent disease. Since small molecules are more likely to cross the blood-
brain barrier than macromolecules, PCs hold promise for the treatment of neuronopathic 
variants of GD. In addition, PCs may be attractive in terms of cost, and may help 
overcome worldwide drug accessibility issues.  
 The desirable properties of a PC are in some ways contradictory.  In the 
environment in which the target mutant enzyme folds (the ER), PCs must have high 




increase the pool that is competent for trafficking. However, in the destination 
environment in which the target mutant enzyme is active, the lysosome, the PC must not 
bind so tightly to the active site that it cannot be displaced by the substrate. In GD, pH-
dependent binding of the PC to GCase is one strategy to accomplishing these ideals. The 
chaperone should bind more tightly at the pH of the ER (~7) than the pH of the lysosome 
(~5). Administration of subinhibitory concentrations of these compounds is thought to be 
sufficient to achieve this goal, but the effective concentration needs to be optimized for 
each compound [319]. Nearly all compounds investigated to date are active-site directed, 
but achieving GCase-selective binding in the presence of other closely-related enzymes is 
an ongoing challenge [320-321]. Another approach to realize selective, pH-dependent 
GCase binders is to identify non-active-site directed binders for GCase, but these efforts 
are in the early stages of development [322-323]. 
 One active-site-directed class of molecules investigated for GCase pharmacologic 
chaperoning activity is the deoxynojirimycins (Fig. 6.1), which have been studied 
extensively in relation to their inhibition of ceramide glucosyl transferase [320], the 
target enzyme of SRT. Some GCase PC activity was noted when 10 M NB-DNJ was 
added to COS-7 cells expressing N370S-mutant GCase [324], but the same effect could 
not be replicated over a range of subinhibitory concentrations in patient-derived 
fibroblasts [325], indicating a weak chaperoning effect, if any. A more promising analog, 
N-(n-nonyl)deoxynojirimycin (NN-DNJ), with a 10-fold lower half maximal inhibitory 
concentration (IC50), exhibited chaperoning capabilities for the non-neuronopathic N370S 
GCase variant, but not the neuronopathic L444P mutant of GCase [325]. Whereas these 
inhibitors were initially assumed to be transition-state-analog-based inhibitors mimicking 
the oxacarbenium-like transition state, it is notable that the crystal structures of GCase 
with either NB- or NN-DNJ bound later revealed that the endocyclic nitrogen mimics the 




toxicity [327] linger and these compounds have not been tested in human clinical trials 
[328].  
 Other candidate GCase PCs such as (cyclic guanidine)-nojirimycin fused hybrids 
[329], bicyclic-NJ analogues [330], iminoxylitos [331], N-substituted δ-lactams [332], 
imino D-glucitols [325, 333], N-octyl--valienamine (NOV) aminocyclitols [334-335], 
the non-sugar Ambroxyl, an FDA-approved drug for an unrelated ailment [307, 336], and 
quinazoline analogues [337], have exhibited only limited promise as clinical candidates 
thus far. One initially promising clinical candidate is isofagomine, an active-site-directed 
[338] and selective [339] iminosugar analog (Fig. 6.1; IFG, Plicera), exhibiting an IC50 in 
the low nanomolar range. Isofagomine exhibited a cellular chaperoning effect for N370S- 
[340] and L444P- [339] mutant GCase, the two most prevalent GD variants. The latter 
variant was not responsive to numerous other chaperones [341], compared to better 
responses to a range of compounds observed for other GCase mutants [158, 333, 341], 
and the effect of IFG on L44P-mutant GCase was modest unless the enzyme was first 
enriched by immunoprecipitation [339]. IFG underwent clinical trials, and although the 
drug was well tolerated, the process was halted after Phase 2 in 2009 due to the lack of 
therapeutic effect [342]. The reason for the lack of effectiveness of this compound in 
patients is not clear at this time; inhibition of the mutant GCase due to high dosing, or 
off-target effects, are two of many possibilities [343].  
 Optimism for the PC approach remains high, but the example of IFG illustrates 
the complexities in design, development, and clinical application of a therapeutic GCase 
pharmacologic chaperone. In spite of a wide body of work detailing the design and 
synthesis of new candidate PCs for mutant GCase, as well as their characterization in 
vitro, in patient derived cell lines, and in some cases in animal models, the characteristics 
that make a PC a good clinical candidate are poorly understood. For example, the pH-
dependent affinity of the candidate PC for GCase, the binding and inhibition kinetics of 




particular conformation of GCase might be required for a clinically effective PC, remain 
open questions.  
 In this study, we synthesized three GCase active-site-directed 3,4,5,6-
tetrahydroxyazepane inhibitors (1-3; Fig. 6.1) that exhibit IC50 values in the low 
millimolar to micromolar range. While the synthesis of polyhydroxylated seven-
membered ring structures has been known for over 40 years [344], exploration of these 
analogs as inhibitors of commercially available glycosidases has only more recently been 
investigated [1, 345-348]. Previous studies have not included human glycosidases like 
GCase, and no analogs previously synthesized contain alkyl ether substructures attached 
to the endocyclic nitrogen like the inhibitors described herein. The crystal structure of the 
core azepane (1) in complex with GCase reveals GCase in its proposed active 
conformation, albeit with nuances not observed previously, whereas the presence of a 
hydroxyethyl tail (2) results in an inactive GCase conformation. Compounds 1-3 
thermally stabilize GCase at pH 7.4 but only 1 increases mutant GCase activity in an 
intact cell assay, the first indication that this scaffold holds promise as a pharmacological 
chaperone. Overall, our results demonstrate that probing the plasticity of the active site of 
GCase offers additional insight into possible molecular determinants that may be 
important factors leading to an effective PC for GD. 
6.2 Results and Discussion 
6.2.1 Inhibitor Design and Synthesis 
 To extend the previously studied 5-membered ring scaffolds and 6-membered 
glucose-derived analog PCs [158, 308, 325, 341], 7-membered 3,4,5,6-
tetrahydroxyazepane iminosugar analogs (1-3; Fig. 6.1) were synthesized as potential 
GCase inhibitors and PCs by procedures slightly modified from those reported in the 




depending on their orientation, protonated iminosugars and azasugars can mimic the 
positive charge of the oxycarbenium-like transition state of glycosidases [350]. However, 
the new design potentially offers several advantages over the earlier scaffolds. First, 
seven-membered rings enable the installation of more functional groups, such as 
hydroxyl substituents, compared to smaller ring systems. This feature could be exploited 
to tune the hydrogen bonding network to select against unwanted inhibition of other 
glucosidases, a known problem [321]. Second, the larger ring structure has several 
options for the positioning of the endocyclic amine, as well as the positioning of the 
anomeric carbon. Finally, instead of the straight alkyl chains used previously, alkyl ether 
tails were installed to assist in discriminating between anomeric carbon configurations 
[351], to reduce the lipophilicity of the candidate PC, to better match the polarity of the 
ceramide component of the substrate to the GCase binding site, and to decrease the 
cytotoxicity found in related compounds [320].  
6.2.2 Inhibition Profiles 
 The inhibitory activities of compounds 1, 2, and 3 toward GCase were determined 
using competition for the widely used fluorogenic substrate 4MU-β-Glc [352]. 
Compound 1 exhibited the strongest competitive inhibition, with an IC50 of 146 μM (Fig. 
6.2A), a value slightly better than the previously characterized iminosugar analogs DNJ 
(IC50= 240 μM) and NB-DNJ (IC50= 270 μM) [353] but 10-fold weaker than NN-DNJ 
[325] and 250-fold weaker than IFG [338]. In contrast, compounds 2 and 3 exhibited 
weaker IC50 values of 3.4 mM and >15 mM, respectively (Fig. 6.2B, C). To address the 
possibility of slow binding kinetics, GCase was preincubated with 2 for 16 h prior to the 
addition of substrate. No change in the IC50 value was observed, suggesting that the on-








































Figure 6.2. Competitive inhibition curves for 1, 2, and 3, respectively, toward 








6.2.3 Stability Profiles 
 The GCase stability change upon inhibitor binding to GCase was measured by 
differential scanning fluorimetry (DSF), which uses Sypro Orange as a reporter for. We 
chose the facile DSF method because GCase unfolding is not reversible when measured 
by differential scanning calorimetry (DSC), which precludes detailed thermodynamic 
insight [354-355], and DSF entails very low sample volume and GCase concentration. 
Melting temperatures (Tms) recorded for GCase using DSF are within ~3 °C of those 
reported by DSC using similar concentrations of enzyme and inhibitor, but with slightly 
different buffers. All three inhibitors stabilize GCase at neutral pH with a ΔTm of + 6-7.5 
°C when added at mM concentrations (Table 6.1). At acidic pH, the inhibitors increased 
the Tm by only 1-3 °C, suggesting a lower affinity for GCase at pH 5.2. Thus, in terms of 
thermal stabilization, all three compounds are comparable over this concentration range, 
but binding confers more stability to GCase at a neutral pH (reflective of the pH in the 
ER) than at the lower lysosomal pH. We note that 1 increases the Tm of GCase slightly 
more than 2 and 3 at the highest concentrations, but it is a much better inhibitor of GCase 
than 2 and 3 (see above). Thus, it appears that inhibition at 37 °C and native state 
stabilization at higher temperatures are only partially correlated.  
6.2.4 Structural Characterization  
 Next, we sought to investigate the structural changes that accompany binding of 
1, 2, and 3 to GCase. We used a new vapor diffusion crystallization condition that 
requires a lower concentration of salt compared to most other conditions previously 
reported. We reasoned that the presence of PEG in the crystallization solution should 
enhance solubility of more hydrophobic compounds compared to molar concentrations of 
sulfate or phosphate salts. Interestingly, the lattice dimensions and space group remain 
the same. We obtained crystals with compounds 1 or 2 bound to GCase by soaking 
























 mean Tm measured for GCase at indicated pH value in the absence of inhibitor.
  1 2 3 IFG 
 Inhibitor (mM) Tm (°C) ΔTm (°C) Tm (°C) ΔTm (°C) Tm (°C) ΔTm (°C) Tm (°C) ΔTm (°C) 
pH 5.2  55.8 ± 0.0
* 
       
 0.5 56.4 ± 0.0 0.6 55.9 ± 0.1 0.3 56.1 ± 0.0 0.3 68.0 ± 0.2 12.2 
 1 56.6 ± 0.0 0.8 56.0 ± 0.0 0.3 56.1 ± 0.1 0.2 68.9 ± 0.3 13.0 
 2 57.3 ± 0.1 1.5 56.7 ± 0.1 1.0 56.7 ± 0.1 0.8 69.7 ± 0.3 13.8 
 5 58.4 ± 0.1 2.7 57.4 ± 0.1 1.7 57.2 ± 0.1 1.3 67.5 ± 0.3 11.6 
 10 59.0 ± 0.1 3.2 57.4 ± 0.0 1.7 56.9 ± 0.0 1.0 63.7 ± 0.2 7.8 
pH 7.2  47.1 ± 0.2
* 
       
 0.5 48.5 ± 0.1 1.4 48.7 ± 0.1 1.7 50.7 ± 0.0 2.1 63.8 ± 0.3 16.9 
 1 49.4 ± 0.1 2.3 49.3 ± 0.0 2.2 52.0 ± 0.1 3.3 65.4 ± 0.1 18.4 
 2 49.9 ± 0.1 2.8 50.1 ± 0.1 3.1 52.6 ± 0.1 3.9 67.2 ± 0.2 20.2 
 5 52.5 ± 0.1 5.4 52.1 ± 0.1 5.0 53.6 ± 0.1 5.0 70.3 ± 0.2 23.4 







Table 6.2. Data collection and refinement statistics. 
a
Data for the highest-resolution shell given in parenthesis; 5% or reflections were 
selected for Rfree. 
 
  
 3RIL (1) 3RIK (2) 
Data Statistics   
space group P2(1) P2(1) 
Cell dimensions   
  a, b, c (Å) 109.2, 91.4, 152.7 108.0, 91.6, 152.2 
 , , γ (deg) 90.0, 110.95, 90.0 90.0, 110.70, 90.0 
Resolution (Å)
a
 44.5-2.4 (2.49-2.40) 46.5-2.5 (2.55-2.48) 
   
Rsym
a
 10.5 (35.7) 12.2 (47.8) 
%>3σ
a
 62.9 (38.3) 64.6 (40.7) 
Completeness (%)
a
 96.3 (76.5) 94.3 (72.3) 
redundancy 2.6 2.9 
   
Refinement Statistics   
resolution (Å) 44.5-2.4 47-2.5 
no. of reflections 100648 (5857) 88126 (4973) 
Rwork/Rfree
a
 20.9/24.9 18.1/23.4 
no. of molecules   
  protein residues 1988 1988 
  N-acetylglucosamine (NAG) 4 4 
  sulfate anion (SO4
2-
) 7 7 
  chaperone 4 2 
  water 1254 702 
B-factor   
  protein 23.6 26.6 
  NAG 29.7 50.4 
  SO4
2-
 60.8 38.1 
  chaperone 38.2 32.9 
  water 27.6 40.0 
rmsd   
  bond lengths (Å) 0.006 0.013 




crystal structure of 3, also the weakest inhibitor, bound to GCase. Crystal structures were 
solved to 2.4 and 2.5 Å resolution (Table 6.2). The global structure of GCase does not 
change upon inhibitor binding, but adjustments are seen in the active site and surrounding 
loop residues, detailed below. 
 Both 1 and 2 bind in the GCase active site and are held in place by an extensive 
hydrogen bonding network (Fig. 6.3A, B). Notably, 1 is found in all four monomers of 
GCase in the asymmetric unit, compared to 2, which is bound in the typical manner, in 
two of the four molecules. This result with 1 is surprising given that there is a 7-
membered ring bound in a sugar pocket, and suggests that binding of 1 causes minimal 
distortion of the nearby loops that are involved in crystal packing. In the case of 2, the 
hydroxyl substituents at positions 3, 4 and 5 (see Fig. 6.1) are within hydrogen bonding 
distance of Asp 127, Trp 179, Asn 234, Glu 340, and Trp 381 side chains on GCase 
whereas the 6-hydroxyl moiety is not involved. The endocyclic nitrogen and 
hydroxyethyl tail are also within hydrogen bonding distance with Glu 340, the catalytic 
nucleophile [356] (Fig. 6.3B). Similar interactions stabilize the hydroxyl groups of 1 in 
the GCase active site, but with the additional interaction of the 6-hydroxyl group with 
Tyr 313 (Fig. 6.3A). Notably, no hydrogen bonding interactions were observed for either 
compound with Glu 235, which, being the residue implicated as the general acid/base in 
catalysis [316, 357], is probably protonated in the resting state of the enzyme [358]. In 
the IFG-bound GCase structure (PDB code 2NSX, Fig. 6.3C), Glu 235 stabilizes the 
imino group of IFG, suggesting that Glu 235 may be deprotonated.  However, an 
analogous shift of 1 or 2 to mimic the orientation of IFG is not compatible with the 
observed electron density. This configuration may not be preferred because the 
hydroxymethyl substituent on IFG, which interacts with Asn 396 and locks IFG into 
position, has been replaced with a shorter hydroxyl moiety in 1 and 2.  
 The binding orientations of 1 and 2 are more similar to those found in NB-DNJ- 






Figure 6.3. Ball-and-stick representation of the GCase active site upon compound 
binding. A) 1 B) 2 C) IFG (PDB code 2NSX) D) NN-DNJ (PDB code 2V3E). Difference 
(Fo-Fc) electron density for 1 and 2 was calculated from the initial phasing solution using 
only protein coordinates and is contoured to 3σ. Hydrogen bonding interactions are 






Figure 6.4. Superposition of 1 and 2 bound GCase structures and comparison of 
loops adjacent to the active site (inset). After binding, Loop 1 adopts either a helical 
turn as seen for compound 1 (yellow) and IFG (green), or an extended loop conformation 
seen in the compound 2 (orange) and glycerol (blue) bound structures. Changes in Loop 2 





there are differences in interactions with GCase. One commonality is that in all four 
structures, Glu 235 is not involved in stabilizing 1 or 2 in the active site. Another share 
feature is that the position of the endocyclic nitrogens of 1, 2, NB- and NN-DNJ overlay 
well. However, the endocyclic nitrogens of NB- and NN- DNJ are held in place by a 
water-mediated hydrogen bond to the hydyroxyl group of Tyr 244. By comparison, for 2, 
the endocyclic nitrogen is within hydrogen bonding distance of Glu 340 (Fig. 6.3B) 
whereas for 1, the endocyclic nitrogen is not held by either water-mediated or direct 
interactions with any active site residues (Fig. 6.3A). Inspection of the Fo-Fc difference 
electron density in this region reveals that several pucker conformations for this location 
on the azepane ring of 1 are plausible. Lastly, like IFG (see above), NB- and NN-DNJ are 
also held in place by Asn 396, an interaction missing in 1 and 2 (compare Fig. 6.3A and 
B to Fig. 6.3C and D). 
 Notable differences in structure are observed in the active site loops (Loop 1: 
residues 311-319 and Loop 2: residues 342-354, Fig. 6.4) when comparing the binding 
modes of 1 (yellow) and 2 (orange) to each other and to previously reported GCase 
structures (green and blue). Loop 2 (residues 342-354) is shifted 3.2 Å from its position 
in the IFG or glycerol (PDB code 2NT0) bound GCase structures (Fig. 6.5). Movements 
in this loop have previously been implicated in crystal contacts, a conclusion supported 
by our observation that the same orientation of Loop 2 is seen in apo GCase crystallized 
under the conditions used here for azepane inhibitor soaking (data not shown), and thus is 
not a function of inhibitor binding.  More important changes are observed in the well-
defined conformation of Loop 1 (residues 311-319), which is in an extended 
conformation that covers the catalytic center when compound 2 binds, and is in an -
helical arrangement (Fig. 6.4, Fig. 6.6) that exposes the active site when 1 is bound. The 
extended Loop 1 has been observed when sulfate (PDB code 1OGS) [357], glycerol 
(PDB code 2NT0) [338], or the suicide inhibitor conduritol--epoxide (CBE, PDB code 





















Figure 6.5. Comparison of Loop 2 orientation for 1- (yellow), 2- (orange), IFG- 
(green), and glycerol- (light blue) bound GCase.  
 
 
Figure 6.6. The final GCase Loop 1 model for 1 (left) and 2 (right) with 2Fo-Fc 





catalytically compromised N370S mutant GCase structure at either neutral or acidic pH 
(PDB codes 3KE0 and 3KEH) [355]. By contrast, the helical conformation of Loop 1 has 
been proposed to be the catalytically active form of GCase [338] and to date, has been 
observed only when a small molecule with chaperoning capabilities, namely NB-DNJ, 
NN-DNJ, or IFG, is bound to the GCase active site.  
 Although GCase adopts conformations that are related to those observed 
previously when bound to 1 and 2, each is unique. Tyr 313 plays an important role in 
Loop 1 conformations. In crystal structures with an extended Loop 1 conformation, Tyr 
313 is observed within hydrogen bonding distance to Glu 235, whereas when Loop 1 is 
helical, such as when IFG is bound (Fig. 6.7A), it interacts with Glu 340.  As with IFG, 
when 1 binds to GCase, the helical Loop 1 is observed, with the same Glu 340 - Tyr 313 
interaction (Fig. 6.7B). By contrast, when 2 binds in the GCase active site, neither of the 
two previously observed Loop 1 conformations is observed. Compound 2 interacts with 
Glu 340 via its hydroxyethyl substituent instead of Tyr 313 (Fig. 6.7C), which results in a 
new interaction between Tyr 313 and Asn 396 mediated by water (Fig. 6.3B) that caps 
the active site entrance. The extended Loop 1 seen with 2 (Fig. 6.7C, bottom panel) is 
otherwise similar to extended loop conformations observed previously, with minor 
alterations in the side chain orientation. We surmise that 3 does not bind well to GCase 
because the extra hydroxyethyl substituent of its tail is involved in steric clashes, or 
makes the compound too polar, which may account for our inability to obtain a bound 
crystal structure.  
 In addition to the particular configuration of the Tyr 313 side chain in the catalytic 
center, the helical turn in Loop 1 is stabilized by a network of water-mediated hydrogen 
bonds between residues on an interior helix of GCase (Fig 6.7, bottom panels). For the 
NB-DNJ, NN-DNJ, and IFG structures (see IFG: Fig. 6.6A, bottom panel), Asp 315 in 
Loop 1 is stabilized by electrostatic interactions with the guanidinium of Arg 285 





Figure 6.7. Comparison of Loop 1 configuration. A) IFG-, B) 1-, and C) 2- bound 
GCase.  Top: orientation of Tyr 313 relative to Glu 340. Bottom: interactions of loop 
with interior GCase helix harboring Asn 370. Hydrogen bonding interactions are 





molecule, while the side chain of Trp 312 interacts with the carbonyl backbone of Cys 
342, located on Loop 2. Unexpectedly, when 1 is bound, the side chain of Trp 312 is 
repositioned to form a new interaction with Ser 366 instead of Cys 342 (Fig. 6.7B, 
bottom panel). This change releases Asp 315 from the location seen in the other 
chaperone-bound structures, resulting in a more relaxed helix in Loop 1 and weaker 
electrostatic interaction with Arg 285.  
6.2.5 Enhancement of Cellular Enzyme Activity 
 To evaluate the potential of 1, 2, and 3 for PC development, namely, their abilities 
to enhance mutant GCase activity in cells, were examined next. Patient-derived 
fibroblasts harboring either mutant G202R GCase (associated with the neuronopathic 
Type 2 GD) or mutant N370S/V394L GCase (associated with the non-neuronopathic 
Type 1 GD) were incubated with compounds 1, 2, or 3 for three days at varying 
concentrations. The upper limit tested was 100 μM due to cytotoxicity concerns. 
Compound 1 increased the cellular GCase activity of G202R fibroblasts by 20% at 100 
μM, whereas 2 and 3 had no effect on activity in the concentration range tested (Fig. 
6.8A). A similar but attenuated result was obtained for N370S/V394L GCase fibroblasts. 
A ~15% increase in activity was observed for cells treated with 10 mM of 1 (Fig. 6.8B), a 
lower concentration than was required for a similar effect with G202R and comparable to 
the optimal concentration observed for NN-DNJ [325]. The maximal 20% activity 
enhancement for G202R GCase is intermediate between the lack of activity enhancement 
seen for NB-DNJ and the 60-65% enhancement seen for NN-DNJ using the same enzyme 
variant and experimental setup [325]. The modest enhancement of the cellular activity of 
mutant GCase seen with the tetrahydroxyazepane core suggests that future optimization 





Figure 6.8. Effects of 1, 2, and 3 on mutant GCase activity in intact patient derived 
fibroblasts G202R. A) and N370S/V394L B). Enzyme activity is normalized to 
untreated and assigned a relative activity of 1.  The right-hand axis is the residual activity 
of the mutant expressed as the percentage of WT GCase activity.  Mean values for 





6.3 Conclusions and Future Outlook 
 In this study, we extended our set of potential pharmacological chaperone 
scaffolds for GCase to include hydroxy alkyl and alkyl ether azepanes 1-3. The active site 
of GCase readily accommodates the larger 7-membered azepane ring, but the enzyme is 
exquisitely sensitive to binding and can propagate changes as far as ~ 13 Å away. The 
three compounds synthesized thermally stabilize GCase to approximately the same extent 
both at neutral and acidic pH. Only the tetrahydroxyl-substituted azepane, 1, which 
exhibits a ~10x better competitive inhibition profile compared to 2 and 3, enhances 
enzyme activity in fibroblasts expressing G202R- and N370S-mutant GCase. Combined 
with the crystal structures, the enhanced cellular enzyme activity of 1 correlates with the 
helical conformation in Loop 1 of GCase, whereas the corresponding extended 
conformation found with 2 bound does not. Therefore, 1, the core azepane structure, 
qualifies as a lead as a potential PC. Based on our study and in line with our previous 
observations, it appears that competitive inhibition of the fluorogenic substrate in the 10-
20 mM range is a lower limit for observing PC activity in cells, although cellular 
penetration and organelle distribution clearly also contribute.  
 Comparison of the crystal structures of 1 and 2 bound to GCase reveals that the 
cores of these two compounds are bound in a distinct fashion in the active site. First, 
whereas all four hydroxyl substituents of 1 are stabilized by hydrogen bonding 
interactions with active site residues, with 2 bound, one interaction is lost. Second, in 
terms of the endocyclic nitrogen, there is no stabilizing interaction for 1, whereas that in 
2 is held in place by Glu 340, a residue that also interacts with the hydroxyethyl 




configurations for 1 or 2, either helical, or extended, respectively, with nuances not 
previously observed in GCase structures. Presumably, other exocyclic substituents that 
can form favorable interactions with Glu 340 would likewise not prove to be effective 
chaperones. One method to improve the PC activity of 1 and/or convert 2 or 3 into a PC 
would be to replace the 6-hydroxyl with a hydroxymethyl or another subsituent that could 
compete favorably for stabilization by Asn 396. This approach could also prevent the 
ether-linked substructure from unintended interactions with catalytic residues, and 
subsequently enable direct evaluation of the effectiveness of the exocyclic substituents of 
2 and 3 on their PC activity. The opening of the hydrophobic binding pocket is 
energetically demanding, but can be compensated by the favorable entropy increase due 
to water desolvation [350]; considerations for optimizing exocyclic substituent binding 
include tuning both lipophilicity and chain length.  
 Finally, even though 2 generates a GCase conformation thought to be inactive, 1 
is a significantly better active-site-directed, competitive inhibitor in vitro. Competitive 
inhibition of GCase and the kinetics of such inhibition toward the hydrolysis of closely 
related natural substrates glucosylceramide and glucosylsphingosine in the context of the 
cell [360] may differ somewhat from that of a model substrate in vivo, but a link is 
emerging among the ability of a molecule to competitively inhibit GCase in vitro, 
nuances regarding the resulting conformation of Loop 1 that exposes the GCase active 
site, and its ability to increase mutant GCase activity in cell culture. Thermal 
stabilization, while typically a feature of a competitive inhibitor, is not a singular good 
predictor of cellular PC activity. We anticipate that GCase structures, in combination 




connection between GCase loop structure and enhancement of cellular mutant enzyme 
activity. A better comprehension of these basic molecular determinants of PCs will 
ultimately lead to the identification of compounds worthy of detailed cellular trafficking 
and animal model studies, and eventually to a successful outcome of clinical trials of a 
therapeutic PC for GD. 
6.4 Methods 
6.4.1 Chemical Synthesis of Compounds 1, 2, and 3 
6.4.1.1 (1R,1'R)-1,1'-((4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(ethane-1,2-diol) 
(S-1)  
 2,2‟-Dimethoxypropane (300 mL) was charged to a 1 L round bottom flask. D-
Mannitol (20 g, 0.11 mol) and pyridinium p-toluenesulfonate (1 mol%, 0.27 g, 2.0 mmol) 
were added, and the resultant suspension was stirred at reflux. After 18 hours, the 
solution was allowed to cool to room temperature and concentrated under reduced 
pressure. The residue was dissolved in ethyl acetate (300 mL) and washed with water (2 x 
100 mL) and brine (100 mL). The organic layer was taken, dried over MgSO4, filtered 
and evaporated under reduced pressure. The resultant white solid was charged to a 1 L 
round bottom flask. Acetic acid (210 mL) and water (90 mL) were added and the 
suspension was stirred at 40 ˚C. After 2 hours, the mixture was concentrated under 
reduced pressure. The residue was suspended in acetone (100 mL) and stirred at room 
temperature. After 1 hour, the mixture was filtered and the filtrate was concentrated 
under reduced pressure to yield S-1 as a white solid (17.1g, 70 %). 
1
H NMR (300 MHz, 






Scheme 6.1. Synthesis of Di-epoxide S-3 
 
Scheme 6.2. Synthesis of Tetrahydroxyazepane 1 
 





LCMS m/z 245.2 [M + Na]
+
, calculated for C9H18NaO6
+
 245.1. Data are consistent with 
literature [361].  
6.4.1.2 (1R,1'R)-((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(2-((tert-
butyldimethylsilyl)oxy)ethane -1,1-diyl) bis(4-methylbenzenesulfonate) (S-2) 
 S-1 (7.5 g, 33.8 mmol) was charged to a 500 mL round bottom flask under a 
nitrogen atmosphere. Anhydrous DMF (200 mL), imidazole (7.0 g, 100 mmol) and 
DMAP (0.16 g, 1.3 mmol) were added and the reaction was stirred at 0 ˚C. After 10 
minutes, TBSCl (10.1 g, 68.0 mmol) was added portionwise and the solution was allowed 
to warm to room temperature. After 18 hours, the reaction mixture was diluted with 
ether/hexane (1:1, 500 mL), washed with water (3 x 100 mL), dried over MgSO4 and 
concentrated under reduce pressure. Purification by flash column chromatography (silica, 
9:1 hexane/ethyl acetate) afforded a colorless oil (8.0 g, 52 %). A sample (6.82 g, 15.15 
mmol) was charged to a 500 mL round bottom flask. Anhydrous DCM (200 mL), DMAP 
(7.39 g, 60.5 mmol) and tosyl chloride were added and the mixture was stirred at room 
temperature. After 18 hours, the reaction was diluted with ethyl acetate (200 mL), washed 
with water (100 mL), aq. HCl (1 M, 100 mL), sat. aq. NaHCO3 (100 mL) and brine (100 
mL). The organic layer was taken dried over MgSO4, filtered and concentrated under 
reduced pressure to afford S-2 (10.0 g, 87 %) as a white solid. 
1
H NMR (300 MHz, 
CDCl3)  ppm 7.81 (d, J = 8.4 Hz, 4H), 7.29 (d, J = 8.4 Hz, 4H), 4.68-4.72 (m, 2H), 4.36-
4.40 (m, 2H), 3.83 (dd, J = 11.6, 4.6 Hz, 2H) 3.74 (dd, J = 11.6, 5.1 Hz, 2H), 2.43 (s, 
6H), 1.14 (s, 6H), 0.83 (s, 18H), 0.1 (s, 12 H); LCMS m/z 781.4 [M + Na]
+








6.4.1.3 (4R,5R)-2,2-dimethyl-4,5-di((S)-oxiran-2-yl)-1,3-dioxolane (S-3)  
 S-2 (10.0 g, 13.2 mmol) was charged to a 500 mL round bottom flask. THF (250 
mL) and TBAF (1M in THF, 29.0 mL, 29.0 mmol) were added and the mixture was 
stirred at room temperature. After 2 hours, the reaction was concentrated under reduced 
pressure and the residues dissolved in ether (100 mL) and washed with sat. aq. MgSO4 (3 
x 100 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was dissolved in anhydrous THF (120 mL), sealed under a nitrogen atmosphere 
and cooled 0 ˚C. Sodium hydride (60 % dispersion in mineral oil, 2.11 g, 52.7 mmol) was 
added portionwise. After 1 hour, the reaction was quenched with ice water (50 mL), and 
extracted with ether (3 x 20 mL). The organic layers were combined, dried over MgSO4, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography (silica, 8:2 hexane/ethyl acetate) afforded S-3 (1.5 g, 60 %) as a white 
solid. 
1
H NMR (300 MHz, CDCl3)  ppm 3.86 (dd, J = 3.2, 1.6 Hz, 2H), 3.04-3.10 (m, 
2H), 2.85 (dd, J = 5.2, 4.1 Hz, 2H), 2.74 (2H, J = 5.2, 2.6 Hz, 2H), 1.41 (s, 6H); LCMS 
m/z 209.0 [M + Na]
+
, calculated for C9H14NaO4
+
 209.0. Data are consistent with 
literature [349]. 
6.4.1.4 (3S,4R,5R,6S)-3,4,5,6-tetrahydroxyazepan-1-ium chloride (1)  
 S-3 (120 mg, 0.64 mmol) was charged to a 5 mL round bottom flask. Water (2 
mL) and benzylamine (freshly distilled, 69 mg, 70 µL, 0.64 mmol) were added and the 
mixture stirred at 95 ˚C. After 2 hours, the reaction was cooled to room temperature and 
concentrated under reduced pressure. Purification by flash chromatography (silica, 1:1 
ethyl acetate/hexane) yielded a white solid which was charged to a 10 mL round bottom 




mg, 1.9 mmol) were added and the mixture stirred at 70 ˚C. After 2 hours, the reaction 
was cooled to room temperature and 1-heptene (1.86 g, 2.66 mL, 19.0 mmol) was 
charged to the vessel. After stirring at room temperature for 1 hour, the reaction was 
filtered through celite, and evaporated under reduced pressure. The residue was dissolved 
in methanol (5 mL) and methanolic HCl (1 M, 5 mL, 5 mmol) was added. The mixture 
was stirred at room temperature. After 1 hour, the reaction was evaporated under reduced 
pressure to yield 1 as a gummy colorless solid (100 mg, 76 % from S-3). 
1
H NMR (300 
MHz, D2O)  ppm 4.06-4.18 (m, 2H), 3.69-3.76 (m, 2H), 3.34-3.44 (m, 2H), 3.18-3.30 
(m, 2H); LCMS m/z 164.3 [M + H]
+
, calculated for C6H14NO4
+




6.4.1.5 (3S,4R,5R,6S)-3,4,5,6-tetrahydroxy-1-(2-hydroxyethyl)azepan-1-ium chloride (2)  
 S-3 (120 mg, 0.64 mmol) was charged to a 5 mL round bottom flask. Water (2 
mL) and ethanolamine (39 mg, 39 µL, 0.64 mmol) were added, and the mixture was 
stirred at 95 ˚C. After 2 hours, the reaction was cooled to room temperature and 
concentrated under reduced pressure. The residue was dissolved in methanol (5 mL) and 
methanolic HCl (1 M, 5 mL, 5 mmol) was added, and the mixture stirred at room 
temperature. After 1 hour, the reaction was evaporated under reduced pressure to yield 2 
as a gummy yellow solid (144 mg, 93 %). 
1
H NMR (300 MHz, D2O)  ppm 4.07-4.24 
(m, 2H), 3.87-4.01 (m, 2H), 3.61-3.77 (m, 4H), 3.44-3.58 (m, 4H); LCMS m/z 208.2 [M 
+ H]
+








chloride (3)  
 S-3 (120 mg, 0.64 mmol) was charged to a 5 mL round bottom flask. Water (2 
mL) and 2-(2-aminoethoxy)ethanol (67 mg, 64 µL, 0.64 mmol) were added and the 
mixture was stirred at 95 ˚C. After 2 hours, the reaction was cooled to room temperature 
and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL) 
and methanolic HCl (1 M, 5 mL, 5 mmol) was added, and the mixture stirred at room 
temperature. After 1 hour, the reaction was concentrated under reduced pressure to yield 
3 as a gummy yellow solid (174 mg, 95 %). 
1
H NMR (300 MHz, D2O)  ppm 4.10-4.23 
(m, 2H), 3.92-3.99 (m, 2H), 3.61-3.80 (m, 4H), 3.34-3.57 (m, 8H); LCMS m/z 208.1 [M 
+ H]
+
, calculated for C8H18NO4
+
 208.1. 
6.4.2 In Vitro GCase Inhibition Assay 
 Approximately 15 ng of Cerezyme® (Genzyme corp.) was mixed with McIlvaine 
buffer (0.1 M citrate, 0.2 M phosphate, pH 5.4), 0.1% Triton X-100, 0.25% taurochloric 
acid, and various concentrations of compound (1, 2, or 3) on ice. A stock of 300 mM 4-
methylumbelliferyl-β-glucopyranoside (4MU--Glc, Sigma) was freshly prepared in 
dimethylsulfoxide (DMSO), and added to the Cerezyme/inhibitor mixture at a final 
concentration of 3 mM. The reaction was then transferred into a microplate (Grenier), 
sealed, and incubated at 37 °C for 30 minutes. An equal volume of 0.4 M glycine and 0.4 
M NaOH was added to each well to quench the reaction. The release of 4-
methylumbelliferone (4MU) was measured by fluorescence (excitation 355 nm, emission 
460 nm) on a BioTek microplate reader. Each reaction was set up in triplicate per plate, 




and the averaged, normalized data was plotted against drug concentration and fitted to a 
log(inhibitor) vs response-variable slope curve in GraphPad Prism to estimate the IC50. 
To investigate the effect of incubation time of premixed inhibitor and enzyme, the 
Cerezyme/2 mixture was incubated at 4 °C for 16 hours. 4MU--Glc was then added and 
the assay carried out as described above. An inhibition assay with IFG (Toronto Research 
Chemicals) was also carried out as a positive control with a result similar to that 
previously published [338].   
6.4.3 Thermal Stability Assay for GCase 
Cerezyme was resuspended in 0.1 M citrate, 0.2 M phosphate, adjusted either to pH 5.2 
or pH 7.2, and protein concentration was determined via Bradford assay [362]. A 
working stock of 10 μM Cerezyme was prepared by diluting in the appropriate buffer. 
Reactions of 30 μL were prepared at room temperature by diluting Cerezyme in water 
(1:10) along with various concentrations of inhibitor (0-10 mM), also prepared in water. 
This resulted in a final buffer concentration of 0.01 M citrate, 0.02 M phosphate, either at 
pH 5.2 or 7.2, and 1 μM protein. Finally, Sypro Orange (Invitrogen, supplied as 5000X 
solution in DMSO) was diluted in water and then added to each reaction with a final 
concentration of 5X. Each reaction was delivered to 96-well optical plates (Applied 
Biosystems) before sealing with optical film. Fluorescence data were acquired on an 
Applied Biosciences Step-One Plus RT-PCR instrument equipped with a fixed excitation 
wavelength (480 nm) and a ROX emission filter (610 nm). Melts were conducted from 
25–95 °C with a 1 °C per min increase. Collected data were baseline subtracted, trimmed 
to include both the boundaries and the transition of interest, and subjected to Boltzmann 




6.4.4 Intact Cell GCase Activity Assay 
 Primary skin fibroblast culture was established from Gaucher patients 
homozygous for the G202R GC (c.721G>A) mutation. The heterozygous Gaucher 
fibroblasts containing the N370S/V394L GC mutation (GM01607) were obtained from 
the Coriell Cell Repositories (Camden, NJ). Fibroblasts were grown in minimal essential 
medium with Earle‟s salts (supplemented with 10 % heat-inactivated fetal bovine serum 
and 1 % glutamine Pen-Strep at 37 °C in 5 % CO2). Cell culture media were obtained 
from Gibco (Grand Island, NY). 
 The intact cell assay was performed as described previously [325]. Briefly, cells 
were plated into 96-well plates (100 μL per well). After cell attachment, the media was 
replaced with fresh media containing small molecules and incubated at 37 °C for 3 days. 
The media was removed and cell monolayers washed with Dulbecco‟s phosphate 
buffered saline. The assay was started by the addition of 50 μl of 2.5 mM 4MU--Glc in 
0.2 M acetate buffer (pH 4.0) to each well, followed by incubation at 37 °C for 1-4 hours. 
The extent of unspecific non-lysosomal GC activity was evaluated by adding CBE 
(Toronto Research Chemicals) to control wells. The reaction was stopped by the addition 
of 150 μL of 0.2 M glycine buffer (pH 10.8). Liberated 4MU was measured (excitation 
365 nm, emission 445 nm) with a Molecular Devices SpectraMax Gemini fluorescence 
plate reader. Small molecules were assayed at least in triplicate at each concentration, and 
on three different days. Cells appeared intact when viewed under a light microscope. The 
data reported were normalized to the enzyme activity of cells of the same type treated 





6.4.5 Crystallization, Data Collection, Structure Determination and Refinement 
 Cerezyme was partially deglycosylated with N-glycosidase F (Promega) as 
described previously [357] and concentrated to 3 mg/mL in 0.02% sodium azide, 10 mM 
citrate buffer, pH 5.5, 7% (v/v) ethanol. Crystals of GCase were grown by vapor 
diffusion at room temperature using a cocktail composed of 11-12% PEG 3350, 0.18-
0.205 M ammonium sulfate, and 0.1 M acetate buffer, pH 4.6. Crystals with 1 and 2 were 
acquired by soaking crystals in the reservoir solution with 1 mM inhibitor for 5 minutes 
or 5 days, respectively. Crystals were cryoprotected with 20% ethylene glycol, 
cryocooled in liquid N2. Data were collected at the Southeast Regional Collaborative 
Access Team (SER-CAT) Beamline 22-BM-C at the Advanced Photon Source at 
Argonne National Labs (Darien, IL). Data sets were indexed and scaled using the 
HKL2000 [218]. The structures were solved by rigid body refinement to 4 Å resolution in 
REFMAC5 [364] utilizing the IFG-bound protein structure as the initial model (PDB 
code 2NSX) after all waters, ligands, and N-acetyl-glucosamines were removed. Each of 
the four monomers in the asymmetric unit of 2NSX was defined as a rigid body. This 
procedure was followed by restrained refinement against the highest resolution of the 
data with REFMAC5 [364] and model rebuilding with Coot [365]. Models for 1 and 2 
were generated using PRODRG [366] and figures generated using PyMOL [367]. For 
both structures, 99% of the residues lie in most favored and additionally allowed regions 









EXPRESSION AND PURIFICATION OF THE LUMINAL DOMAIN 
OF LIMP-2 
A.1 Introduction 
 Lysosomal storage disorders are „loss of function‟ disorders, due to deficient 
lysosomal glycolipid hydrolase activity [368]. Gaucher disease (GD), the most common 
lysosomal storage disorder, is caused by inherited point mutations in acid--glucosidase 
(GCase), the enzyme that hydrolyzes glucosylceramide (GlcCer) in the lysosome. These 
point mutations result in GCase degradation in the endoplamic reticulum (ER) by ER 
associated degradation instead of trafficking to the lysosome. This results in an 
accumulation of GlcCer in the lysosome and leads to the many symptoms of Gaucher 
disease including hepatomegaly, splenomegally, anemia, weakened skeleton, and in 
severe cases, central nervous system (CNS) complications [369].  
 As part of our long-term drug discovery efforts, we are working to understand the 
molecular details of GCase as it is trafficked to the lysosome. Although most lysosomal 
proteins are synthesized in the ER and are selectively transported via the Golgi complex 
to the lysosome by the mannose-6-phosphate receptor (MPR) pathway, GCase does not 
[370-371]. Until 2007, the trafficking mechanism of GCase remained unclear when the 
477 residue lysosomal integral membrane protein 2 (LIMP-2), of no known definitive 
function [372], was shown to be a trafficking partner of GCase. The LIMP-2/GCase 
complex was identified by affinity chromatography, and the role of LIMP-2 as a sorting 
receptor for GCase was verified by immunoprecipitation and fluorescence studies in 
vitro. GCase activity, level, and localization correlated with the presence or absence of 
LIMP-2. In vivo studies involving LIMP-2 knockout mice, revealed 50% or less wild 




luminal domain of LIMP-2, specifically a coiled-coiled motif, and disruption of this 
domain eliminated the interaction. Complex formation is pH dependent, with association 
occurring at the neutral pH similar to that in the ER, and dissociation occurring at acidic 
pH corresponding to that of the lysosome. This is the first time that a lysosomal 
membrane protein has been shown to be a trafficking receptor. Not only is this complex a 
novel pathway for protein sorting, but over expression of LIMP-2 has been shown to 
enhance trafficking of mutant GCase [373].  The aim of the project originally was to 
characterize the LIMP-2/GCase complex utilizing biophysical methods and identify 
compounds that stabilize this interaction. Unfortunately, purification of a stable construct 
in sufficient quantities for biophysical studies was unattainable and the project was 
abandoned. 
A.2 Methods and Discussion 
A.2.1 LIMP-2/ pET-30 (-32) Xa/LIC Constructs  
 LIMP-2 is a 477 residue lysosomal membrane protein that is composed of a 400 
residue luminal domain, two transmembrane domains, and a 20 amino acid cytoplasmic 
domain [373]. As membrane-bound proteins are notoriously difficult to purify and 
analyze by typical biophysical methods, we chose to express only the soluble luminal 
domain of LIMP-2 (L2LD). We initially annealed L2LD into the pET-30 Xa/LIC vector 
which provided a poly-histidine affinity tag for subsequent purifications and a Factor Xa 
cleavage site for removal of this tag. In an effort to yield a more soluble construct, L2LD 
was also annealed into the pET-32 Xa/LIC vector which contains the same affinity tag, 
but also encodes for a thioredoxin fusion protein for better folding. As detailed below, 
other vectors, including those for periplasmic expression and N-terminal MBP tag, were 





A.2.1.1 Molecular Biology 
 L2LD was first amplified (5-PRIME Master Mix, Fisher Scientific) from a 
plasmid containing the gene purchased from Origene and annealed into the pET-30 
Xa/LIC (L2LD30; Novagen) or pET-32 Xa/LIC vector (L2LD32; Novagen). The pET-30 
Xa/LIC vector encodes for the following features: N-terminal hexa-histidine and S-tags, a 
Factor Xa cleavage site, and a C-terminal hexa-histidine tag. The pET-32 Xa/LIC vector 
encodes for the same features as pET-30 Xa/LIC with the addition of a thioredoxin fusion 
protein encoded at the N-terminus. Both constructs eliminated the C-terminal histidine 
tag. After plasmid replication in NovaBlue Giga Singles E. coli (Novagen), the entire 
coding region was verified by DNA sequencing (MWG Operon) and compared to the 
sequence deposited in the NCBI repository. 
A.2.1.2 Protein Expression and Purification 
 Since LIMP-2 is a human protein possessing five cysteine residues in the luminal 
domain, expression trials of both L2LD plasmids were conducted in a bacterial strain that 
corrects for rare codons and favors disulfide bond formation, specifically Rosetta-Gami 
2(DE3)pLysS (Novagen). When protein expression, induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG, 0.1-1 mM), was carried out at 37 °C, inclusion bodies were 
formed. However, when cultures were induced overnight at 17 °C with the same 
concentrations of IPTG, L2LD30 was expressed in the soluble E. coli fraction. Liter 
cultures were grown to an OD600= 0.6, induced with 0.1 mM IPTG, and incubated for 15 
hours at 17 °C while shaking. The cells were harvested by centrifugation, resuspended in 
lysis buffer (50 mM Hepes, 0.2 M NaCl, 40 mM Imidazole, pH 7.5) and lysed by French 
press. The suspension was centrifuged at 8,000 x g to remove cell debris. 
 Initial purification attempts were conducted with the L2LD30 construct in which 
the soluble fraction of the cell lysate was loaded onto a 1 mL HisTrap FF crude column 




volume (CV) wash with lysis buffer containing 0.1% Triton X-100 and an elution 
gradient of 40 mM to 200 mM imidazole over 25 CVs was necessary to resolve L2LD30 
from most of the contaminants. Elution fractions were visualized by sodium 
dodecylsulfate polyacrylamide electrophoresis (SDS-PAGE). Coomassie staining 
revealed that the fraction containing L2LD30 (MW ~53 kDa) was still contaminated with 
an ~60 kDa impurity (Fig. A.1A, lane 2). Attempts to remove the ~60 kDa protein from 
L2LD30 by ion exchange and size-exclusion chromatography failed to separate the two 
proteins. 
 Cleavage of L2LD30 was achieved by incubating 1 U Factor Xa (NEB) per 50 μg 
of protein at room temperature overnight. Cleavage was confirmed by SDS-PAGE (Fig. 
A.1A, lane 3). Cleaved L2LD30 was initially purified over a nickel affinity column to 
remove any uncleaved protein as well as the cleaved tags. A final purification by size-
exclusion on a HiLoad 16/60 Superdex 75 prep grade column was employed to remove 
L2LD from Factor Xa. However, cleaved L2LD30 co-eluted with the ~60 kDa protein in 
the void volume. 
 This purification protocol was also repeated for the L2LD32 construct. However, 
SDS-PAGE followed by coomassie staining revealed a doublet of bands corresponding to 
the L2LD32 (MW 64 kDa) protein and the ~60 kDa impurity seen in the L2LD30 
purifications (Fig. A.1B). Due to the close proximity of the L2LD32 band with this 
contaminate, this construct was abandoned and further attempts to remove the impurity 
were focused on the L2LD30 construct.   
A.2.1.3 Verification of L2LD30 and L2LD32 Expression and Identification of GroEL 
 The presence of both L2LD30 and L2LD32 was confirmed by western blot 
analysis using a 1:2000 dilution of Penta-His mouse monoclonal antibody (Invitrogen) 







Figure A.1. SDS-PAGE analysis of L2LD30 and L2LD32 constructs. A) Lane 1, 
L2LD30 inclusion bodies; lane 2, L2LD30 uncleaved and GroEL; lane 3, L2LD30 
cleaved (dashed arrow) and GroEL (solid arrow). B) Lane 1, purified L2LD32. C) Lane 




(Invitrogen). Both blots were recorded on a Typhoon imager (GE Healthcare) (Fig.A. 
2A-B).  
 The identification of L2LD in both constructs, as well as the ~60 kDa contaminate 
protein, was further verified by in-gel trypsin digestion and MALDI-TOF mass spec 
analysis. The protocol was carried out as described in Chapter 3. L2LD was confirmed 
and the ~60 kDa impurity was identified to be the bacterial heat shock protein GroEL 
(monomer MW 57 kDa).   
A.2.1.4 Removal of GroEL  
 Attempts to remove GroEL included optimizing the expression conditions of 
L2LD30. An overnight culture of LB was inoculated and incubated overnight at 37 °C 
while shaking. This was used to inoculate various nutrient-rich broths, including Power, 
Turbo, Hyper, Superior, Glucose M9Y, Terrific +4% glycerol, and LB broths (Athena 
Enzyme Systems). Cultures were grown to an OD600 of 0.6 to 0.8 and protein expression 
was induced by 0.2 mM IPTG and incubated at either 17 °C overnight or for three hours 
at 37 °C. Nickel affinity batch purification of the soluble fraction followed by SDS-
PAGE analysis revealed GroEL to be present in all samples.  
 Ultimately, purification from the ~60 kDa contaminate was achieved by 
conducting an initial nickel affinity purification as described above. The elution was then 
concentrated to 250 μL and then diluted to 10 mL in 5% milk and incubated on ice for 3 
minutes followed by the addition of 10 mM ATP and 5 mM MgSO4. During this step, 
ATP binds to active GroEL and induces the release of L2LD. The free GroEL then 
preferentially binds to casein, a highly abundant protein in milk that contains a 
considerable amount of exposed hydrophobic residues in its native state [374]. The 
reaction was incubated while rocking at 37 °C for 1 hr, ultracentrifuged for 30 minutes at 



















Figure A.2. Western blot analysis of L2LD30 and L2LD32. A) Benchmark his-tag 
protein standard; lane 1, A. fulgidus signal peptide peptidase possessing an N-terminal 
his-tag as a positive control; lane 2, L2LD30 inclusion bodies; lane 3; batch purified 
L2LD30. B) Benchmark his-tag protein standard; lane 1, L2LD30 inclusion bodies; lane 





analysis of the eluted sample revealed a ~99% pure sample (Fig. A.1C, lane 1). 
Unfortunately, the yield was very low and attempts to scale-up the procedure failed. 
Therefore, other constructs to increase the solubility of L2LD and minimize GroEL 
content were created, as described below. 
A.2.2 LIMP-2/ pET-22b(+) Construct 
 We next sought to express L2LD in the periplasmic space of E. coli. This was 
believed to reduce, if not eliminate, GroEL contamination as GroEL is a cytoplasmic 
protein and would be physically separated from L2LD in the periplasmic space by the 
inner membrane.  
A.2.2.1 Molecular Biology 
 L2LD was amplified from the original PCR product used to create the pET-30 
and -32 Xa/LIC constructs and ligated (Roche Quick Ligation Kit) into the pET-22b(+) 
(L2LD22; Novagen) vector using SacI and EcoRI (New England Biolabs) endonuclease 
restriction sites, respectively. The final L2LD22 construct encodes for an N-terminal pelB 
signal sequence for periplasmic localization and a C-terminal His-tag. After 
transformation into NovaBlue Giga Singles and overnight growth, the plasmid was 
isolated, and its sequence verified. An N386D mutation was present in the final construct, 
which was corrected by site-directed mutagenesis (Stratagene QuikChange) according to 
the manufacturer‟s instructions. After treatment with Dpn I to remove the parental strand, 
transformation into XL1-Blue cells and overnight growth, the mutant plasmid was 
isolated and sequenced, as above. 
A.2.2.2 Protein Expression and Purification 
 The L2LD22 plasmid was transformed into Rosetta-Gami 2(DE3)pLysS. Liter 
cultures were grown to an OD600= 0.6, induced with 1 mM IPTG, and incubated for 3 




 Initially, the L2LD22 construct was purified as described above for L2LD30. 
However, GroEL was present after elution from the nickel affinity column. 
Spheroplasting, a lysis method which removes only the outer membrane of gram-negative 
bacteria was then used to purify L2LD22 expressed only in the periplasmic space. The 
procedure was adapted from a previously published protocol [375] in which about three 
grams of cell pellet were thawed and resuspended in 5 mL ice-cold spheroplast buffer 
(40% sucrose, 33 mM Tris HCl, pH 8.0). Lysozyme and EDTA were then added at 5 
μg/mL and 1 mM, respectively. The reaction was incubated on ice for 1 hr and then 
subjected to ultracentrifugation at 42,000 rpm. The supernatant was loaded onto a 1 mL 
HisTrap FF crude column and the elution fractions were analyzed by SDS-PAGE (Fig. 
A.3A). GroEL was again present in the elution and the yield of L2LD22 was low. One 
likely source of error was the use of frozen cells, as it is possible that some cells lysed in 
the thawing procedure, thus releasing GroEL from the cytoplasm and allowing it to bind 
to the otherwise isolated L2LD22. Therefore, the spheroplasting procedure should be 
conducted the same day as cell growth.    
A.2.3 LIMP-2/ pMAL-c4x Construct 
 We next sought to test the E. coli maltose binding protein (MBP) as a fusion 
partner with  L2LD. MBP is reported to be a more effective solubilizing agent than the 
thioredoxin tag and can promote the proper folding of the attached protein into its 
biologically active conformation [376].  
A.2.3.1 Molecular Biology 
 L2LD was amplified from pET-30 Xa/LIC (retaining the N-terminal Factor Xa 
cleavage site) and ligated into the pMAL-c4x vector (New England Biolabs) using SacI 
and EcoRI restriction sites, respectively. Our pMAL-c4x construct (L2LDc4x) 






Figure A.3. SDS-PAGE analysis of L2LD22 and L2LDc4x constructs. A) Lane 1, 
purified L2LD22 and GroEL; lane 2, concentrated purified L2LD22 (dashed arrow) and 
GroEL (solid arrow). B) Lane 1, purified L2LDc4x; lane 2, concentrated purified 





Factor Xa cleavage sequence is leftover from pET-30 Xa/LIC. After transformation into 
NovaBlue Giga Singles and overnight growth, the plasmid was isolated, and its sequence 
verified.   
A.2.3.2 Protein Expression and Purification 
 As described above, the L2LDc4x plasmid was transformed into Rosetta-gami 
2(DE3)pLysS. Cells were cultured in Superior Broth (US Biological) to an optical 
density of 0.6 at 600 nm, induced with 0.1 mM IPTG, and incubated for three hours at 37 
°C. The cells were pelleted by centrifugation, flash frozen with liquid nitrogen and stored 
at -80 °C.   
 Approximately 3 g of cell pellet were lysed by sonication in the presence of 50 
mM HEPES, pH 7.5, 200 mM NaCl, 1 mM EDTA (Buffer A), supplemented with Roche 
Complete Protease Inhibitor. Cell debris was removed by ultracentrifugation (42,000 rpm 
for 20 min) and supernatant loaded onto a 20 ml High Flow Amylose Resin (New 
England Biolabs) column equilibrated with Buffer A. The MBP-L2LDc4x protein (MW 
~96 kDa) was eluted with Buffer A supplemented with 10 mM maltose. The elution 
fractions were analyzed by SDS-PAGE and GroEL was found to be present in each 
sample (Fig. A.3B).  
A.2.4 LIMP-2/ pPICZα-C Construct 
 Finally, expression in the methylotropic yeast, Pichia pastoris, was attempted as 
L2LD may be better expressed in a eukaryotic system. P. pastoris was chosen as it has 
several advantages over other eukaryotic and prokaryotic expression systems including 
rapid growth rate, ease of high cell-density fermentation, high levels of productivity in an 
almost protein-free medium, diverse posttranslational modifications, and the ability to 





A.2.4.1 Molecular Biology 
 L2LD was amplified from pET-30 Xa/LIC and ligated into the pPICZα C vector 
(L2LD αC; Invitrogen) using EcoRI and Kpn I (New England Biolabs) restriction sites, 
respectively. This vector encodes for an α-factor secretion signal, a C-terminal myc 
eptiope and polyhistidine tag. The ligated plasmid was transformed into NovaBlue Giga 
Singles to propogate the plasmid, and transformants were selected for on low salt Luria–
Bertani (LB) agar plates supplemented with the antibiotic Zeocin (25 μg/ml). The 
L2LDαC transformants were subjected to overnight growth, isolated by mini-prep, and 
the sequence was verified.   
A.2.4.2 Protein Expression and Purification 
 The L2LDαC plasmid was linearized after digestion with SacI followed by heat 
inactivation of the restriction enzyme. The digestion reaction was immediately 
transformed into the X-33 wild-type strain using the EasyComp (Invitrogen) method and 
propagated on YPD medium (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) 
dextrose, 1 M sorbitol, 2% (w/v) agar) containing Zeocin (100 μg/ml). A small-scale 
expression trial was then conducted in which 25 mL of BMGY (buffered glycerol-
complex medium; 1% (w/v)  yeast extract, 2% (w/v) peptone, 100 mM potassium 
phosphate, pH 6.0, 1.34% (w/v) yeast nitrogen base, 4 x 10
-5
% (w/v) biotin, 1% glycerol) 
was inoculated and grown at 30 °C for 16 hrs while shaking. The cells were pelleted and 
induced by resuspension in BMMY (buffered methanol-complex medium; 1% (w/v)  
yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate, pH 6.0, 1.34% (w/v) 
yeast nitrogen base, 4 x 10
-5
% (w/v) biotin, 0.5% methanol) to an OD600= 1.0 and the 
culture was returned to 30 °C for continued growth. Methanol was added every 24 hrs to 
a final concentration of 0.5% to maintain induction. A 1 mL aliquot of the culture was 
removed every 6 hrs for the first day and then every 12 hrs for a total of 4 days (96 hrs) to 




supernatant was transferred to a separate microcentrifuge tube. Both pellet and 
supernatant were frozen in liquid nitrogen and stored at -80 °C.  
 Each supernatant fraction was thawed, and batch purified with Nickel Sepharose 
High Performance resin (GE Life Sciences). Unfortunately the samples were too dilute to 
be visualized by SDS-PAGE or western blot. Therefore, all samples were pooled and 
concentrated (Fig. A.4A). A western blot was performed with the Penta-His monoclonal 
antibody as described above and an 80 kDa band consistent with a glycosylated L2LD 
was observed (Fig. A.4B). To confirm the band was corresponding to a glycosylated 
L2LD, the sample was subjected to PNGase F cleavage, an amidase that cleaves between 
the innermost GlcNAc and asparagine residues of high mannose, hybrid, and complex 
oligosaccharides from N-linked glycoproteins. The cleavage reaction was incubated at 
room temperature for 80 hrs, resulting in a lower molecular weight species consistent 
with the L2LD with affinity tags (Fig. A.4C). However, attempts to scale-up this protocol 
failed.    
A.2.5 Conclusions 
 Ultimately, we were unable to generate soluble L2LD for further characterization 
in spite of repeated attempt to optimize expression conditions, cellular distribution, fusion 
tags, and eukaryotic expression. Incubation with milk, ATP and Mg
2+
 allowed for the 
removal of GroEL, however this procedure failed to scale-up.  
 Analysis of the L2LD sequence by the DAS transmembrane prediction server 
predicts a hydrophobic region in the area of the coiled-coil domain of LIMP-2, which 
may explain GroEL binding. However, this is the identified potential binding region of 
GCase [373] and decreasing the hydrophobic nature of this region by site-directed 
mutagenesis may also impact its ability to bind to GCase as well. Ultimately, it may be 
necessary to express this protein in mammalian cells such as Chinese hamster ovary, 





Figure A.4. SDS-PAGE and western blot analysis of glycosylated and de-
glycosylated L2LDαC. A) SDS-PAGE: Lane 1, L2LDαC. B) Western blot: Benchmark 
his-tag protein standard; lane 1, L2LDαC (solid arrow). C) Western blot: Benchmark his-
tag protein standard; lane 1, L2LD30; lane 2, glycosylated L2LDαC (solid arrow); lane 3, 
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